Document,Phrase,RakeVal,SimVal
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predict risk allows healthcare providers,23.555555555555557,0.13763638958334923
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf present particular concerns according,21.333333333333336,0.0777988001704216
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assessed using prediction model risk,20.72222222222222,0.06924197152256965
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identify risk prediction models conducted,17.12222222222222,0.09658324345946312
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,left ventricular ejection fraction,16.0,0.06285456009209156
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,distinct risk prediction variables,14.722222222222221,0.06918284250423312
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,characteristics including male sex,14.5,0.042833952233195305
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx distinct predictor variables,14.431372549019608,0.026009444147348404
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx %) external validation,12.764705882352942,0.05874064130087694
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,"xxx ), hf hospitalizations",12.598039215686274,0.14395860147972903
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx models assessed xxx,12.596078431372547,0.034537860192358494
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,"xxx ), cardiovascular death",11.764705882352942,0.2265488039702177
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,risk prediction models,10.455555555555556,0.12669244656960169
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identify common variables,10.333333333333332,0.047371236607432365
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identify hf risk,10.055555555555555,0.11752037828167279
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx %) models,9.66470588235294,0.046229408122599125
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,terminal prohormone brain,9.0,0.10691695908705394
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systolic blood pressure,9.0,0.19706550737222037
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,patients might benefit,9.0,0.17430907239516577
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,machine learning tools,9.0,0.017356942718227703
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,handling missing data,9.0,0.029383260756731033
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,blood urea nitrogen,9.0,0.08491628368695577
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,systematic literature review,8.5,0.11429194112618764
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assess statistical approach,8.5,0.0682396503786246
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,publications reported detail,8.333333333333334,0.061810540656248726
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx identified risk,8.320261437908496,0.09385622354845206
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,overall low rob,8.0,0.036160012086232506
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,bias assessment tool,7.5,0.02515859839816888
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction models,6.9,0.09293749555945396
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx risk,6.3202614379084965,0.08913372922688723
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,assess risk,6.055555555555555,0.1279876697808504
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cardiovascular death,6.0,0.3477906510233879
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prediction publications,5.833333333333334,0.0990343950688839
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,"hf ),",5.833333333333334,0.1109897643327713
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,"xxx ),",5.764705882352941,-0.015934890136122704
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,outcomes assessed,5.666666666666666,0.14744332060217857
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ranked according,5.5,0.03414288908243179
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx publications,5.098039215686274,0.05232630763202906
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf hospitalization,4.833333333333334,0.18449676781892776
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx non,4.764705882352941,0.024027195759117603
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx ).,4.764705882352941,-0.015934890136122704
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx %).,4.764705882352941,-0.015934890136122704
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,may xxx,4.764705882352941,-0.012824242003262043
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,march xxx,4.764705882352941,-0.02176338154822588
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rob assessment,4.5,0.046648452058434486
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,literature databases,4.5,0.148965522646904
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rob ).,4.0,0.009379956871271133
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,registration number,4.0,0.019475161097943783
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,primary outcomes,4.0,0.15430442243814468
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predictors included,4.0,0.09621145948767662
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,potential utility,4.0,0.09313226863741875
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,nyha class,4.0,0.02183631807565689
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,novel approaches,4.0,0.0687826182693243
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,natriuretic peptide,4.0,0.1839265078306198
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,mainly due,4.0,0.016958811786025763
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,justify clinical,4.0,0.25655319821089506
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hospital setting,4.0,0.23481094278395176
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,heart rate,4.0,0.20280320569872856
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,heart failure,4.0,0.2074820026755333
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,generally better,4.0,0.03557589091360569
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,economic value,4.0,0.04851515172049403
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,duplicated citations,4.0,0.02788121998310089
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,crdxxx ).,4.0,0
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,composite endpoints,4.0,0.09084805846214294
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,certain therapies,4.0,0.19523299857974052
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,cause mortality,4.0,0.18113460391759872
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,probast ).,3.5,0
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,discriminatory ability,3.5,0.016360502690076828
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,deemed relevant,3.5,0.06971338763833046
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,conducted,3.0,0.055469855666160583
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,hf,2.8333333333333335,0.1109897643327713
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,xxx,2.764705882352941,-0.015934890136122704
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,validation,2.5,0.09198760986328125
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,including,2.5,0.06332606077194214
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,rob,2.0,0.009379956871271133
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,identified,2.0,0.10330121219158173
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,bias,2.0,0.01831863634288311
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,relevant,1.5,0.09132666885852814
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,probast,1.5,0
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,ability,1.5,-0.022223003208637238
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,yet,1.0,-0.03675409406423569
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,within,1.0,0.06455390155315399
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,understand,1.0,-0.004381440579891205
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,total,1.0,0.003683900460600853
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,studies,1.0,0.24976284801959991
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,sodium,1.0,0.11925020068883896
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,slr,1.0,0.0981777086853981
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,searched,1.0,0.027823450043797493
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,robustness,1.0,0.028073906898498535
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,results,1.0,0.0652550756931305
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,registered,1.0,0.016251616179943085
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,prospero,1.0,0
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,propose,1.0,0.06627984344959259
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,predicting,1.0,0.043349962681531906
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,payers,1.0,0.18115882575511932
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,n,1.0,-0.021267158910632133
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,methods,1.0,0.024640876799821854
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,majority,1.0,0.026061898097395897
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,lack,1.0,0.0400080606341362
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,incorporation,1.0,0.05103994905948639
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,id,1.0,0.0023845192044973373
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,extent,1.0,0.017291061580181122
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,diabetes,1.0,0.31405115127563477
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,determined,1.0,-0.03170712664723396
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,demands,1.0,0.033390387892723083
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,creatinine,1.0,0.20824791491031647
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,conclusions,1.0,0.07628431916236877
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,co,1.0,0.08638649433851242
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,calibration,1.0,0.21323038637638092
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,bmi,1.0,0.0934591069817543
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,based,1.0,0.08516917377710342
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,background,1.0,0.03833860531449318
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,application,1.0,0.023733139038085938
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,age,1.0,0.10348664224147797
Evaluating risk prediction models for adults with heart failure: A systematic literature review.,adults,1.0,0.051906388252973557
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,approach evaluated anonymized cardiac images,23.666666666666668,0.17590658068656922
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,advanced machine learning methods,16.0,0.05202275887131691
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,reproducible cardiac pathological assessment,15.666666666666666,0.253646831959486
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,fully automatic processing pipeline,15.666666666666666,0.07228710362687707
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac cine sequencing provides,15.666666666666666,0.24283761950209737
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,independent test set using,15.5,0.015956244431436062
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,initial processing element consists,15.166666666666666,0.03378185909241438
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ary pathology classification accuracy,14.333333333333334,0.14713991759344935
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx patients per group,13.1,0.12655634619295597
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,final processing element,10.166666666666666,0.023160612831513088
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiac pathology classifier,10.0,0.4012519071499507
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,quantify cardiac measures,9.666666666666666,0.21810053630421558
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,manual cardiac evaluation,9.666666666666666,0.26817435150345165
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,training data set,9.5,0.07900424053271611
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx healthy group,9.1,0.045565174892544746
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,"rv ), respectively",9.0,0.06496892496943474
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,performance results demonstrate,9.0,0.04285929352045059
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,enabling improved extraction,9.0,0.055905758713682495
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx pathology groups,8.933333333333334,0.1653616956124703
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,cardiovascular disease staging,8.5,0.25692620997627574
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,"lv ), myocardium",8.0,0.16202591359615326
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,combining semantic segmentation,8.0,0.05596125001708666
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx patients,5.6,0.2216808618977666
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,disease classification,5.5,0.09134924225509167
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,wise segmentation,4.0,0.06757503096014261
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ventricular cavities,4.0,0.19728557020425797
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,university hospital,4.0,0.32684318721294403
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,structure segmentation,4.0,0.08185387216508389
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,right ventricle,4.0,0.08423669962212443
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,observer bias,4.0,0.04053699877113104
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,morphological features,4.0,0.1226752009242773
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,left ventricle,4.0,0.1010191198438406
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,important functional,4.0,0.11301657184958458
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,ejection fraction,4.0,-0.013899685814976692
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,deliver accurate,4.0,0.03067811205983162
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,trained model,3.5,0.08922233246266842
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,xxx,2.6,-0.015934890136122704
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,segmentation,2.0,0.13467922806739807
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,myocardium,2.0,0.27229008078575134
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,model,1.5,0.05463607236742973
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,voxel,1.0,0.22100672125816345
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,utilized,1.0,0.03543274104595184
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,recorded,1.0,0.01999819651246071
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,presented,1.0,0.10993251949548721
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,potential,1.0,0.06813585013151169
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,method,1.0,0.016362402588129044
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,expense,1.0,0.08347275108098984
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,examined,1.0,0.1701224148273468
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,efficient,1.0,0.10318800061941147
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,dijon,1.0,0.010735955089330673
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,curtails,1.0,0.028310272842645645
Automated Cardiovascular Pathology Assessment Using Semantic Segmentation and Ensemble Learning.,basis,1.0,-0.04432522505521774
Physiological Assessment of Coronary Lesions in 2020.,term data demonstrating improved outcomes,25.0,0.10536950230598449
Physiological Assessment of Coronary Lesions in 2020.,determine lesion functional significance,16.0,0.1012946218252182
Physiological Assessment of Coronary Lesions in 2020.,beyond fractional flow reserve,16.0,0.04637357534375042
Physiological Assessment of Coronary Lesions in 2020.,"ffrct ), invasive angiography",14.25,0.3308231234550476
Physiological Assessment of Coronary Lesions in 2020.,guided percutaneous coronary intervention,13.722222222222221,0.22295109555125237
Physiological Assessment of Coronary Lesions in 2020.,evaluating coronary stenosis physiology,13.722222222222221,0.2790856324136257
Physiological Assessment of Coronary Lesions in 2020.,coronary physiological assessment remains,12.222222222222221,0.1741553032770753
Physiological Assessment of Coronary Lesions in 2020.,invasive coronary ct,9.722222222222221,0.23524800688028336
Physiological Assessment of Coronary Lesions in 2020.,coronary physiological assessment,9.222222222222221,0.23429864148298898
Physiological Assessment of Coronary Lesions in 2020.,coronary artery disease,9.222222222222221,0.2953575849533081
Physiological Assessment of Coronary Lesions in 2020.,acute coronary syndromes,9.222222222222221,0.348122239112854
Physiological Assessment of Coronary Lesions in 2020.,technical aspects involved,9.0,0.05736500769853592
Physiological Assessment of Coronary Lesions in 2020.,rest without hyperemia,9.0,0.0856664205590884
Physiological Assessment of Coronary Lesions in 2020.,residual ischemia post,9.0,0.10443652172883351
Physiological Assessment of Coronary Lesions in 2020.,optical coherence tomography,9.0,0.16895723839600882
Physiological Assessment of Coronary Lesions in 2020.,interventional cardiology toolbox,9.0,0.5282939846316973
Physiological Assessment of Coronary Lesions in 2020.,improve patient care,9.0,0.25580136477947235
Physiological Assessment of Coronary Lesions in 2020.,hyperemic pressure ratios,9.0,0.10968661680817604
Physiological Assessment of Coronary Lesions in 2020.,exciting technological future,9.0,0.09376745671033859
Physiological Assessment of Coronary Lesions in 2020.,enable detailed pre,9.0,0.046365381528933845
Physiological Assessment of Coronary Lesions in 2020.,artificial intelligence algorithms,9.0,0.11491399258375168
Physiological Assessment of Coronary Lesions in 2020.,alternative ffr approaches,9.0,0.055263230577111244
Physiological Assessment of Coronary Lesions in 2020.,assess coronary physiology,8.722222222222221,0.2895762088398139
Physiological Assessment of Coronary Lesions in 2020.,refine clinical practice,8.0,0.21875642985105515
Physiological Assessment of Coronary Lesions in 2020.,"ffr ), non",7.75,0.06398928165435791
Physiological Assessment of Coronary Lesions in 2020.,physiological assessment,6.0,0.12038403004407883
Physiological Assessment of Coronary Lesions in 2020.,coronary physiology,5.722222222222222,0.40347781777381897
Physiological Assessment of Coronary Lesions in 2020.,remains underutilized,5.0,0.05646817572414875
Physiological Assessment of Coronary Lesions in 2020.,"ffroct ),",4.75,0
Physiological Assessment of Coronary Lesions in 2020.,"ffrangio ),",4.75,0
Physiological Assessment of Coronary Lesions in 2020.,current practice,4.5,0.09676923789083958
Physiological Assessment of Coronary Lesions in 2020.,clinical scenarios,4.5,0.2632120056077838
Physiological Assessment of Coronary Lesions in 2020.,well established,4.0,0.07649984396994114
Physiological Assessment of Coronary Lesions in 2020.,serial lesions,4.0,0.08666558656841516
Physiological Assessment of Coronary Lesions in 2020.,robust tools,4.0,0.012099930085241795
Physiological Assessment of Coronary Lesions in 2020.,related arteries,4.0,0.1908680871129036
Physiological Assessment of Coronary Lesions in 2020.,recent findings,4.0,0.12625432386994362
Physiological Assessment of Coronary Lesions in 2020.,left main,4.0,0.046499328687787056
Physiological Assessment of Coronary Lesions in 2020.,latest developments,4.0,0.08507654257118702
Physiological Assessment of Coronary Lesions in 2020.,indispensable tool,4.0,0.005240730941295624
Physiological Assessment of Coronary Lesions in 2020.,including non,4.0,0.06365767121315002
Physiological Assessment of Coronary Lesions in 2020.,essential component,4.0,0.018949024379253387
Physiological Assessment of Coronary Lesions in 2020.,especially helpful,4.0,0.08433499187231064
Physiological Assessment of Coronary Lesions in 2020.,despite long,4.0,-0.004904087632894516
Physiological Assessment of Coronary Lesions in 2020.,catheterization laboratory,4.0,0.39266934990882874
Physiological Assessment of Coronary Lesions in 2020.,also emerging,4.0,0.08303185738623142
Physiological Assessment of Coronary Lesions in 2020.,additional advances,4.0,0.09927589446306229
Physiological Assessment of Coronary Lesions in 2020.,stable cad,3.666666666666667,0.040095262229442596
Physiological Assessment of Coronary Lesions in 2020.,multivessel cad,3.666666666666667,0.12174112349748611
Physiological Assessment of Coronary Lesions in 2020.,review outlines,3.5,0.06390692293643951
Physiological Assessment of Coronary Lesions in 2020.,physiology,2.5,0.3448277711868286
Physiological Assessment of Coronary Lesions in 2020.,intervention,2.5,0.06027820706367493
Physiological Assessment of Coronary Lesions in 2020.,non,2.0,0.06398928165435791
Physiological Assessment of Coronary Lesions in 2020.,cad,1.6666666666666667,0.008538410067558289
Physiological Assessment of Coronary Lesions in 2020.,review,1.5,0.06275224685668945
Physiological Assessment of Coronary Lesions in 2020.,virtual,1.0,-0.016268359497189522
Physiological Assessment of Coronary Lesions in 2020.,today,1.0,0.028057290241122246
Physiological Assessment of Coronary Lesions in 2020.,realized,1.0,-0.013345438987016678
Physiological Assessment of Coronary Lesions in 2020.,purpose,1.0,-0.006926483474671841
Physiological Assessment of Coronary Lesions in 2020.,procedure,1.0,0.2543809711933136
Physiological Assessment of Coronary Lesions in 2020.,pci,1.0,0.06185466796159744
Physiological Assessment of Coronary Lesions in 2020.,nhpr,1.0,0
Physiological Assessment of Coronary Lesions in 2020.,infarct,1.0,0.29678159952163696
Physiological Assessment of Coronary Lesions in 2020.,indications,1.0,0.12957578897476196
Physiological Assessment of Coronary Lesions in 2020.,however,1.0,-0.011453256011009216
Physiological Assessment of Coronary Lesions in 2020.,focusing,1.0,0.07314138859510422
Physiological Assessment of Coronary Lesions in 2020.,field,1.0,0.11301998794078827
Physiological Assessment of Coronary Lesions in 2020.,benefits,1.0,0.05126548931002617
Physiological Assessment of Coronary Lesions in 2020.,addition,1.0,0.1140233725309372
Physiological Assessment of Coronary Lesions in 2020.,abound,1.0,0.029980715364217758
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,"ai ), although well established",23.0,0.055529759265482426
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,editorial review highlights progress,16.0,0.055371860042214394
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,common clinical conditions,8.0,0.21186517924070358
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,many areas,4.0,0.10166110098361969
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,everyday life,4.0,0.03412359766662121
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,artificial intelligence,4.0,0.1279079094529152
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,ai,3.0,0.07966839522123337
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,conditions,2.0,0.047392018139362335
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,trials,1.0,0.12281295657157898
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,trialed,1.0,0.007933016866445541
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,suggests,1.0,0.041627660393714905
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,recently,1.0,0.026306796818971634
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,management,1.0,0.23943668603897095
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,improvements,1.0,0.08724521100521088
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,hypertension,1.0,0.364623486995697
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,diagnosis,1.0,0.24688632786273956
Of Machines and Men: Intelligent Diagnosis and the Shape of Things to Come.,date,1.0,-0.02209126204252243
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.","unsorted cortical tissue ), liver",23.5,0.13676342368125916
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.","neurodegenerative ataxia ), slowing",16.5,0.09183459045986335
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",pick disease type c,16.0,0.05154294241219759
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",optimized dual aavs enable,12.833333333333334,0.05696753909190496
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",therapeutically relevant efficiencies,9.0,0.12600423892339072
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",targeted point mutations,9.0,0.0671967143813769
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",relevant cell types,9.0,0.08464814225832622
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mouse brain tissue,9.0,0.11349478860696156
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",genetic diseases depends,9.0,0.1369860221942266
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aav packaging capacity,9.0,0.06035717390477657
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",optimized delivery vectors,8.833333333333334,0.06485484788815181
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base editing corrects,8.8,0.03478117287158966
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",length base editors,8.466666666666667,0.020101820429166157
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",adenine base editors,8.466666666666667,0.005505541960398356
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",delivery via adeno,8.333333333333334,0.09841644763946533
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.","xxx %), retina",8.2,0.0725649269297719
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.","xxx %), heart",8.2,0.14438461977988482
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",vivo base editing,7.8,0.09603611379861832
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",base editors,5.466666666666667,0.005307380110025406
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",dual aavs,5.333333333333334,0.05582564324140549
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mouse brain,5.0,0.08274193853139877
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx %).,4.2,-0.015934890136122704
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx %),4.2,-0.015934890136122704
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",therapeutic interest,4.0,0.1769992895424366
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",split cytosine,4.0,0.029614080674946308
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",splicing inteins,4.0,0.03305492177605629
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",skeletal muscle,4.0,0.10633536614477634
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",multiple tissues,4.0,0.09319684654474258
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",increasing lifespan,4.0,0.05654631368815899
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",efficient introduction,4.0,0.062367403879761696
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",causes niemann,4.0,0.0955091118812561
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",associated viruses,4.0,0.06252634525299072
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",also show,4.0,0.02594495750963688
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",delivery,2.3333333333333335,0.08233281970024109
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",aavs,2.3333333333333335,0
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",xxx,2.2,-0.015934890136122704
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",vivo,2.0,0.22206149995326996
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",use,1.0,0.0033735278993844986
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",treatment,1.0,0.27399298548698425
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",trans,1.0,0.035792045295238495
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",success,1.0,0.02648092433810234
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",study,1.0,0.2376001477241516
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",report,1.0,0.05636989697813988
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",reconstituted,1.0,0.051905177533626556
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",precludes,1.0,-0.0305861197412014
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",neurodegeneration,1.0,0.20730683207511902
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",mutation,1.0,0.07678423076868057
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",limited,1.0,0.009723823517560959
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",full,1.0,0.008461154997348785
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",facilitate,1.0,0.07707814872264862
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",dosages,1.0,0.16614286601543427
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",deliver,1.0,0.048547469079494476
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",application,1.0,0.023733139038085938
"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.",ability,1.0,-0.022223003208637238
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,current literature exists regarding,16.0,0.07642204780131578
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,also cause significant lesions,14.5,0.09312801156193018
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,less commonly affected species,14.0,0.03716933075338602
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human arboviral neuroinvasive disease,13.833333333333334,0.1755093988031149
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west nile virus infection,13.25,0.075938087888062
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,prior human wnv infection,12.283333333333335,0.0854246977251023
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,west nile virus,10.0,0.04166504368185997
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,commonly affected birds,10.0,0.006251970926920573
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,also briefly discussed,9.5,0.05715696637829145
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human infection involve,9.083333333333334,0.11089861144622166
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,viral pathogenesis derived,9.0,0.05232189502567053
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,severe systemic disease,9.0,0.12626137087742487
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,renal injury leading,9.0,0.1803122895459334
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,central nervous system,9.0,0.09717598309119542
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,experimental animal models,8.0,0.12631584952274957
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv infection,5.45,0.12057871744036674
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,virus propagation,5.0,0.008435415104031563
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,major cause,5.0,0.08084611594676971
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,avian species,5.0,0.059786129742860794
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,animal models,5.0,0.10543617233633995
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human animals,4.833333333333334,0.06385773420333862
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurologic disease,4.5,0.20460288226604462
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human non,4.5,0.07672946527600288
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,human vertebrates,4.333333333333334,0.0828995481133461
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv pathology,4.2,0.27686580643057823
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv maintenance,4.2,0.11021209880709648
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,vertebrate host,4.0,0.08990686014294624
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,review summarizes,4.0,0.05325387790799141
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,prominent manifestation,4.0,0.07033965550363064
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,pathology seen,4.0,0.2737777568399906
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,pathology caused,4.0,0.2596761416643858
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,particularly diverse,4.0,0.10571541264653206
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,natural infections,4.0,0.13648249581456184
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,known findings,4.0,0.12461254186928272
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,knowledge gaps,4.0,0.06761082634329796
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,knowledge gains,4.0,0.021418079733848572
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,host animals,4.0,0.03248347342014313
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,future directions,4.0,0.06682271603494883
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,susceptible non,3.666666666666667,0.06416111439466476
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurotropic nature,3.5,-0.0009654052555561066
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,wnv,2.2,0.0624002143740654
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,non,1.6666666666666667,0.06398928165435791
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,vertebrates,1.5,0.07632944732904434
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,neurologic,1.5,0.24617043137550354
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,nature,1.5,-0.06284593045711517
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,well,1.0,0.09099400043487549
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,transmission,1.0,0.07843247056007385
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,time,1.0,0.05442593991756439
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,similarly,1.0,0.015414413064718246
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,serve,1.0,0.044177670031785965
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,research,1.0,0.27731871604919434
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,relationship,1.0,0.0036004912108182907
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,ranging,1.0,-0.015200847759842873
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,occur,1.0,0.06010684743523598
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,kidneys,1.0,0.14581722021102905
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,intestinal,1.0,0.14243550598621368
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,humans,1.0,0.06040411442518234
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,however,1.0,-0.011453256011009216
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,horses,1.0,0.05137117952108383
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,heart,1.0,0.30470412969589233
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,gap,1.0,0.07254616916179657
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,eyes,1.0,0.0620502233505249
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,death,1.0,0.12083880603313446
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,continues,1.0,-0.03620941564440727
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,cardiac,1.0,0.619275689125061
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,alligators,1.0,0.003468889743089676
Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.,addressed,1.0,0.10165482014417648
Photoplethysmography based atrial fibrillation detection: a review.,sensors record blood volume variations,24.0,0.08834755159914494
Photoplethysmography based atrial fibrillation detection: a review.,challenges towards clinical applications,16.0,0.1738534076139331
Photoplethysmography based atrial fibrillation detection: a review.,deep learning approaches used,15.0,0.03189744148403406
Photoplethysmography based atrial fibrillation detection: a review.,cardiac rhythm disorder associated,14.0,0.24421579390764236
Photoplethysmography based atrial fibrillation detection: a review.,af detection using ppg,11.5,0.07864008843898773
Photoplethysmography based atrial fibrillation detection: a review.,implement optical sensors,10.0,0.1003437452018261
Photoplethysmography based atrial fibrillation detection: a review.,possible using low,9.5,0.012498260786135992
Photoplethysmography based atrial fibrillation detection: a review.,patient management tools,9.0,0.21142581291496754
Photoplethysmography based atrial fibrillation detection: a review.,new wearable devices,9.0,0.14939591040213904
Photoplethysmography based atrial fibrillation detection: a review.,leading risk factor,9.0,0.09249850610891978
Photoplethysmography based atrial fibrillation detection: a review.,large prospective trials,9.0,0.08907155940930049
Photoplethysmography based atrial fibrillation detection: a review.,grade wearable devices,9.0,0.08568766713142395
Photoplethysmography based atrial fibrillation detection: a review.,enabling transformative diagnostic,9.0,0.18593546686073145
Photoplethysmography based atrial fibrillation detection: a review.,devices would allow,9.0,0.08195636545618375
Photoplethysmography based atrial fibrillation detection: a review.,today possible thanks,8.5,0.00540257307390372
Photoplethysmography based atrial fibrillation detection: a review.,secondary stroke prevention,8.333333333333334,0.204373300075531
Photoplethysmography based atrial fibrillation detection: a review.,cardiac rhythm,6.0,0.39142943918704987
Photoplethysmography based atrial fibrillation detection: a review.,ppg )-,5.0,0.12077879160642624
Photoplethysmography based atrial fibrillation detection: a review.,machine learning,5.0,0.03610682301223278
Photoplethysmography based atrial fibrillation detection: a review.,af detection,5.0,0.11775946244597435
Photoplethysmography based atrial fibrillation detection: a review.,early detection,4.666666666666666,0.10575852356851101
Photoplethysmography based atrial fibrillation detection: a review.,today equip,4.5,0.04264319594949484
Photoplethysmography based atrial fibrillation detection: a review.,prevent stroke,4.333333333333334,0.1360683385282755
Photoplethysmography based atrial fibrillation detection: a review.,cardioembolic stroke,4.333333333333334,0.2529298663139343
Photoplethysmography based atrial fibrillation detection: a review.,user activity,4.0,0.04194623976945877
Photoplethysmography based atrial fibrillation detection: a review.,thorough account,4.0,0.012766440398991108
Photoplethysmography based atrial fibrillation detection: a review.,technology known,4.0,0.12273937650024891
Photoplethysmography based atrial fibrillation detection: a review.,signal processing,4.0,0.08321457356214523
Photoplethysmography based atrial fibrillation detection: a review.,physiological parameters,4.0,0.10987468808889389
Photoplethysmography based atrial fibrillation detection: a review.,increased morbidity,4.0,0.1984947919845581
Photoplethysmography based atrial fibrillation detection: a review.,heart rate,4.0,0.20280320569872856
Photoplethysmography based atrial fibrillation detection: a review.,early screening,4.0,0.09201321564614773
Photoplethysmography based atrial fibrillation detection: a review.,cost easy,4.0,0.007938457652926445
Photoplethysmography based atrial fibrillation detection: a review.,atrial fibrillation,4.0,0.26550570130348206
Photoplethysmography based atrial fibrillation detection: a review.,continuous monitoring,3.5,0.08128756657242775
Photoplethysmography based atrial fibrillation detection: a review.,af,2.3333333333333335,0.058493904769420624
Photoplethysmography based atrial fibrillation detection: a review.,monitoring,1.5,0.158101424574852
Photoplethysmography based atrial fibrillation detection: a review.,xxx,1.0,-0.015934890136122704
Photoplethysmography based atrial fibrillation detection: a review.,work,1.0,0.06322342157363892
Photoplethysmography based atrial fibrillation detection: a review.,wearables,1.0,0.09958787262439728
Photoplethysmography based atrial fibrillation detection: a review.,therapy,1.0,0.29505598545074463
Photoplethysmography based atrial fibrillation detection: a review.,summary,1.0,0.08503544330596924
Photoplethysmography based atrial fibrillation detection: a review.,studies,1.0,0.24976284801959991
Photoplethysmography based atrial fibrillation detection: a review.,sleep,1.0,0.16289515793323517
Photoplethysmography based atrial fibrillation detection: a review.,review,1.0,0.06275224685668945
Photoplethysmography based atrial fibrillation detection: a review.,recently,1.0,0.026306796818971634
Photoplethysmography based atrial fibrillation detection: a review.,primary,1.0,0.07534971833229065
Photoplethysmography based atrial fibrillation detection: a review.,presented,1.0,0.10993251949548721
Photoplethysmography based atrial fibrillation detection: a review.,photoplethysmography,1.0,0
Photoplethysmography based atrial fibrillation detection: a review.,mortality,1.0,0.27426618337631226
Photoplethysmography based atrial fibrillation detection: a review.,majority,1.0,0.026061898097395897
Photoplethysmography based atrial fibrillation detection: a review.,limitations,1.0,0.020679235458374023
Photoplethysmography based atrial fibrillation detection: a review.,introduced,1.0,0.0400276780128479
Photoplethysmography based atrial fibrillation detection: a review.,initiation,1.0,0.09276364743709564
Photoplethysmography based atrial fibrillation detection: a review.,inform,1.0,0.01317903958261013
Photoplethysmography based atrial fibrillation detection: a review.,health,1.0,0.31966903805732727
Photoplethysmography based atrial fibrillation detection: a review.,followed,1.0,0.06544908136129379
Photoplethysmography based atrial fibrillation detection: a review.,fitness,1.0,0.18124014139175415
Photoplethysmography based atrial fibrillation detection: a review.,extracted,1.0,0.012193005532026291
Photoplethysmography based atrial fibrillation detection: a review.,evidenced,1.0,-0.023355547338724136
Photoplethysmography based atrial fibrillation detection: a review.,discussion,1.0,0.10436347126960754
Photoplethysmography based atrial fibrillation detection: a review.,crucial,1.0,0.045712754130363464
Photoplethysmography based atrial fibrillation detection: a review.,consumer,1.0,0.12918971478939056
Photoplethysmography based atrial fibrillation detection: a review.,cases,1.0,0.1337328851222992
Photoplethysmography based atrial fibrillation detection: a review.,capable,1.0,0.04132876545190811
Photoplethysmography based atrial fibrillation detection: a review.,body,1.0,0.014940984547138214
Photoplethysmography based atrial fibrillation detection: a review.,author,1.0,0.1725224107503891
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",source r package flowmapr via,25.0,0.02748046233318746
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mouse embryonic stem cells differentiating,24.5,0.041282980144023894
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell technologies present new opportunities,23.625,0.11003904938697814
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",gui )- based software tool,21.5,0.059671323746442795
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",vitro stem cell differentiation,16.125,0.10967454873025417
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",change across time points,15.666666666666666,0.04481137450784445
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",identify unique cell populations,15.625,0.07011363562196493
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",uses graph layout analysis,14.571428571428571,0.04619096498936415
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",previously published scrnaseq dataset,14.5,0.084927332897981
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell time course datasets,14.291666666666666,0.08688928745687008
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",sequential time ordering,9.666666666666666,0.040717649894456066
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell signaling dynamics,9.625,0.07717842360337575
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell rna sequencing,9.625,0.14709154143929482
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell datasets obtained,9.625,0.08115091112752755
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",cell analysis methods,9.196428571428571,0.07716615870594978
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",visualize cellular trajectories,9.0,0.08103281383713086
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",three germ layers,9.0,0.015514960512518883
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",resulting datasets makes,9.0,0.040843154614170395
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",one particular challenge,9.0,0.06298240336279075
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",many dynamic processes,9.0,0.05819833775361379
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",graphical user interface,9.0,0.03447173535823822
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",perform comprehensive analysis,7.571428571428571,0.09863713632027309
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map analysis side,6.571428571428571,0.06406636163592339
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",based commands,5.5,0.1051076091825962
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",experimental datasets,5.0,0.1543521136045456
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map analysis,4.571428571428571,0.08488576486706734
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",step analysis,4.071428571428571,0.05773446336388588
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",vivo development,4.0,0.20071841031312943
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",protocol takes,4.0,0.08096887031570077
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mass cytometry,4.0,0.12563294544816017
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map algorithm,4.0,0.06980007514357567
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",drug resistance,4.0,0.07900293543934822
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",detailed description,4.0,0.01719026267528534
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",complex nature,4.0,0.008451268076896667
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",biological discovery,4.0,0.11704317480325699
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",perform flow,3.8,0.08166857808828354
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow cytometry,3.8,0.14311635494232178
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",developed flow,3.8,0.09296619892120361
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",xxx min,3.666666666666667,0.027676456607878208
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",xxx h,3.666666666666667,0.006312788464128971
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map approach,3.5,0.04827821999788284
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",dimensional single,3.5,0.048512762412428856
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",demonstrate flow,3.3,0.04625438153743744
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",gui,3.0,0.04591921716928482
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",analysis,2.5714285714285716,0.10335448384284973
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",scrnaseq,2.5,0
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",side,2.0,0.022427555173635483
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",perform,2.0,0.09922076761722565
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",map,2.0,0.06641704589128494
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",flow,1.8,0.06411638855934143
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",xxx,1.6666666666666667,-0.015934890136122704
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",step,1.5,0.012114442884922028
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",single,1.5,0.015469912439584732
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",demonstrate,1.5,0.028392374515533447
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",approach,1.5,0.030139394104480743
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",using,1.0,-0.04173736274242401
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",use,1.0,0.0033735278993844986
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",track,1.0,0.04564104974269867
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",text,1.0,0.04602084308862686
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",synthetic,1.0,0.00509323924779892
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",provide,1.0,0.01998533308506012
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",open,1.0,0.04772356525063515
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",oncogenesis,1.0,0.18533475697040558
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",mesoderm,1.0,0.12716028094291687
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",including,1.0,0.06332606077194214
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",illustrate,1.0,-0.009545623324811459
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",high,1.0,0.06070782244205475
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",facilitate,1.0,0.07707814872264862
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",experiments,1.0,0.11820036172866821
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",endoderm,1.0,0.15505863726139069
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",emergence,1.0,0.041484735906124115
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",ectoderm,1.0,0.1283458173274994
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",complete,1.0,-0.01845567114651203
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",comparison,1.0,0.11286726593971252
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",challenging,1.0,0.0013546105474233627
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",applied,1.0,0.006987035274505615
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",advantageous,1.0,0.10459944605827332
"FLOW-MAP: a graph-based, force-directed layout algorithm for trajectory mapping in single-cell time course datasets.",addition,1.0,0.1140233725309372
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,yet available methods using pcr,23.166666666666668,-0.0036433180794119835
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,virus detection using msspe arboviral,20.46666666666667,0.09966944623738527
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,enriching targeted rna viral sequences,18.166666666666664,0.02730653714388609
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,successfully enriched using msspe,15.466666666666669,0.02615826080242793
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,additional target enrichment step,15.333333333333334,0.05413145758211613
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,haemorrhagic fever viral panels,15.166666666666666,0.05390750081278384
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,(± xxx %) increase,14.75,0.023331080563366413
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,simultaneously retaining metagenomic sensitivity,13.666666666666666,0.08221469447016716
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,spiked primer enrichment,9.333333333333334,-0.001618103434642156
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,median tenfold enrichment,9.333333333333334,0.09705824156602223
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,yellow fever viruses,9.166666666666666,0.008568771493931612
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,spectrum pathogen detection,9.0,0.10307461271683376
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,portable nanopore sequencers,9.0,0.11907924214998881
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sensitivity pathogen identification,8.666666666666666,0.0676748404900233
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,xxx different viruses,8.416666666666666,0.025164537752668064
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,developed metagenomic sequencing,8.333333333333334,0.16355501115322113
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,method directly applicable,8.0,0.04245349392294884
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,viral outbreaks,5.666666666666666,0.03406250849366188
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,specifically targeted,5.5,0.06474586948752403
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,specific pcr,5.5,0.08915150165557861
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,metagenomic next,5.0,0.12817152589559555
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,"msspe ),",4.8,0
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,evaluated msspe,4.8,0.1149546355009079
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,mean xxx,4.75,0.030888752080500126
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,demonstrating xxx,4.75,0.013101867400109768
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,infecting viruses,4.666666666666666,0.021462706848978996
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,shotgun sequencing,4.333333333333334,0.095013995654881
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,generation sequencing,4.333333333333334,0.12652655690908432
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,titre infections,4.0,0.15311158820986748
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,proved useful,4.0,0.04149645706638694
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,plasma samples,4.0,0.11209489591419697
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,narrow scope,4.0,0.03682776726782322
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,mngs alone,4.0,0.04610326886177063
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,"mngs ),",4.0,0
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,lengthy protocols,4.0,0.1216435506939888
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,infected patients,4.0,0.2552550472319126
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,including powassan,4.0,0.06332606077194214
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,genomic surveillance,4.0,0.19439147785305977
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,genome coverage,4.0,0.09967924654483795
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,generally needed,4.0,0.02674674242734909
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,field use,4.0,0.058196757920086384
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,either benchtop,4.0,0.11202492192387581
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,diagnostic laboratory,4.0,0.3936236500740051
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,clinical samples,4.0,0.27576604671776295
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,capture probes,4.0,0.07700442895293236
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,low cost,3.5,0.04937576688826084
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,high cost,3.5,0.047133004292845726
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sequences,3.0,0.03171074762940407
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,rna,3.0,0
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,detection,3.0,0.17702502012252808
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,msspe,2.8,0
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,sensitivity,2.6666666666666665,0.0724399983882904
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,method,2.0,0.016362402588129044
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,low,1.5,0.06519334763288498
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,high,1.5,0.06070782244205475
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,zika,1.0,0
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,yielding,1.0,0.021416712552309036
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,usutu,1.0,0
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,simple,1.0,-0.0471973717212677
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,priori,1.0,0.06202193722128868
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,pathogens,1.0,0.09530304372310638
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,notably,1.0,0.056873396039009094
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,making,1.0,-0.03939424455165863
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,limited,1.0,0.009723823517560959
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,fast,1.0,0.029178690165281296
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,emerging,1.0,0.12356212735176086
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,ebola,1.0,0.021312974393367767
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,dna,1.0,-0.015949951484799385
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,deployable,1.0,0.03742877021431923
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,dengue,1.0,0.12166149169206619
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,cross,1.0,0.1382628083229065
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,contamination,1.0,0.02167564444243908
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,comparable,1.0,0.07046344876289368
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,co,1.0,0.08638649433851242
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,chikungunya,1.0,0.12630540132522583
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,broad,1.0,0.06394508481025696
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,breadth,1.0,0.07947862148284912
Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.,accuracy,1.0,0.05023651197552681
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,random forest classification algorithm revealed,23.0,0.023757678642868995
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam markers across three tissues,18.733333333333334,0.0709637813270092
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,three different sample sources,16.5,0.041682141716592014
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,peripheral blood mononuclear cells,15.666666666666666,0.16128713637590408
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,central airway epithelial cells,15.166666666666666,0.12305069155991077
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,rapgefxxx gene might interact,15.0,0.06221134463946024
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,based dnam signatures exerted,14.166666666666666,0.01980481979747613
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,specific dnam markers classify,13.566666666666666,0.04337199653188387
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,"pbmc -, nec -,",13.0,0.11377857625484467
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,wide dna methylation levels,12.5,0.05782374134287238
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,"xxx ), xxx loci",10.666666666666666,0.02788062517841657
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,nasal epithelial cells,10.166666666666666,0.1074996069073677
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma across tissues,10.166666666666666,0.1304762860139211
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,machine learning algorithm,10.0,0.048465583473443985
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,lower classification error,10.0,0.029133873681227367
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,based dnam markers,9.566666666666666,0.06165548413991928
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,associated methylation markers,9.4,0.0851381594936053
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,overlap analysis across,9.166666666666666,0.08697239061196645
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,unique pathophysiological processes,8.5,0.09294130156437556
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,top xxx asthma,8.0,0.08313834853470325
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,obtained xxx subjects,8.0,0.040198939541975655
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,bag errors using,8.0,-0.02964676295717557
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,predict asthma risk,7.0,0.148760624229908
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,specific markers,6.4,0.06364664807915688
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dna methylation,6.0,0.0501743545755744
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam levels,5.666666666666666,0.04464932531118393
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx loci,5.5,0.04978838283568621
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,analysis based,5.5,0.09426182880997658
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,"xxx ),",5.166666666666666,-0.015934890136122704
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx subjects,5.0,0.060638112016022205
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cdhxxx gene,5.0,0.13568075001239777
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx controls,4.5,0.021380837075412273
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx ).,4.5,-0.015934890136122704
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathway levels,4.5,0.0496255848556757
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathological processes,4.5,0.11578480899333954
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,jointly predict,4.5,0.03758827969431877
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,efficacy levels,4.5,0.11919186636805534
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,"necs ),",4.166666666666666,0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,results using,4.0,0.011758856475353241
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pivotal role,4.0,0.06431124173104763
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pathological changes,4.0,0.08055469393730164
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,optimal subset,4.0,0.10311964154243469
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,measured using,4.0,0.01618562638759613
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,may play,4.0,0.02951589785516262
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,key role,4.0,0.05408843792974949
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,investigate shared,4.0,0.04026031494140625
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,diagnostic performance,4.0,0.26163750514388084
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,current study,4.0,0.1360595915466547
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cpg sites,4.0,0.05223437398672104
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,also discovered,4.0,0.029014802537858486
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,locus interaction,3.666666666666667,0.05765111744403839
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,locus effects,3.666666666666667,0.0617215633392334
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pbmcs ).,3.5,0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cell junction,3.5,0.08838457986712456
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dnam,3.1666666666666665,0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,xxx,2.5,-0.015934890136122704
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pbmc,2.5,0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,nec,2.5,0.11377857625484467
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,asthma,2.5,0.2230728715658188
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,using,2.0,-0.04173736274242401
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,risk,2.0,0.19420234858989716
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,locus,1.6666666666666667,0.08330907672643661
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,pbmcs,1.5,0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,necs,1.5,0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,cell,1.5,0.10350311547517776
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,warranted,1.0,0.049046266824007034
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,value,1.0,0.012530318461358547
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,tissue,1.0,0.17500048875808716
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,suggests,1.0,0.041627660393714905
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,studied,1.0,0.20383524894714355
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,respectively,1.0,0.08458003401756287
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,research,1.0,0.27731871604919434
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,profiles,1.0,0.015331141650676727
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,p,1.0,0.11820723116397858
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,multi,1.0,0.048057474195957184
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,goal,1.0,0.06500711292028427
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,found,1.0,0.03727259859442711
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,focused,1.0,0.060328997671604156
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,evaluate,1.0,0.08850531280040741
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,epigenome,1.0,0.2085411250591278
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,dataset,1.0,0.1345919519662857
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,curve,1.0,-0.04778170958161354
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,context,1.0,0.04743277281522751
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,compare,1.0,0.09237030148506165
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,classifiers,1.0,0.01899723708629608
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,auc,1.0,-0.016484811902046204
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,area,1.0,0.1299571692943573
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,aecs,1.0,0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,aec,1.0,0
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma.,additionally,1.0,0.012068133801221848
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,automatically detect nocturnal hypoglycemia using,22.666666666666668,0.07286923974752427
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,visualisation method enabling clinicians,16.0,0.15729086908201376
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,tight glucose monitoring reduces,15.5,0.10141230933368206
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,raw ecg signal recorded,14.0,0.08821557089686394
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,blood glucose levels,9.5,0.12890821943680444
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,xxx consecutive days,9.0,-0.007747483129302661
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,previous studies based,9.0,0.12067770461241405
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,monitored xxx hours,9.0,0.05900219144920508
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,crucial diabetic patients,8.0,0.2570076634486516
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ecg signal,6.0,0.18263478577136993
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,diabetic patients,5.0,0.3626551181077957
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia affects,4.666666666666666,0.10820268839597702
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,wearable devices,4.0,0.17093516886234283
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subjects failed,4.0,0.06553647574037313
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,strong inter,4.0,0.060590051114559174
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,specific conditions,4.0,0.06827175989747047
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,significantly associated,4.0,0.10379760712385178
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,results advance,4.0,0.0595612283796072
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,learning methods,4.0,0.026072733104228973
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,intelligibility problem,4.0,0.04237242182716727
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemic event,4.0,0.09281031414866447
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,healthy subjects,4.0,0.1198251061141491
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,healthy individuals,4.0,0.07825295999646187
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,"g .,",4.0,0.02275453880429268
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,deploy electrocardiogram,4.0,0.17002745997160673
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,artificial intelligence,4.0,0.1279079094529152
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subject heterogeneity,3.5,0.08142948150634766
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,hypoglycemia,2.6666666666666665,0.166548490524292
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,subject,1.5,0.022654160857200623
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,wave,1.0,0.00466490164399147
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,visualise,1.0,0
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,tracking,1.0,0.03154240548610687
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,time,1.0,0.05442593991756439
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,st,1.0,-0.026569277048110962
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,series,1.0,0.054160453379154205
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,seizure,1.0,0.036535464227199554
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,risk,1.0,0.19420234858989716
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,result,1.0,0.009511183947324753
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,real,1.0,0.02762891724705696
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,present,1.0,0.0756206065416336
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,part,1.0,0.037912048399448395
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,overcoming,1.0,0.02182142436504364
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,non,1.0,0.06398928165435791
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,irritability,1.0,0.03948258236050606
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,invasive,1.0,0.19703441858291626
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,interval,1.0,0.14205302298069
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,important,1.0,0.07185453921556473
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,however,1.0,-0.011453256011009216
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,heartbeats,1.0,0.22334828972816467
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,heart,1.0,0.30470412969589233
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,fluctuations,1.0,0.0738903284072876
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,feasibility,1.0,0.11239571869373322
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,fatal,1.0,0.10084082186222076
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,even,1.0,0.015417572110891342
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,especially,1.0,0.09752822667360306
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,electrophysiology,1.0,0.6528501510620117
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,e,1.0,0.042460739612579346
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,due,1.0,-0.005625979043543339
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,deep,1.0,0.045967910438776016
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,confusion,1.0,0.014717166312038898
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,complications,1.0,0.2546522915363312
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,cohort,1.0,0.15340903401374817
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,ai,1.0,0.07966839522123337
Precision Medicine and Artificial Intelligence: A Pilot Study on Deep Learning for Hypoglycemic Events Detection based on ECG.,additionally,1.0,0.012068133801221848
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,induced cardiac toxicity among patients,19.055555555555557,0.2611809652298689
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,repeat ann analysis using dosimetry,17.166666666666664,0.10916580557823181
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,undergone stereotactic ablative radiotherapy,15.0,0.2738480754196644
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dose neutral structure confirmed,14.666666666666666,0.01576175494119525
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,including cardiac dosimetry parameters,14.38888888888889,0.2722908668220043
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,stage nsclc undergoing sabr,12.0,0.10231232643127441
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,modulate confounding behaviors,9.0,0.04818002010385195
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,locally advanced non,9.0,0.06425461297233899
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cell lung cancer,9.0,0.19772735486427942
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,artificial neural network,9.0,0.10054086024562518
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx years vs,8.75,0.03865000667671362
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx input features,8.75,0.0004933439195156097
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac radiation dosimetry,8.63888888888889,0.3874152998129527
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx years ).,8.25,0.017363430000841618
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx cardiac substructures,8.13888888888889,0.24399154198666415
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,significantly longer os,8.0,0.06576568509141605
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac radiation dose,7.805555555555555,0.2923531432946523
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rv vxxxgy dose,6.666666666666666,0.05191740021109581
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac toxicity,6.388888888888889,0.3775479719042778
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac dosimetry,6.388888888888889,0.4814695715904236
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,stage nsclc,5.666666666666666,0.05508729815483093
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,os using,5.5,0.006993578746914864
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx patients,5.416666666666666,0.2216808618977666
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac substructures,5.388888888888889,0.37395475804805756
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,undergone sabr,5.333333333333334,0.11024421453475952
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,nsclc ).,5.166666666666666,0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann analysis,5.166666666666666,0.06903650611639023
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation dose,4.916666666666666,0.12889187037944794
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,cardiac follow,4.888888888888889,0.3526470884680748
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx %.,4.75,-0.015934890136122704
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,mean dose,4.666666666666666,0.06809468939900398
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,maximum dose,4.666666666666666,0.018855048343539238
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,present analysis,4.5,0.08948754519224167
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,test accuracy,4.0,0.06708875112235546
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,single institution,4.0,0.06403937749564648
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rv vxxxgy,4.0,0.04535781592130661
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,risk might,4.0,0.09812851250171661
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rights reserved,4.0,0.030988029204308987
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,right ventricle,4.0,0.08423669962212443
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predictive power,4.0,0.10997296869754791
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,meier method,4.0,0.02466774173080921
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,less well,4.0,0.07417707145214081
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,important predictor,4.0,0.09338973462581635
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,dosimetric variables,4.0,0.16231437306851149
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,decreased os,4.0,0.050335654988884926
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,data support,4.0,0.060604334343224764
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,whole heart,3.5,0.1958015188574791
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,overall survival,3.5,0.08623267896473408
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,negatively predicted,3.5,0.03199911257252097
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,xxx,2.75,-0.015934890136122704
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,patients,2.6666666666666665,0.4592966139316559
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,ann,2.6666666666666665,0.034718528389930725
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analysis,2.5,0.10335448384284973
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,sabr,2.3333333333333335,0.09470625221729279
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,radiation,2.25,0.19930675625801086
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,vxxxgy,2.0,0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,rv,2.0,0.04535781592130661
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,os,2.0,0.05572452023625374
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,survival,1.5,0.13855862617492676
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predicted,1.5,0.05830582231283188
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,heart,1.5,0.30470412969589233
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,warranted,1.0,0.049046266824007034
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,total,1.0,0.003683900460600853
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,subvolumes,1.0,0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,small,1.0,0.03130773827433586
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,results,1.0,0.0652550756931305
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,received,1.0,0.012420294806361198
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,prioritizing,1.0,0.07201765477657318
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,predict,1.0,0.029006652534008026
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,performed,1.0,0.1553603708744049
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,organ,1.0,0.20346218347549438
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,objective,1.0,0.01818794757127762
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,minimizing,1.0,0.0323416143655777
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,methods,1.0,0.024640876799821854
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,materials,1.0,0.04768626391887665
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,kaplan,1.0,0
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,introduction,1.0,0.021546807140111923
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,included,1.0,0.029688812792301178
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,importance,1.0,0.08358374238014221
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,however,1.0,-0.011453256011009216
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,early,1.0,0.03449202701449394
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,considered,1.0,0.11262063682079315
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,conclusion,1.0,0.03420025110244751
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,characterized,1.0,0.05963318794965744
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,associations,1.0,0.07526065409183502
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,association,1.0,0.10596190392971039
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,associated,1.0,0.10097402334213257
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,assess,1.0,0.061772990971803665
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,analyzed,1.0,0.13667140901088715
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.,additionally,1.0,0.012068133801221848
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,induced injury models representing ckd,18.583333333333332,0.06428309204056859
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reperfusion injury model showed increase,18.166666666666664,0.08531399518251419
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,implicates aryl hydrocarbon receptor,16.0,0.07877596653997898
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,blood urea nitrogen levels,15.0,0.07484954409301281
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,transgenic mouse line expressing,14.5,0.044462861493229866
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,translationally relevant animal models,14.25,0.10451737605035305
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,serum indoxyl sulfate levels,12.5,0.057381595174471535
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,acute kidney injury,10.333333333333332,0.22788383439183235
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,serum indoxyl sulfate,9.5,0.06374773010611534
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reporter gene mouse,9.5,0.052178144454956055
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,persisted despite reduction,9.0,0.05686705435315768
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,kidney diseases using,9.0,0.14261628687381744
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl sulfate levels,9.0,0.07446230575442314
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,following validation using,9.0,0.03875246147314707
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,fed mice showed,9.0,0.046836684147516884
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,"dioxin derivative ),",9.0,0.02039101254194975
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,chronic kidney disease,9.0,0.20107183357079825
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase increase coincided,8.583333333333334,0.0375749704738458
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase reporter gene,8.25,0.06700308124224345
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,distal renal tubules,8.0,0.2618601322174072
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,canonical ahr ligand,8.0,0.04182950034737587
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,"aki ), respectively",8.0,0.07446910440921783
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,animal models,6.25,0.10543617233633995
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,indoxyl sulfate,6.0,0.10427528619766235
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,significant increase,5.333333333333334,0.06752268224954605
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,discrete models,5.25,0.07559778541326523
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,specific model,5.166666666666667,0.07189378701150417
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,transgenic mice,5.0,0.11334550380706787
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,renal tubules,5.0,0.3186631500720978
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase expression,4.25,0.019622274674475193
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,various tissues,4.0,0.08639504015445709
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,uremic toxicity,4.0,0.18517572432756424
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,study demonstrates,4.0,0.13596440106630325
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,results demonstrate,4.0,0.04682372510433197
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,provide hypothesis,4.0,0.0792127326130867
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,promoter tethered,4.0,0.02839609421789646
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,generating insights,4.0,0.11741924285888672
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,emerging evidence,4.0,0.09086420573294163
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,elsevier inc,4.0,0.007824641652405262
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,drinking water,4.0,0.06393536180257797
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,dependent activation,4.0,0.05984760448336601
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,comprehensive analysis,4.0,0.0983453206717968
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,cerebral cortex,4.0,0.16239580512046814
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,cardiac myocytes,4.0,0.404574990272522
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,artificially increased,4.0,0.047837682999670506
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr responsive,4.0,0.023736486211419106
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr induction,4.0,0.05226786620914936
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr activation,4.0,0.04509698413312435
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,specific manifestations,3.666666666666667,0.06636909395456314
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,probe tissue,3.5,0.1443043164908886
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,reperfusion,3.0,0.21687349677085876
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,levels,3.0,0.04464932531118393
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,induced,3.0,-0.006984012201428413
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ckd,3.0,0
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,galactosidase,2.25,0.038687899708747864
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mice,2.0,0.08878521621227264
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,aki,2.0,0.0643581748008728
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ahr,2.0,0.006809871643781662
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,specific,1.6666666666666667,0.08915150165557861
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,tissue,1.5,0.17500048875808716
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,β,1.0,0.06373848021030426
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,warrant,1.0,0.09318732470273972
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,use,1.0,0.0033735278993844986
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,urine,1.0,0.049266472458839417
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,uremia,1.0,0.19908669590950012
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,time,1.0,0.05442593991756439
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,thus,1.0,-0.023273250088095665
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,subjected,1.0,-0.031078075990080833
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,signaling,1.0,0.05109945684671402
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,response,1.0,0.05596902221441269
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,relationship,1.0,0.0036004912108182907
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,recapitulated,1.0,0.09843818843364716
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,published,1.0,0.10513044893741608
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,proximal,1.0,0.17394670844078064
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,pattern,1.0,0.04877403751015663
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,microvasculature,1.0,0.27667921781539917
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mediator,1.0,0.0685284212231636
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,mechanism,1.0,0.045044392347335815
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,machine,1.0,0.04470905661582947
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,learning,1.0,0.027504589408636093
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,ischemia,1.0,0.27857813239097595
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,investigation,1.0,0.0926906168460846
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,inhibiting,1.0,0.01660192385315895
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,humans,1.0,0.06040411442518234
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,however,1.0,-0.011453256011009216
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,hepatocytes,1.0,0.09208139777183533
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,excretion,1.0,0.04911281168460846
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,distinct,1.0,0.00011970847845077515
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,details,1.0,0.005935193970799446
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,conducted,1.0,0.055469855666160583
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,changes,1.0,-0.006772637367248535
Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease.,adenine,1.0,0.005901865661144257
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,previously published machine learning algorithm,25.0,0.05311735942959785
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,participants ≥ xxx years old,22.142857142857142,0.05992766655981541
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep heart health study,14.4,0.2562171183526516
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,years per standard,10.0,0.05278274230659008
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx [- xxx,9.285714285714285,-0.015934890136122704
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,"xxx ], p",9.142857142857142,0.05113617051392794
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,adjusted hazard ratio,9.0,0.0643040935198466
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,overnight sleep electroencephalogram,8.4,0.13963889641066393
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,"age norms ),",8.333333333333334,0.09089286625385284
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,reduced life expectancy,8.333333333333332,0.07977507884303729
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life expectancy decreased,8.333333333333332,0.08221983412901561
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,excess brain age,8.0,0.09863210531572501
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,comparing eeg features,8.0,0.06427210755646229
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain age index,8.0,0.12767832477887472
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,life expectancy,5.333333333333333,0.10085635632276535
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx ).,5.142857142857142,-0.015934890136122704
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,brain age,5.0,0.13737871497869492
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep microstructure,4.4,0.11192703992128372
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep eeg,4.4,0.16289515793323517
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,chronological age,4.333333333333334,0.10039451345801353
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,rights reserved,4.0,0.030988029204308987
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,quantified using,4.0,-0.0027791615575551987
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,patterns normal,4.0,0.07037824019789696
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,independent predictor,4.0,0.06677553988993168
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,findings show,4.0,0.1106913685798645
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,based biomarker,4.0,0.19838448241353035
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,deviation increase,3.5,0.07744038105010986
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ca );,3.5,0.030504325404763222
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,xxx,3.142857142857143,-0.015934890136122704
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,sleep,2.4,0.16289515793323517
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,age,2.3333333333333335,0.10348664224147797
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,eeg,2.0,0
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,deviation,1.5,0.0922837108373642
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ca,1.5,0.030504325404763222
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,underwent,1.0,0.19980251789093018
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,part,1.0,0.037912048399448395
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,n,1.0,-0.021267158910632133
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,measures,1.0,0.031176652759313583
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,individual,1.0,0.01554524153470993
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,estimated,1.0,0.0099962018430233
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,difference,1.0,0.05812316760420799
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,cohort,1.0,0.15340903401374817
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,bai,1.0,0.06427306681871414
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,ba,1.0,0.02534140646457672
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,associated,1.0,0.10097402334213257
Excess brain age in the sleep electroencephalogram predicts reduced life expectancy.,apparent,1.0,0.05247381702065468
Gated recurrent unit-based heart sound analysis for heart failure screening.,novel hf screening framework based,20.083333333333332,0.09322609603405
Gated recurrent unit-based heart sound analysis for heart failure screening.,conveys relevant information related,16.0,0.07303400139790028
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf screening without de,14.75,0.07420177292078733
Gated recurrent unit-based heart sound analysis for heart failure screening.,reduced ejection fraction automatically,14.0,0.015764055773615837
Gated recurrent unit-based heart sound analysis for heart failure screening.,preserved ejection fraction,10.0,-0.0003367569297552109
Gated recurrent unit-based heart sound analysis for heart failure screening.,based hidden semi,9.333333333333334,0.031127265344063442
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf early screening,9.25,0.09833873187502225
Gated recurrent unit-based heart sound analysis for heart failure screening.,gated recurrent unit,9.0,0.15254432956377664
Gated recurrent unit-based heart sound analysis for heart failure screening.,crafted feature extraction,9.0,0.0278667410214742
Gated recurrent unit-based heart sound analysis for heart failure screening.,cardiovascular disease caused,9.0,0.2552662380039692
Gated recurrent unit-based heart sound analysis for heart failure screening.,abnormal cardiac structure,9.0,0.28137923156221706
Gated recurrent unit-based heart sound analysis for heart failure screening.,good performance demonstrates,8.0,0.04549215485652288
Gated recurrent unit-based heart sound analysis for heart failure screening.,gru model gives,7.533333333333333,0.027140002232044935
Gated recurrent unit-based heart sound analysis for heart failure screening.,segment hs frames,7.5,0.010015912664433321
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed gru model,6.533333333333334,0.054264677688479424
Gated recurrent unit-based heart sound analysis for heart failure screening.,early screening,6.0,0.09201321564614773
Gated recurrent unit-based heart sound analysis for heart failure screening.,therefore based,5.333333333333334,0.054697250947356224
Gated recurrent unit-based heart sound analysis for heart failure screening.,automatically learn,5.0,0.03765938617289066
Gated recurrent unit-based heart sound analysis for heart failure screening.,normalized frames,4.5,0.020375743974000216
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed model,4.2,0.054264677688479424
Gated recurrent unit-based heart sound analysis for heart failure screening.,markov model,4.2,0.05463607236742973
Gated recurrent unit-based heart sound analysis for heart failure screening.,timely manner,4.0,0.01326160691678524
Gated recurrent unit-based heart sound analysis for heart failure screening.,satisfactory performance,4.0,0.053107086569070816
Gated recurrent unit-based heart sound analysis for heart failure screening.,logistic regression,4.0,0.08010278269648552
Gated recurrent unit-based heart sound analysis for heart failure screening.,learn features,4.0,0.03278607875108719
Gated recurrent unit-based heart sound analysis for heart failure screening.,important implication,4.0,0.06380340456962585
Gated recurrent unit-based heart sound analysis for heart failure screening.,identify subjects,4.0,0.09229006804525852
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs signals,4.0,-0.003248268738389015
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs directly,4.0,0.012654533609747887
Gated recurrent unit-based heart sound analysis for heart failure screening.,heart sound,4.0,0.16543865762650967
Gated recurrent unit-based heart sound analysis for heart failure screening.,heart failure,4.0,0.2074820026755333
Gated recurrent unit-based heart sound analysis for heart failure screening.,expert knowledge,4.0,0.1035585068166256
Gated recurrent unit-based heart sound analysis for heart failure screening.,efficient tool,4.0,0.03821410611271858
Gated recurrent unit-based heart sound analysis for heart failure screening.,deep features,4.0,0.04473218321800232
Gated recurrent unit-based heart sound analysis for heart failure screening.,average accuracy,4.0,0.0271481997333467
Gated recurrent unit-based heart sound analysis for heart failure screening.,"xxx %,",3.5,-0.015934890136122704
Gated recurrent unit-based heart sound analysis for heart failure screening.,three methods,3.5,0.0509991105645895
Gated recurrent unit-based heart sound analysis for heart failure screening.,results show,3.5,0.037321701645851135
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs analysis,3.5,0.048361023887991905
Gated recurrent unit-based heart sound analysis for heart failure screening.,comparison models,3.5,0.11063048616051674
Gated recurrent unit-based heart sound analysis for heart failure screening.,hf,3.25,0.1109897643327713
Gated recurrent unit-based heart sound analysis for heart failure screening.,gru,2.3333333333333335,0
Gated recurrent unit-based heart sound analysis for heart failure screening.,model,2.2,0.05463607236742973
Gated recurrent unit-based heart sound analysis for heart failure screening.,proposed,2.0,0.053893283009529114
Gated recurrent unit-based heart sound analysis for heart failure screening.,performance,2.0,0.034930430352687836
Gated recurrent unit-based heart sound analysis for heart failure screening.,hs,2.0,-0.006632436066865921
Gated recurrent unit-based heart sound analysis for heart failure screening.,xxx,1.5,-0.015934890136122704
Gated recurrent unit-based heart sound analysis for heart failure screening.,results,1.5,0.0652550756931305
Gated recurrent unit-based heart sound analysis for heart failure screening.,methods,1.5,0.024640876799821854
Gated recurrent unit-based heart sound analysis for heart failure screening.,comparison,1.5,0.11286726593971252
Gated recurrent unit-based heart sound analysis for heart failure screening.,analysis,1.5,0.10335448384284973
Gated recurrent unit-based heart sound analysis for heart failure screening.,used,1.0,0.010911919176578522
Gated recurrent unit-based heart sound analysis for heart failure screening.,type,1.0,0.038444433361291885
Gated recurrent unit-based heart sound analysis for heart failure screening.,treatment,1.0,0.27399298548698425
Gated recurrent unit-based heart sound analysis for heart failure screening.,taken,1.0,0.015877021476626396
Gated recurrent unit-based heart sound analysis for heart failure screening.,study,1.0,0.2376001477241516
Gated recurrent unit-based heart sound analysis for heart failure screening.,objective,1.0,0.01818794757127762
Gated recurrent unit-based heart sound analysis for heart failure screening.,nosing,1.0,-0.027487633749842644
Gated recurrent unit-based heart sound analysis for heart failure screening.,normal,1.0,0.08618243783712387
Gated recurrent unit-based heart sound analysis for heart failure screening.,means,1.0,-0.011965315788984299
Gated recurrent unit-based heart sound analysis for heart failure screening.,input,1.0,-0.02608153410255909
Gated recurrent unit-based heart sound analysis for heart failure screening.,independent,1.0,0.018626149743795395
Gated recurrent unit-based heart sound analysis for heart failure screening.,hand,1.0,-0.03252475708723068
Gated recurrent unit-based heart sound analysis for heart failure screening.,function,1.0,0.11069313436746597
Gated recurrent unit-based heart sound analysis for heart failure screening.,evaluate,1.0,0.08850531280040741
Gated recurrent unit-based heart sound analysis for heart failure screening.,effectiveness,1.0,0.07677281647920609
Gated recurrent unit-based heart sound analysis for heart failure screening.,develop,1.0,0.10439212620258331
Gated recurrent unit-based heart sound analysis for heart failure screening.,conclusion,1.0,0.03420025110244751
Gated recurrent unit-based heart sound analysis for heart failure screening.,complete,1.0,-0.01845567114651203
Gated recurrent unit-based heart sound analysis for heart failure screening.,better,1.0,0.06907322257757187
Gated recurrent unit-based heart sound analysis for heart failure screening.,background,1.0,0.03833860531449318
Gated recurrent unit-based heart sound analysis for heart failure screening.,adopted,1.0,0.036430153995752335
Gated recurrent unit-based heart sound analysis for heart failure screening.,addition,1.0,0.1140233725309372
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,improve coronary heart disease,16.0,0.2537367455661297
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,even advanced multivariate subgrouping,14.75,0.08917408064007759
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,comprehensive lipoprotein subclass data,12.333333333333332,0.11742260865867138
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,advance chd risk assessment,11.833333333333334,0.11066222563385963
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,artificial intelligence methodology,9.0,0.1003768468896548
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,also striking dose,9.0,0.02974361926317215
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,driven metabolic subgrouping,8.75,0.15189987793564796
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,distinct lipoprotein profiles,8.666666666666666,0.0863042523463567
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,detailed lipoprotein profiles,8.666666666666666,0.102725800126791
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,containing lipoprotein particles,8.666666666666666,0.07924254486958186
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,scale population cohorts,8.0,0.06907390306393306
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,identified four som,8.0,0.040186176697413124
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,mediated chd risk,7.833333333333334,0.13930997997522354
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein b quartiles,7.833333333333334,0.11799608170986176
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,define subgroups based,7.5,0.06915139313787222
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,comprehensive data,5.666666666666666,0.09975692257285118
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk assessment,5.333333333333334,0.1390596479177475
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd risk,4.833333333333334,0.19420234858989716
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,apolipoprotein b,4.833333333333334,0.11756717413663864
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,univariate subgrouping,4.75,0.17608550190925598
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,population subgrouping,4.75,0.1400190144777298
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,unsupervised data,4.666666666666666,0.062471356242895126
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein metabolism,4.666666666666666,0.2194259911775589
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based subgroups,4.5,0.10964987054467201
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lowest risk,4.333333333333334,0.10560203809291124
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,elsevier b,4.333333333333334,0.033724576234817505
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,xxx ).,4.0,-0.015934890136122704
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,would work,4.0,0.049196621403098106
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,trained som,4.0,0.0373152419924736
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,rights reserved,4.0,0.030988029204308987
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,response behaviour,4.0,0.05596902221441269
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,organizing map,4.0,0.04522853624075651
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lowest concentrations,4.0,0.05109940189868212
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,independent cohort,4.0,0.08601759187877178
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,hdl measures,4.0,0.04244064353406429
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based cohort,4.0,0.1192891038954258
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,results suggest,3.5,0.05601985938847065
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,highest concentrations,3.5,0.059084730222821236
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based subgroup,3.5,0.08692967146635056
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,lipoprotein,2.6666666666666665,0.24346190690994263
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,chd,2.5,0
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,risk,2.3333333333333335,0.19420234858989716
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,xxx,2.0,-0.015934890136122704
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,som,2.0,-0.0491781085729599
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,population,2.0,0.1400190144777298
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,based,2.0,0.08516917377710342
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,subgroup,1.5,0.08869016915559769
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,results,1.5,0.0652550756931305
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,highest,1.5,0.03297238424420357
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,v,1.0,0.019843820482492447
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,utilised,1.0,0
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,therefore,1.0,0.024225328117609024
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,suggested,1.0,0.05237164720892906
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,self,1.0,0.05501733347773552
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,published,1.0,0.10513044893741608
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,non,1.0,0.06398928165435791
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,n,1.0,-0.021267158910632133
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,methods,1.0,0.024640876799821854
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,means,1.0,-0.011965315788984299
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,may,1.0,-0.009713593870401382
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,majority,1.0,0.026061898097395897
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,large,1.0,0.07130777090787888
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,individuals,1.0,0.054066821932792664
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,however,1.0,-0.011453256011009216
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,explored,1.0,0.10362917929887772
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,explained,1.0,0.09177323430776596
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,conclusions,1.0,0.07628431916236877
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,compared,1.0,0.10162706673145294
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,background,1.0,0.03833860531449318
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,authors,1.0,0.21598771214485168
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,applied,1.0,0.006987035274505615
Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease.,aims,1.0,0.04269438236951828
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,angptlxxx show instead lower tg,20.3,0.06504038535058498
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,targets also partially reduces ldl,20.166666666666668,0.03516053128987551
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,"c ), ascvd risk",13.333333333333334,0.11769891902804375
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,new therapeutic targets,9.5,0.14279050131638846
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,"ascvd ), genetic",9.333333333333334,0.14568692445755005
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,metabolic abnormalities characterized,9.0,0.18973019470771155
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,better pharmacological target,9.0,0.1205684741338094
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,atherosclerotic cardiovascular disease,9.0,0.32278160750865936
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,angptlxxx induces activation,8.8,0.047091588377952576
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,major side effects,8.5,0.045416937520106636
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx clinical trials,8.333333333333334,0.20175497544308504
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,"lpl ), antagonizing",8.333333333333334,0.0913989245891571
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,like proteins xxx,8.333333333333334,0.049062421545386314
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antisense oligonucleotide angptlxxx,8.3,0.1572440043091774
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,density lipoprotein cholesterol,7.833333333333334,0.20296098291873932
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,also dependent,5.5,0.03940634988248348
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,new angptlxxx,5.3,0.10631739348173141
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,density lipoprotein,4.833333333333334,0.18309740722179413
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ldl receptor,4.666666666666666,0.09437026083469391
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg ).,4.5,0.11089863628149033
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,plasma tg,4.5,0.1409715972840786
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,major role,4.5,0.057752544060349464
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,antisense oligonucleotides,4.5,0.1439826749265194
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx antagonists,4.333333333333334,0.045743984170258045
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,phase xxx,4.333333333333334,-0.001776871271431446
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoprotein lipase,4.333333333333334,0.1796080730855465
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,still needed,4.0,0.02503137569874525
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,similar evidence,4.0,0.07097295485436916
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,significant increase,4.0,0.06752268224954605
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,provided data,4.0,0.04858158901333809
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,prandial levels,4.0,0.07011855766177177
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,plasma levels,4.0,0.1078469417989254
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,murine models,4.0,0.11007319390773773
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,monoclonal antibodies,4.0,0.12355393916368484
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,marked reduction,4.0,0.05334847792983055
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,including non,4.0,0.06365767121315002
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,human primates,4.0,0.09901634976267815
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,genetic studies,4.0,0.19772488623857498
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,function mutations,4.0,0.10775118693709373
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,experimental evidence,4.0,0.11312074400484562
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,elsevier ltd,4.0,0.036545224487781525
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,elevated fasting,4.0,0.11189347133040428
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,efficacy profile,4.0,0.13016825541853905
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,conclusive data,4.0,0.09317950531840324
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,atherogenic dyslipidemias,4.0,0.2651878297328949
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,apparently without,4.0,-0.03499055653810501
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,animal models,4.0,0.10543617233633995
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,term treatment,3.5,0.16576884500682354
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,head comparison,3.5,0.09867046773433685
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,hdl ).,3.5,0.053704634308815
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,beyond low,3.5,0.03432120382785797
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,rich lipoproteins,3.0,0.08345704339444637
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,angptlxxx,2.8,0
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,ldl,2.6666666666666665,0
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,tg,2.5,0.11089863628149033
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,c,2.5,0.04119548946619034
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,xxx,2.3333333333333335,-0.015934890136122704
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lpl,2.0,0
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,treatment,1.5,0.27399298548698425
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,studies,1.5,0.24976284801959991
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,rich,1.5,0.03535805270075798
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,low,1.5,0.06519334763288498
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lipoproteins,1.5,0.13155603408813477
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,head,1.5,0.08447366952896118
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,hdl,1.5,0.053704634308815
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,way,1.0,-0.018800776451826096
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,vldl,1.0,0
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,triglycerides,1.0,0.22974732518196106
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,short,1.0,0.011583387851715088
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,safety,1.0,0.19278490543365479
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,remnants,1.0,-0.07162114977836609
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,relevance,1.0,0.032082222402095795
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,regulating,1.0,0.07387600094079971
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,published,1.0,0.10513044893741608
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,proven,1.0,0.05978071689605713
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,post,1.0,0.10225207358598709
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,paved,1.0,0.008062216453254223
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,order,1.0,-0.015195201151072979
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,observed,1.0,0.08740169554948807
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,modest,1.0,0.026598036289215088
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,lrx,1.0,0
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,loss,1.0,0.0528750903904438
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,inhibition,1.0,0.03232728689908981
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,independent,1.0,0.018626149743795395
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,indeed,1.0,0.02782384306192398
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,hypertriglyceridemia,1.0,0.2080441117286682
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,hydrolysis,1.0,-0.02199055254459381
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,humans,1.0,0.06040411442518234
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,high,1.0,0.06070782244205475
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,found,1.0,0.03727259859442711
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,former,1.0,0.023285511881113052
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,development,1.0,0.1793753206729889
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,determinants,1.0,0.14320151507854462
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,demonstrated,1.0,0.0564635805785656
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,define,1.0,-0.011845561675727367
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,cluster,1.0,0.13339947164058685
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,carriers,1.0,0.0009299982339143753
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,associated,1.0,0.10097402334213257
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,angiopoietin,1.0,0.098587267100811
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,among,1.0,0.09849628061056137
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia.,activity,1.0,0.01650470495223999
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,approved drug targeting ikkε,15.0,0.11822428057591121
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,combined genetic mouse model,14.5,0.06208374258130789
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,human breast cancer tissues,13.95,0.17000863142311573
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast cancer oncogene ikkε,13.45,0.20383465538422266
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,human healthy donors,9.5,0.10483638445536296
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast cancer associated,9.45,0.19615726669629416
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast tissue leading,9.2,0.15831726292769113
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,vivo tumour formation,9.0,0.11437010392546654
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,serine biosynthesis pathway,9.0,0.03813344364364942
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,potential therapeutic strategy,9.0,0.14621483782927194
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,factor considered responsible,9.0,0.052743569016456604
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,pathway connecting obesity,8.0,0.11911950632929802
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,grade chronic inflammation,8.0,0.09798703094323476
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,breast cancer,6.45,0.24374888837337494
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,pharmacological tools,4.0,0.11925086658447981
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,medium conditioned,4.0,-0.005938710644841194
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,macrophages infiltrate,4.0,0.09092675149440765
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,macrophages derived,4.0,0.047424687538295984
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,induced obesity,4.0,0.12821147497743368
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,homologue tbkxxx,4.0,0.03471856564283371
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,formally demonstrate,4.0,0.028481854125857353
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,fat diet,4.0,0.09509199112653732
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,driven inflammation,4.0,0.10050170496106148
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,downstream target,4.0,0.03712199069559574
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cellular metabolism,4.0,0.1656900942325592
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,xxx license,3.666666666666667,0.015934241004288197
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,higher risk,3.5,0.15365959703922272
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,ikkε,3.0,0
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,genetic,2.5,0.14568692445755005
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,obesity,2.0,0.2634069621562958
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,inflammation,2.0,0.16907447576522827
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,xxx,1.6666666666666667,-0.015934890136122704
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,risk,1.5,0.19420234858989716
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,validated,1.0,0.08453492820262909
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,terms,1.0,0.08489501476287842
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,reduce,1.0,0.08915511518716812
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,published,1.0,0.10513044893741608
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,mediated,1.0,0.08441761136054993
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,low,1.0,0.06519334763288498
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,link,1.0,0.0573977567255497
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,identified,1.0,0.10330121219158173
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,high,1.0,0.06070782244205475
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,furthermore,1.0,-0.04380498453974724
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,finally,1.0,-0.036436013877391815
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,fda,1.0,0.12308475375175476
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,exposed,1.0,0.025203905999660492
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,effects,1.0,0.04013404995203018
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,demonstrated,1.0,0.0564635805785656
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,delayed,1.0,0.022720033302903175
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,cc,1.0,0.1696670651435852
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,authors,1.0,0.21598771214485168
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,amlexanox,1.0,0
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,altogether,1.0,0.0018933191895484924
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.,alteration,1.0,0.0038754730485379696
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technologies mostly target older adults,20.2,0.08236526995897293
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,included three external variables,16.0,0.05303584737703204
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,using wearable healthcare technologies,14.25,0.16370974108576775
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,"e ., technology anxiety",13.666666666666666,0.10642477869987488
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived ubiquity construct affects,13.5,0.017020114697515965
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,sensor technologies represent,9.75,0.16466748714447021
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,including older adults,9.45,0.08684574936827023
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,using new technology,9.166666666666666,0.09094270318746567
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wearing smart clothes,9.0,0.04992654174566269
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,hypothesized model showed,9.0,0.06986963128050168
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,everyday health conditions,9.0,0.12047616268197696
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,continuously recording people,9.0,0.046656198178728424
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,among older adults,8.95,0.09856915598114331
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,mobile wireless technologies,8.75,0.16541812320550284
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology acceptance model,8.666666666666666,0.1127035307387511
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology acceptance behavior,8.666666666666666,0.10546111563841502
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,"xxx participants ),",8.5,0.025789902545511723
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,determining older users,8.2,0.0700897965580225
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,older adults,6.45,0.09860559366643429
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology anxiety,5.666666666666666,0.13840679824352264
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived ubiquity,5.5,-0.002799723297357559
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wearable devices,5.0,0.17093516886234283
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,xxx outpatients,4.5,0.19742601830512285
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,relationships among,4.5,0.05285274423658848
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived usefulness,4.5,0.04540914669632912
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perceived ease,4.5,0.03608732670545578
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,user groups,4.0,0.04403817653656006
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,traditional components,4.0,0.0581503976136446
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,original constructs,4.0,-0.018015174195170403
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,negative effect,4.0,0.01399598247371614
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,may enhance,4.0,0.04312879033386707
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,indirect effect,4.0,-0.011605968931689858
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,cardiovascular disease,4.0,0.3688889145851135
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,biomedical signals,4.0,0.2268461138010025
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,behavioral intention,4.0,0.07342912163585424
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,affect users,4.0,0.05771458335220814
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,tam ).,3.666666666666667,0.010671783238649368
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,extended tam,3.666666666666667,-0.0042148251086473465
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,risk patients,3.5,0.3267494812607765
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,technology,2.6666666666666665,0.2082480788230896
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,wireless,2.0,0.16406379640102386
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,users,2.0,0.05023464933037758
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,tam,1.6666666666666667,0.010671783238649368
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,patients,1.5,0.4592966139316559
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,validity,1.0,0.028293684124946594
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,validated,1.0,0.08453492820262909
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,use,1.0,0.0033735278993844986
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,understanding,1.0,0.037985511124134064
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,treatment,1.0,0.27399298548698425
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,study,1.0,0.2376001477241516
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,shown,1.0,0.044945128262043
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,results,1.0,0.0652550756931305
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,resistance,1.0,-0.012645460665225983
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,perception,1.0,0.037292104214429855
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,obtain,1.0,0.024071499705314636
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,method,1.0,0.016362402588129044
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,interestingly,1.0,0.01742842048406601
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,given,1.0,0.014340896159410477
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,general,1.0,0.14236244559288025
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,found,1.0,0.03727259859442711
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,examine,1.0,0.12551988661289215
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,diagnosis,1.0,0.24688632786273956
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,considered,1.0,0.11262063682079315
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,confirm,1.0,0.02169613540172577
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,characteristic,1.0,0.01731044426560402
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,change,1.0,-0.0021246224641799927
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,attitude,1.0,0.02193225920200348
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,advances,1.0,0.1283981204032898
Technology anxiety and resistance to change behavioral study of a wearable cardiac warming system using an extended TAM for older adults.,addition,1.0,0.1140233725309372
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,four thousand three hundred thirty,24.0,0.027090127021074294
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,population reporting positive dietary behaviours,17.533333333333335,0.07728529302403331
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx nationally representative surveys,14.375,0.022509508300572634
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,males reported positive sub,13.166666666666668,0.05812704190611839
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,related cvd risk factors,12.5,0.11482787256439526
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,"sub ), meeting fruit",11.833333333333334,0.09417998418211937
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive salt use behaviour,11.333333333333334,-0.0023972907414038977
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,three dietary behaviours,10.2,0.11732501164078712
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary behaviours related,9.7,0.14038702845573425
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive behaviours increases,9.533333333333333,0.0335276834666729
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,generalized linear models,9.0,0.053460544596115746
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary behaviour measurements,9.0,0.15240547806024551
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd risk factors,9.0,0.1105011198669672
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,"xxx %, varying",8.375,-0.019439718686044216
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,middle income countries,8.333333333333334,0.04233554440240065
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vegetable oil rather,8.0,0.05858286718527476
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,understand whether associations,8.0,0.03418383623162905
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sex would change,8.0,0.019359012444814045
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,"xxx %, p",7.375,0.05113617051392794
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary behaviours,6.2,0.1572926789522171
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dietary behaviour,6.0,0.1572926789522171
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd risk,5.5,0.19420234858989716
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,"xxx ),",5.375,-0.015934890136122704
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive subs,5.333333333333334,0.03651653602719307
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,positive manner,5.333333333333334,0.011260611936450005
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,poor sub,5.333333333333334,0.11069182306528091
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,understand whether,5.0,0.01364542730152607
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,meeting f,4.666666666666667,0.04576711729168892
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx ).,4.375,-0.015934890136122704
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,seven countries,4.333333333333334,0.055816229432821274
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx vs,4.041666666666667,0.03264413494616747
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vs xxx,4.041666666666667,0.03264413494616747
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,waist circumference,4.0,0.10453496873378754
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,urgently needed,4.0,0.07509406842291355
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,urgent action,4.0,0.04816771298646927
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,two participants,4.0,0.07082313299179077
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,st vincent,4.0,0.014862632378935814
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,small proportion,4.0,0.049277735874056816
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sex differences,4.0,0.08822785504162312
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,nutrition transition,4.0,0.12113450840115547
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,notably different,4.0,0.062111616134643555
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,lmic ).,4.0,0
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,leading causes,4.0,0.07052885740995407
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interaction terms,4.0,0.05844408646225929
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,included countries,4.0,0.050362151116132736
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diets high,4.0,0.08853452652692795
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diagnosed hypertension,4.0,0.2424214482307434
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cardiovascular diseases,4.0,0.40692125260829926
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,animal fats,4.0,0.11840036511421204
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,aid identification,4.0,0.060509104281663895
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,v intake,3.666666666666667,0.0829950887709856
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,undiagnosed hypertension,3.666666666666667,0.2591855525970459
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,increasing prevalence,3.666666666666667,0.10552124865353107
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,increase f,3.666666666666667,0.03340049088001251
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,included data,3.666666666666667,0.06793325021862984
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,higher prevalence,3.666666666666667,0.13447841256856918
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,high wc,3.5,0.05496258661150932
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,effective interventions,3.5,0.07961596548557281
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,v recommendations,3.166666666666667,0.06333994679152966
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,undiagnosed diabetes,3.166666666666667,0.23389938473701477
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,reporting,3.0,0.002092784270644188
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,use,2.5,0.0033735278993844986
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,salt,2.5,-0.020302094519138336
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,males,2.5,0.06523969769477844
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,fruit,2.5,0.03746720775961876
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cvd,2.5,0
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,xxx,2.375,-0.015934890136122704
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vegetable,2.0,0.10064415633678436
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sex,2.0,0.025031838566064835
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,p,2.0,0.11820723116397858
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vs,1.6666666666666667,0.08122316002845764
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,v,1.6666666666666667,0.019843820482492447
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,undiagnosed,1.6666666666666667,0.15374761819839478
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,prevalence,1.6666666666666667,0.1558399796485901
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,included,1.6666666666666667,0.029688812792301178
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,f,1.6666666666666667,0.004203930497169495
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,wc,1.5,0.0492173507809639
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,recommendations,1.5,0.10683607310056686
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interventions,1.5,0.13485746085643768
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diabetes,1.5,0.31405115127563477
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,women,1.0,0.14002981781959534
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,vegetables,1.0,0.11610875278711319
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,value,1.0,0.012530318461358547
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,used,1.0,0.010911919176578522
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,twenty,1.0,0.025144485756754875
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,trend,1.0,0.07326872646808624
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,test,1.0,0.08394099026918411
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sugar,1.0,0.04370478540658951
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,sexes,1.0,0.05338051915168762
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,reverse,1.0,-0.026650352403521538
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,results,1.0,0.0652550756931305
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,research,1.0,0.27731871604919434
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,required,1.0,-0.0036199837923049927
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,recorded,1.0,0.01999819651246071
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,parallel,1.0,0.08594085276126862
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,nepal,1.0,-0.010250802151858807
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,need,1.0,0.09471543878316879
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,methods,1.0,0.024640876799821854
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,men,1.0,0.09247083961963654
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,low,1.0,0.06519334763288498
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,lmics,1.0,0
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,limited,1.0,0.009723823517560959
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,kenya,1.0,-0.02073751948773861
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,investigated,1.0,0.0572904571890831
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,investigate,1.0,0.04426265507936478
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,interactions,1.0,0.01733073592185974
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,identifies,1.0,0.0749189555644989
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,however,1.0,-0.011453256011009216
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,guyana,1.0,0
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,grenadines,1.0,0
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,georgia,1.0,0.0072740111500024796
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,findings,1.0,0.21199440956115723
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,females,1.0,0.09382091462612152
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,fat,1.0,0.07365494966506958
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,eswatini,1.0,0
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,diet,1.0,0.11652903258800507
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,death,1.0,0.12083880603313446
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,dataset,1.0,0.1345919519662857
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,crucial,1.0,0.045712754130363464
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,country,1.0,0.03611394017934799
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,cooking,1.0,0.09309457987546921
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,conclusion,1.0,0.03420025110244751
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,bhutan,1.0,0
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,background,1.0,0.03833860531449318
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,association,1.0,0.10596190392971039
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,associated,1.0,0.10097402334213257
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,adults,1.0,0.051906388252973557
Evaluation of sex differences in dietary behaviours and their relationship with cardiovascular risk factors: a cross-sectional study of nationally representative surveys in seven low- and middle-income countries.,added,1.0,0.07914778590202332
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",continuous combined oestrogen plus progestogen,24.0,0.07330138981342316
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",three groups taking daily xxx,22.81818181818182,0.01966947615146637
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",suggesting decreased cholesterol loading,15.0,0.08325034100562334
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein ai (- xxx,13.068181818181818,0.08838109237452348
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",tibolone reduces serum hdl,12.666666666666666,0.09641320072114468
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",principal hdl protein component,12.666666666666666,0.05905203428119421
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",neta reduces ldl cholesterol,12.166666666666666,0.11936797201633453
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",continuous oral oestradiol,10.0,0.10616718977689743
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",reduced (- xxx,9.068181818181818,0.010838816873729229
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",similarly diminished relative,9.0,0.026002008467912674
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",main outcome measures,9.0,0.054799883315960564
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",fasting serum lipid,9.0,0.1366153433918953
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",tibolone (- xxx,8.568181818181818,0.1231960179284215
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cvd risk needs,8.5,0.13244888186454773
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",blind study patients,8.5,0.2387076516946157
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein concentrations measured,8.5,0.12023848791917165
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",neta reduced hdl,8.333333333333332,0.05344395712018013
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",c (- xxx,8.068181818181818,0.012630299665033817
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",density lipoprotein cholesterol,7.0,0.20296098291873932
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",protein component,6.0,0.04374817572534084
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl concentrations,5.166666666666666,0.06945085525512695
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",apolipoprotein b,5.0,0.11756717413663864
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx post,4.818181818181818,0.043158591724932194
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx months,4.818181818181818,0.012255401350557804
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx ).,4.818181818181818,-0.015934890136122704
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.","xxx ),",4.818181818181818,-0.015934890136122704
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl apolipoproteins,4.666666666666666,0.15053748339414597
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxxmg tibolone,4.5,0.2623269259929657
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",study design,4.5,0.18439188599586487
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",plasma lipid,4.5,0.2079559564590454
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cardiovascular risk,4.5,0.38447242230176926
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",sons ltd,4.0,0.05613034591078758
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",respectively ).,4.0,0.08458003401756287
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",menopausal women,4.0,0.13960367441177368
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipoprotein markers,4.0,0.14080185070633888
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lesser extent,4.0,0.030761336907744408
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",healthy post,4.0,0.10234558582305908
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",greatest reduction,4.0,0.0704815499484539
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",changes may,4.0,-0.008243115618824959
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",also apparent,4.0,0.04748770222067833
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",significant effect,3.666666666666667,0.03837192221544683
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",greatest effect,3.666666666666667,0.013444689800962806
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",cholesterol,3.0,0.2426881343126297
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",xxx,2.8181818181818183,-0.015934890136122704
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",neta,2.6666666666666665,0.06901471316814423
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",hdl,2.6666666666666665,0.053704634308815
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",tibolone,2.5,0.2623269259929657
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",ldl,2.5,0
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",lipoprotein,2.0,0.24346190690994263
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",density,2.0,0.12273290753364563
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",c,2.0,0.04119548946619034
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",effect,1.6666666666666667,0.004295531194657087
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",vldl,1.0,0
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",treatment,1.0,0.27399298548698425
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",single,1.0,0.015469912439584732
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",results,1.0,0.0652550756931305
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",randomised,1.0,0
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",placebo,1.0,0.1521017700433731
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",p,1.0,0.11820723116397858
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",one,1.0,0.060579702258110046
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",objective,1.0,0.01818794757127762
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",low,1.0,0.06519334763288498
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",investigation,1.0,0.0926906168460846
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",impact,1.0,0.029600899666547775
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",however,1.0,-0.011453256011009216
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",high,1.0,0.06070782244205475
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",exxx,1.0,0
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",effects,1.0,0.04013404995203018
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",double,1.0,0.06585106253623962
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",controlled,1.0,0.01649477332830429
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",contrast,1.0,0.11486168205738068
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",conclusion,1.0,0.03420025110244751
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",compare,1.0,0.09237030148506165
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",centre,1.0,0
"Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, HDL subfractions and apolipoproteins in post-menopausal women in a two-year, randomised, double-blind, placebo-controlled trial.",baseline,1.0,0.05839666724205017
Heart Failure With Mid-range Ejection Fraction.,randomized controlled trials exist,16.0,0.1081011202186346
Heart Failure With Mid-range Ejection Fraction.,aha )/ american college,15.5,0.05913352329904834
Heart Failure With Mid-range Ejection Fraction.,ef ≥ xxx %).,14.0,0.06831229043503602
Heart Failure With Mid-range Ejection Fraction.,ef ≤ xxx %),14.0,0.03809540035823981
Heart Failure With Mid-range Ejection Fraction.,unique phenotype altogether,9.0,0.04243475695451101
Heart Failure With Mid-range Ejection Fraction.,remains poorly understood,9.0,0.017611078917980194
Heart Failure With Mid-range Ejection Fraction.,mortality rates among,9.0,0.15200363844633102
Heart Failure With Mid-range Ejection Fraction.,include overlap suggest,9.0,0.06843713546792667
Heart Failure With Mid-range Ejection Fraction.,heterogeneous clinical characteristics,9.0,0.22591565921902657
Heart Failure With Mid-range Ejection Fraction.,american heart association,9.0,0.13888628330702582
Heart Failure With Mid-range Ejection Fraction.,mineralocorticoid receptor antagonists,8.666666666666666,0.12379894157250722
Heart Failure With Mid-range Ejection Fraction.,reduced ejection fraction,8.5,0.003271050751209259
Heart Failure With Mid-range Ejection Fraction.,preserved ejection fraction,8.5,-0.0003367569297552109
Heart Failure With Mid-range Ejection Fraction.,times resembles hfref,8.0,0.010520853102207184
Heart Failure With Mid-range Ejection Fraction.,angiotensin receptor blockers,7.666666666666666,0.1153479553759098
Heart Failure With Mid-range Ejection Fraction.,range ejection fraction,7.5,0.017157687495152157
Heart Failure With Mid-range Ejection Fraction.,hfmref patients represent,7.0,0.28996559977531433
Heart Failure With Mid-range Ejection Fraction.,ejection fraction,5.5,-0.013899685814976692
Heart Failure With Mid-range Ejection Fraction.,angiotensin receptor,5.166666666666666,0.15015103667974472
Heart Failure With Mid-range Ejection Fraction.,heart failure,4.5,0.2074820026755333
Heart Failure With Mid-range Ejection Fraction.,beta blockers,4.5,0.04017282463610172
Heart Failure With Mid-range Ejection Fraction.,ultimately came,4.0,0.009806003421545029
Heart Failure With Mid-range Ejection Fraction.,though hfref,4.0,0.000676378607749939
Heart Failure With Mid-range Ejection Fraction.,recent findings,4.0,0.12625432386994362
Heart Failure With Mid-range Ejection Fraction.,potential benefit,4.0,0.06485588848590851
Heart Failure With Mid-range Ejection Fraction.,others still,4.0,0.022606109268963337
Heart Failure With Mid-range Ejection Fraction.,neprilysin inhibitors,4.0,0.11038336157798767
Heart Failure With Mid-range Ejection Fraction.,hfmref population,4.0,0.1400190144777298
Heart Failure With Mid-range Ejection Fraction.,hfmref ).,4.0,0
Heart Failure With Mid-range Ejection Fraction.,gray zone,4.0,0.0446006297133863
Heart Failure With Mid-range Ejection Fraction.,future research,4.0,0.19114605337381363
Heart Failure With Mid-range Ejection Fraction.,complex disorder,4.0,0.08638937026262283
Heart Failure With Mid-range Ejection Fraction.,classification created,4.0,0.0072456467896699905
Heart Failure With Mid-range Ejection Fraction.,better elucidate,4.0,0.06758690997958183
Heart Failure With Mid-range Ejection Fraction.,others hfpef,3.666666666666667,0.04656439274549484
Heart Failure With Mid-range Ejection Fraction.,hfpef studies,3.666666666666667,0.24976284801959991
Heart Failure With Mid-range Ejection Fraction.,xxx,3.0,-0.015934890136122704
Heart Failure With Mid-range Ejection Fraction.,ef,3.0,0.0846770852804184
Heart Failure With Mid-range Ejection Fraction.,range,2.0,0.07927243411540985
Heart Failure With Mid-range Ejection Fraction.,patients,2.0,0.4592966139316559
Heart Failure With Mid-range Ejection Fraction.,hfref,2.0,0
Heart Failure With Mid-range Ejection Fraction.,hfmref,2.0,0
Heart Failure With Mid-range Ejection Fraction.,hfpef,1.6666666666666667,0
Heart Failure With Mid-range Ejection Fraction.,similar,1.0,0.08377962559461594
Heart Failure With Mid-range Ejection Fraction.,significant,1.0,0.07244831323623657
Heart Failure With Mid-range Ejection Fraction.,review,1.0,0.06275224685668945
Heart Failure With Mid-range Ejection Fraction.,purpose,1.0,-0.006926483474671841
Heart Failure With Mid-range Ejection Fraction.,prognosis,1.0,0.23093095421791077
Heart Failure With Mid-range Ejection Fraction.,pathophysiology,1.0,0.3145177364349365
Heart Failure With Mid-range Ejection Fraction.,needed,1.0,0.05141492560505867
Heart Failure With Mid-range Ejection Fraction.,mid,1.0,0.01741810142993927
Heart Failure With Mid-range Ejection Fraction.,management,1.0,0.23943668603897095
Heart Failure With Mid-range Ejection Fraction.,known,1.0,0.03723067417740822
Heart Failure With Mid-range Ejection Fraction.,group,1.0,0.05019131675362587
Heart Failure With Mid-range Ejection Fraction.,epidemiology,1.0,0.5018433332443237
Heart Failure With Mid-range Ejection Fraction.,efs,1.0,0
Heart Failure With Mid-range Ejection Fraction.,describe,1.0,-0.011884354054927826
Heart Failure With Mid-range Ejection Fraction.,condition,1.0,0.1885339617729187
Heart Failure With Mid-range Ejection Fraction.,cardiology,1.0,1.0
Heart Failure With Mid-range Ejection Fraction.,borderline,1.0,0.04753698781132698
Heart Failure With Mid-range Ejection Fraction.,assigned,1.0,0.027462657541036606
Heart Failure With Mid-range Ejection Fraction.,acc,1.0,0.031766559928655624
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,simple adequate diagnosis approach enabling,23.0,0.05546252690255642
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,obtain efficient algorithm classification models,23.0,0.06569989249110222
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,femoral pulse wave velocity,16.0,0.09601000463590026
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,"artificial neural networks ,""",15.0,0.0984438161055247
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,renal circulations models,9.0,0.21952311942974725
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,measured using carotid,9.0,0.10692945122718811
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,mean blood pressure,9.0,0.1193637525041898
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv index determinations,8.6,0.040988555178046227
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,individual pwv index,8.6,0.06191139295697212
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,usual clinical practice,8.5,0.23101734121640524
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,high cardiovascular risk,8.5,0.27655088901519775
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,large arteries prediction,8.25,0.1356812839706739
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,angiographic chd decisions,8.25,0.18281084764748812
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,"pwv ), particularly",8.1,0.09882432222366333
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,present review focuses,8.0,0.06809098273515701
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,index involving age,8.0,0.0970173900326093
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,coronary heart disease,8.0,0.30995577573776245
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv index may,7.6,0.049281975254416466
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,defined chd prediction,7.5,0.04327132040634751
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,artificial intelligence,5.0,0.1279079094529152
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,coronary prediction,4.75,0.26980457454919815
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,particularly relevant,4.5,0.09507549554109573
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,high levels,4.5,0.05267857387661934
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,heart rate,4.5,0.20280320569872856
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,clinical characteristics,4.5,0.2635910790413618
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,chd ).,4.25,0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,vulnerable plaques,4.0,0.100182194262743
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,substantial marker,4.0,0.053410956636071205
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,recent works,4.0,0.06085926666855812
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,recent findings,4.0,0.12625432386994362
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,major predictor,4.0,0.0943070687353611
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,decision tree,4.0,0.01597189251333475
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,aortic stiffness,4.0,0.2073110193014145
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,also used,4.0,0.02670675329864025
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,widely associated,3.5,0.07393751665949821
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,models,3.0,0.10839370638132095
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,enabling,3.0,0.018889283761382103
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,pwv,2.6,0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,prediction,2.25,0.07748128473758698
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,chd,2.25,0
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,review,2.0,0.06275224685668945
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,may,2.0,-0.009713593870401382
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,involving,2.0,0.07928798347711563
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,associated,1.5,0.10097402334213257
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,variability,1.0,0.1899898201227188
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,use,1.0,0.0033735278993844986
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,together,1.0,0.0037281587719917297
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,symptoms,1.0,0.1447140872478485
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,results,1.0,0.0652550756931305
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,relation,1.0,0.07857805490493774
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,purpose,1.0,-0.006926483474671841
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,presence,1.0,0.03234631195664406
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,possible,1.0,0.014038797467947006
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,patients,1.0,0.4592966139316559
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,parameter,1.0,0.057895369827747345
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,measurement,1.0,0.1633169949054718
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,interest,1.0,0.08689615875482559
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,improve,1.0,0.08507965505123138
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,imperfections,1.0,-0.05309125781059265
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,hypertension,1.0,0.364623486995697
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,gender,1.0,0.08549608290195465
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,due,1.0,-0.005625979043543339
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,damage,1.0,0.03876449540257454
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,constitute,1.0,0.08978849649429321
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,considered,1.0,0.11262063682079315
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,consider,1.0,0.0554787740111351
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,cerebrovascular,1.0,0.42472130060195923
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,calculation,1.0,0.006885142996907234
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,addition,1.0,0.1140233725309372
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms.,accuracy,1.0,0.05023651197552681
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell subsets compared across tissues,20.0,0.10764573961496353
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,provide effective recall responses,15.0,0.018439022824168205
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lung draining lymph node,14.666666666666666,0.11497419560328126
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,abundance throughout tissues,10.0,0.055957432836294174
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell receptor analysis,9.25,0.1004092867175738
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,recognize distinct antigens,9.0,0.0217315877477328
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,including higher expression,9.0,0.058999851966897644
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,different precursor pools,9.0,0.04467801873882612
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,paired human lung,8.666666666666666,0.1341235116124153
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,innate immune receptors,8.5,0.04317892932643493
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,identified substantial differences,8.0,0.10255308200915654
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,clonal overlap observed,8.0,0.11239932229121526
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell subsets within,8.0,0.11093318214019139
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cell subsets,6.0,0.1341228224337101
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,immune responses,5.5,0.0350717157125473
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,clonal overlap,5.0,0.12489813566207886
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,transcriptional landscape,4.0,0.08073817985132337
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,study focused,4.0,0.14896457269787788
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,separate roles,4.0,0.06673466600477695
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,results suggest,4.0,0.05601985938847065
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,flow cytometry,4.0,0.14311635494232178
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,specific memory,3.8,0.08743619918823242
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,many memory,3.8,0.06628750264644623
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cells persist,3.666666666666667,0.05757993459701538
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cells originate,3.666666666666667,0.04161769896745682
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,ldln memory,3.3,0.08572089672088623
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cdxxx memory,3.3,0.08572089672088623
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,subsets,2.75,0.16474252939224243
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,lung,2.6666666666666665,0.2565838694572449
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,within,2.0,0.06455390155315399
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,identified,2.0,0.10330121219158173
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,memory,1.8,0.08572089672088623
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cells,1.6666666666666667,0.06259886920452118
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,ldln,1.5,0
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,cdxxx,1.5,0
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,years,1.0,0.05066175013780594
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,validated,1.0,0.08453492820262909
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,using,1.0,-0.04173736274242401
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,samples,1.0,0.053145233541727066
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,pathogen,1.0,0.08378986269235611
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,likely,1.0,0.06529493629932404
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,greater,1.0,0.09047040343284607
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,exposure,1.0,0.00614194106310606
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,differ,1.0,0.033852480351924896
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,determined,1.0,-0.03170712664723396
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,array,1.0,0.0669817253947258
Transcriptional programming and T cell receptor repertoires distinguish human lung and lymph node memory T cells.,antigen,1.0,0.06479129940271378
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,human induced pluripotent stem cell,25.0,0.07952122204005718
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,free organoids expressing characteristic markers,23.333333333333336,0.034582868218421936
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cdxxxx expression throughout directed differentiation,23.0,0.04985477635636926
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,directed differentiation protocol,11.0,0.11331250766913097
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,free defined conditions,9.333333333333334,0.025532946301003296
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,therapeutic screening applications,9.0,0.17459005862474442
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,derived ipsc lines,9.0,0.0009401352144777775
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cdxxxxegfp ipsc knock,9.0,0.01082112267613411
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,inflammatory bowel disease,8.5,0.153837059934934
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,proximal intestinal lineages,8.333333333333334,0.1378726065158844
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,employ hios generated,8.0,0.033244432881474495
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,free hios,5.333333333333334,0.026203567162156105
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,disease modeling,4.5,0.12076562270522118
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,small intestinal,4.333333333333334,0.08687162213027477
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,intestinal progenitors,4.333333333333334,0.115701824426651
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,would facilitate,4.0,0.05612398497760296
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,vitro models,4.0,0.16052529588341713
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,reporter line,4.0,0.00481969490647316
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,primed towards,4.0,0.04214552044868469
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hindgut progenitors,4.0,0.07798996567726135
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,gastrointestinal tract,4.0,0.19168946519494057
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,future potential,4.0,0.0865546204149723
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cystic fibrosis,4.0,0.19149300456047058
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,cftr mutation,4.0,0.07678423076868057
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,robust generation,3.666666666666667,0.053357912227511406
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,efficient generation,3.666666666666667,0.08278057351708412
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,colonic epithelium,3.5,0.1331745684146881
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,hios,2.0,0.032261669635772705
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,generation,1.6666666666666667,0.062373146414756775
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,colonic,1.5,0.14906805753707886
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,way,1.0,-0.018800776451826096
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,variety,1.0,0.07650606334209442
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,using,1.0,-0.04173736274242401
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,track,1.0,0.04564104974269867
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,serum,1.0,0.02322017401456833
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,report,1.0,0.05636989697813988
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,purification,1.0,0.13488033413887024
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,mesenchyme,1.0,0.14130011200904846
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,kinetics,1.0,0.09281712025403976
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,follow,1.0,0.08601848781108856
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,enabling,1.0,0.018889283761382103
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,emergence,1.0,0.041484735906124115
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,diseases,1.0,0.23910000920295715
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,development,1.0,0.1793753206729889
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,demonstrating,1.0,0.04213862493634224
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,correction,1.0,0.11102229356765747
Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.,affect,1.0,0.0651945173740387
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,"one unknown metabolite ), demonstrating",23.333333333333332,0.025808981619775295
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,potentially clinically useful diagnostic panel,22.0,0.20840480476617812
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,left ventricular ejection fraction,15.0,0.06285456009209156
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,reduced ejection fraction,10.0,0.003271050751209259
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,novel diagnostic panel,10.0,0.22091330587863922
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,diagnostic value seems,9.166666666666666,0.16479080636054277
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,forest models fitted,9.0,0.09681257357199986
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fasting serum samples,9.0,0.07270796969532967
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,"learning methods ),",8.833333333333334,0.026072733104228973
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,two innovative tools,8.5,0.050241141890486084
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx controls without,8.4,0.007266528283556302
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,selected metabolites correlated,8.333333333333334,0.06965835516651471
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,confirm clinical utility,8.0,0.2127372274796168
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx ± xxx,7.800000000000001,0.04078221941987673
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx vs xxx,7.800000000000001,0.01645112658540408
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,feature selection based,7.5,0.06597682336966197
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,"xxx ),",5.733333333333333,-0.015934890136122704
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolites panel,5.666666666666667,0.09040232002735138
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,two isomers,4.5,0.07948259636759758
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,predictive value,4.5,0.09369275299832225
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,model based,4.5,0.06990262307226658
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx %),4.4,-0.015934890136122704
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,lvef xxx,4.4,-0.015934890136122704
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,lpc xxx,4.4,-0.015934890136122704
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,eight metabolites,4.333333333333334,0.07447085157036781
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,uric acid,4.0,-0.01845341920852661
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,test set,4.0,0.04346809536218643
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,resampled data,4.0,0.06245528906583786
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,proposed markers,4.0,0.046017538756132126
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolic derangement,4.0,0.16070407256484032
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,mass spectrometry,4.0,0.11169328168034554
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,machine learning,4.0,0.03610682301223278
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,liquid chromatography,4.0,0.059112719260156155
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,linear modelling,4.0,-0.02034170553088188
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,large scale,4.0,0.03372824937105179
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,heart failure,4.0,0.2074820026755333
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,functional parameters,4.0,0.1085384339094162
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,enables identification,4.0,0.020660273730754852
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,docosahexaenoic acid,4.0,-0.007209718227386475
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,deoxycholic acid,4.0,-0.1316230595111847
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,current knowledge,4.0,0.034344976767897606
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,combined approach,4.0,0.041969139128923416
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,check feasibility,4.0,0.06530202552676201
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,untargeted metabolomics,3.5,0.1833551749587059
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,hfref ).,3.5,0
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,xxx,2.4,-0.015934890136122704
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,selection,2.0,0.05145580321550369
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,clinical,2.0,0.49838685989379883
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,metabolomics,1.5,0.2973555326461792
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,machine,1.5,0.04470905661582947
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,hfref,1.5,0
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,verified,1.0,0.020177435129880905
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,unrestrained,1.0,-0.03551895171403885
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,study,1.0,0.2376001477241516
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,simple,1.0,-0.0471973717212677
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,resulted,1.0,-0.0046446360647678375
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,random,1.0,-0.09545474499464035
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,multi,1.0,0.048057474195957184
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,gaps,1.0,0.1010507345199585
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,followed,1.0,0.06544908136129379
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,fingerprinted,1.0,0.08695214986801147
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,echocardiographic,1.0,0.39793336391448975
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,disease,1.0,0.1630353331565857
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,crucial,1.0,0.045712754130363464
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,create,1.0,0.025220831856131554
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,comparable,1.0,0.07046344876289368
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,common,1.0,0.08981665968894958
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,combination,1.0,-0.03356827795505524
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,bnp,1.0,0.07405637949705124
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,aim,1.0,0.040013544261455536
Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.,accuracy,1.0,0.05023651197552681
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,learning methods represents nowadays,15.0,0.04544960428029299
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,provide functional quantitative maps,12.5,0.09108909219503403
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,multiple quantitative maps,9.5,0.09117300808429718
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,underlying physiological processes,9.0,0.09540027628342311
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,specific vascular receptors,9.0,0.22801082084576288
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,reflecting complementary variables,9.0,0.06849972407023112
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,red blood cells,9.0,0.08733377108971278
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,probabilistic framework based,9.0,0.06603620449701945
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,extracted complementary information,9.0,0.09788103277484576
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,different pathological conditions,9.0,0.09420795987049739
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,new kinetic models,8.5,0.08923088262478511
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,indicator dilution principles,8.5,0.06337719162305196
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,immense diagnostic possibilities,8.5,0.20748108377059302
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,molecular imaging modality,8.2,0.31370048721631366
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultrasound contrast agents,7.5,0.17141840606927872
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,uca intravascular kinetics,7.5,0.2210892103612423
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us imaging based,7.2,0.20267962167660394
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,functional imaging,5.2,0.3125504329800606
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,uca kinetics,5.0,0.09281712025403976
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,intravascular indicator,5.0,0.21760058403015137
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,available methods,5.0,0.03195909224450588
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ucas provide,4.666666666666667,0.01998533308506012
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,quantitative dce,4.666666666666667,0.09732342511415482
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,several models,4.5,0.0992397628724575
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dynamic contrast,4.5,0.08945749700069427
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,diagnostic accuracy,4.5,0.26929054595530033
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us imaging,4.2,0.2614348456263542
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultimate approach,4.0,-0.020622991025447845
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,spatiotemporal analysis,4.0,0.10792147368192673
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,rights reserved,4.0,0.030988029204308987
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,rheology comparable,4.0,0.08506524562835693
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,recent introduction,4.0,0.031030522659420967
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,optimal combination,4.0,0.022879071533679962
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,microbubbles encapsulated,4.0,0.08751724287867546
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,integrative approach,4.0,0.1669810451567173
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,increased complexity,4.0,0.03582800552248955
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,future perspective,4.0,0.06049598008394241
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,enhanced ultrasound,4.0,0.23202553391456604
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,emerging machine,4.0,0.08413559198379517
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,elsevier inc,4.0,0.007824641652405262
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,current value,4.0,0.02352467691525817
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,critically discussed,4.0,0.09196114167571068
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,comprehensive review,4.0,0.07804420217871666
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,combined use,4.0,0.028586206026375294
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,biocompatible shell,4.0,0.05245092511177063
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,aiding diagnosis,4.0,0.12259403243660927
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,novel ucas,3.666666666666667,0.09435988962650299
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,advanced dce,3.666666666666667,0.08296222984790802
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,imaging,2.2,0.4709222614765167
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,us,2.0,0.05194742977619171
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ultrasound,2.0,0.39892449975013733
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,ucas,1.6666666666666667,0
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,dce,1.6666666666666667,0.054687947034835815
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,vasculature,1.0,0.242548406124115
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,temporal,1.0,0.09402984380722046
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,targeted,1.0,0.06072039157152176
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,spatial,1.0,0.08762417733669281
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,requires,1.0,-0.041584912687540054
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,published,1.0,0.10513044893741608
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,proposed,1.0,0.053893283009529114
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,parallel,1.0,0.08594085276126862
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,opened,1.0,0.050522319972515106
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,micro,1.0,0.06720928847789764
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,medicine,1.0,0.497326135635376
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,interpretation,1.0,0.059899576008319855
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,improving,1.0,0.09750453382730484
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,extraction,1.0,0.06110062450170517
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,developed,1.0,0.1218160092830658
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,biology,1.0,0.32473820447921753
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,article,1.0,0.0808369517326355
Contrast-Enhanced Ultrasound Quantification: From Kinetic Modeling to Machine Learning.,advances,1.0,0.1283981204032898
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,important factor affecting patient prognosis,25.0,0.15825233310461045
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,several circulating long noncoding rnas,23.0,0.06038216594606638
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,multivariate regression analysis indicated,16.0,0.09539835806936026
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,left ventricular ejection fraction,15.0,0.06285456009209156
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,stage ami remain unclear,13.714285714285715,0.04258148279041052
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,"e ., xxx h",13.571428571428571,0.01836210551361243
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chast levels obviously decreased,12.166666666666666,0.05551470071077347
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx controls without ami,11.785714285714285,0.031174405943602324
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami cardiac remodeling remains,11.647619047619049,0.2195061882957816
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,left ventricular short,10.0,0.09693366661667824
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,different time points,9.0,0.061143690099318825
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chronic pathological process,9.0,0.11591181593636672
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,acute myocardial infarction,9.0,0.3220969835917155
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,axis shortening rate,8.5,0.056283374316990376
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac contractile function,8.1,0.3139617418249448
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,stage ami,5.714285714285714,0.07899266853928566
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,circulating levels,5.666666666666666,0.02894296869635582
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx h,5.571428571428571,0.006312788464128971
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac function,5.1,0.3649844117462635
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,substantially decreased,5.0,0.0594140961766243
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac remodeling,4.933333333333334,0.39070071280002594
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami population,4.714285714285714,0.12145852670073509
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression levels,4.666666666666666,0.022602987475693226
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiac hypertrophy,4.6,0.4386647641658783
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx days,4.571428571428571,0.008284521289169788
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx ).,4.571428571428571,-0.015934890136122704
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,mortality rate,4.5,0.18758423253893852
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,circulating lncrnas,4.5,0.01323661208152771
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami patients,4.380952380952381,0.28109732642769814
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,standardized β,4.0,0.057075146585702896
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,significantly increased,4.0,0.08945312350988388
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,reportedly involved,4.0,0.027414369396865368
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,quartile values,4.0,0.06170115154236555
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,potential roles,4.0,0.07343285530805588
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,positively associated,4.0,0.05594427511096001
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,may serve,4.0,0.01723203808069229
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,independent predictor,4.0,0.06677553988993168
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,grouped according,4.0,0.05860742926597595
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,expression level,4.0,0.029294763691723347
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,elsevier b,4.0,0.033724576234817505
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,consecutively enrolled,4.0,0.10446788836270571
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,clinical parameters,4.0,0.2806425616145134
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,cardiovascular diseases,4.0,0.40692125260829926
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,candidate biomarker,4.0,0.22020019590854645
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,blood samples,4.0,0.10585649497807026
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,associated transcript,4.0,0.06365201808512211
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,three patients,3.666666666666667,0.2683269791305065
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,highest quartiles,3.5,0.07591314055025578
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,ami,2.7142857142857144,0.10289803892374039
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,xxx,2.5714285714285716,-0.015934890136122704
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,controls,2.5,0.05869656428694725
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,chast,2.5,0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,remodeling,2.3333333333333335,0.16212573647499084
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,patients,1.6666666666666667,0.4592966139316559
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,quartiles,1.5,0.11885389685630798
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,lncrnas,1.5,0
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,v,1.0,0.019843820482492447
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,study,1.0,0.2376001477241516
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,results,1.0,0.0652550756931305
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,published,1.0,0.10513044893741608
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,post,1.0,0.10225207358598709
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,phase,1.0,0.012381147593259811
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,p,1.0,0.11820723116397858
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,methods,1.0,0.024640876799821854
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,measured,1.0,0.07410861551761627
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,however,1.0,-0.011453256011009216
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,fifty,1.0,0.0258838701993227
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,early,1.0,0.03449202701449394
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,conclusion,1.0,0.03420025110244751
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,compared,1.0,0.10162706673145294
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,collected,1.0,-0.03091895952820778
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,biomarkers,1.0,0.28697043657302856
Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction.,background,1.0,0.03833860531449318
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,goes beyond standard clinical biomarkers,22.166666666666668,0.178989914059639
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,essential step towards personalized,15.5,0.035362593829631805
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,poor metabolic health outcome,15.166666666666666,0.1793831493705511
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,comprehensive multimodal health assessments,14.833333333333332,0.14907078724354506
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,unsupervised machine learning methods,14.5,0.028904886916279793
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,preventative health risk assessment,14.166666666666666,0.20199226960539818
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,biomarkers identified distinct subsets,13.916666666666666,0.13878347165882587
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,collected xxx data features,13.523809523809524,0.02570507349446416
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identify multimodal biomarker signatures,13.466666666666665,0.12330984883010387
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,diabetes signature included xxx,13.357142857142858,0.08308797655627131
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identified potential early signatures,11.883333333333333,0.04955928213894367
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,established clinical biomarkers,10.166666666666666,0.2824543279906114
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,rapidly moving towards,9.5,0.029875487710038822
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,multimodal data integration,9.333333333333332,0.11867383619149525
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,similar health statuses,9.166666666666666,0.15692517161369324
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,longitudinal validation cohort,9.0,0.13385053475697836
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,lean mass percentage,9.0,0.04488169401884079
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,body mass index,9.0,0.05078936616579691
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,uncovering novel biomarkers,8.916666666666666,0.14477243771155676
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,palmitoyl )- xxx,8.857142857142858,0.005649363622069359
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,found novel associations,8.75,0.06896438077092171
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx -( xxx,8.714285714285715,-0.015934890136122704
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,novel biomarker signatures,8.55,0.1327559066315492
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,gut microbiome health,8.5,0.1406711538632711
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,microbiome genera intestinimonas,8.333333333333334,0.11025713384151459
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,driven paradigm based,8.0,0.077513853708903
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,novel biomarkers,5.916666666666666,0.19066516309976578
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,potential biomarker,5.333333333333334,0.18986782059073448
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,cardiometabolic biomarkers,5.166666666666666,0.3330060839653015
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease risk,5.0,0.17861884087324142
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease signatures,4.8,0.07767168618738651
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,method identified,4.75,0.059831807389855385
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx individuals,4.523809523809524,0.01906596589833498
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,individuals based,4.166666666666667,0.06961799785494804
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,uremic toxin,4.0,0.106047541834414
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,unclassified genus,4.0,0.06559236347675323
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,subset membership,4.0,0.09650228172540665
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,modern medicine,4.0,0.28829772770404816
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,integrated analysis,4.0,0.10105378925800323
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,insulin resistance,4.0,0.07306778058409691
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,including metabolome,4.0,0.13026027381420135
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,erysipelotrichaceae family,4.0,0.11515630781650543
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,driven stratification,4.0,0.07956575229763985
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,diverse modalities,4.0,0.16604063287377357
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,disease subtypes,4.0,0.15105699747800827
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,different modalities,4.0,0.1434122994542122
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,cresol sulfate,4.0,0.11512698978185654
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,better predictor,4.0,0.09199907630681992
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,another metabolite,4.0,0.04009090177714825
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,advanced imaging,4.0,0.2910793870687485
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,results demonstrate,3.5,0.04682372510433197
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,health,3.1666666666666665,0.31966903805732727
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,xxx,2.857142857142857,-0.015934890136122704
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,signatures,2.8,-0.007691960781812668
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identified,2.75,0.10330121219158173
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,data,2.6666666666666665,0.1061776876449585
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,methods,2.5,0.024640876799821854
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,diabetes,2.5,0.31405115127563477
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,potential,2.3333333333333335,0.06813585013151169
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,microbiome,2.3333333333333335,0.1713476926088333
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,individuals,1.6666666666666667,0.054066821932792664
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stratification,1.5,0.127202570438385
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,results,1.5,0.0652550756931305
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,utilized,1.0,0.03543274104595184
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stearoyl,1.0,0
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,stages,1.0,0.01961425319314003
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,set,1.0,0.0029952004551887512
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,p,1.0,0.11820723116397858
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,oleoyl,1.0,0
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,methodology,1.0,0.045314721763134
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,linolenoyl,1.0,0
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,identification,1.0,0.04679466038942337
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,hypertension,1.0,0.364623486995697
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,gpc,1.0,0
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,glucose,1.0,0.18350757658481598
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,genetics,1.0,0.35186567902565
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,enyl,1.0,0
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,dihomo,1.0,0
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,conclusions,1.0,0.07628431916236877
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,combination,1.0,-0.03356827795505524
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,cinnamoylglycine,1.0,0
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,background,1.0,0.03833860531449318
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,additionally,1.0,0.012068133801221848
An unsupervised learning approach to identify novel signatures of health and disease from multimodal data.,abundance,1.0,0.031378280371427536
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,symptoms experienced following allergen exposure,24.5,0.0666883459314704
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergen immunotherapy may modulate,16.166666666666664,0.09228260908275843
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,study selections authors assessment,16.0,0.14127464313060045
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,supervised oral food challenge,14.375,0.09149938123300672
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,may impact upon risk,14.333333333333332,0.04491367004811764
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,specific reaction phenotypes exist,12.1,0.06609362829476595
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,unpublished literature relating,9.0,0.12284465009967487
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinically useful predictors,9.0,0.18619909137487411
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,applying unbiased machine,9.0,0.025486625575770933
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,facilitating risk stratification,8.666666666666666,0.12443741286794345
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food anaphylaxis may,8.375,0.07499146834015846
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,different reaction phenotypes,8.1,0.0635421338180701
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,major research theme,8.0,0.11968768884738286
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food allergy encompasses,7.875,0.11814224471648534
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,different clinical phenotypes,7.433333333333334,0.23598669469356537
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,reaction phenotypes,5.6,0.06163828261196613
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food allergy,4.875,0.1314816176891327
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,different pathophysiology,4.5,0.19093378633260727
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,different cohorts,4.5,0.06920190155506134
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,severe food,4.375,0.08559423685073853
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,many food,4.375,0.06290549039840698
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food hypersensitivities,4.375,0.10860107094049454
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,severe anaphylaxis,4.333333333333334,0.12398136407136917
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinical practice,4.333333333333334,0.3287031501531601
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clinical experience,4.333333333333334,0.2710565775632858
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,anaphylaxis caused,4.333333333333334,0.09187600575387478
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,prescribe eai,4.0,0.18838778138160706
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,predict patients,4.0,0.24415163323283195
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,nonfood triggers,4.0,0.08045602403581142
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,integrating datasets,4.0,0.10757995769381523
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,important area,4.0,0.10090585425496101
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,endotype discovery,4.0,0.10541436076164246
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,elsevier inc,4.0,0.007824641652405262
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,current inability,4.0,0.006383638828992844
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic reactions,4.0,0.047186478972435
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,allergic individuals,4.0,0.054546818137168884
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patient management,3.666666666666667,0.32721012830734253
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,one patient,3.666666666666667,0.23778163641691208
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,data sources,3.666666666666667,0.06687838211655617
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,available data,3.666666666666667,0.0727274976670742
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,similar way,3.5,0.03248942457139492
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,emerging evidence,3.5,0.09086420573294163
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,risk,2.6666666666666665,0.19420234858989716
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,phenotypes,2.6,0.14222338795661926
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,exist,2.5,0.05194644629955292
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,food,2.375,0.07895687222480774
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,research,2.0,0.27731871604919434
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,patient,1.6666666666666667,0.4149835705757141
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,data,1.6666666666666667,0.1061776876449585
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,way,1.5,-0.018800776451826096
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,emerging,1.5,0.12356212735176086
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,whether,1.0,0.031672295182943344
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,varies,1.0,0.011406470090150833
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,severity,1.0,0.06077773869037628
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,robust,1.0,0.04434267804026604
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,results,1.0,0.0652550756931305
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,remains,1.0,-0.006274711340665817
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,relevance,1.0,0.032082222402095795
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,range,1.0,0.07927243411540985
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,published,1.0,0.10513044893741608
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,perhaps,1.0,0.026446938514709473
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,objective,1.0,0.01818794757127762
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,number,1.0,0.03055502660572529
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,much,1.0,0.04524269700050354
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,manner,1.0,0.012784529477357864
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,likely,1.0,0.06529493629932404
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,improvements,1.0,0.08724521100521088
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,impacting,1.0,0.0265291016548872
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,given,1.0,0.014340896159410477
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,g,1.0,0.02275453880429268
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,future,1.0,0.10497339069843292
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,e,1.0,0.042460739612579346
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,discuss,1.0,0.09245206415653229
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,devices,1.0,0.20759570598602295
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,determined,1.0,-0.03170712664723396
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,decision,1.0,0.016830462962388992
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,currently,1.0,0.0543237179517746
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,confirm,1.0,0.02169613540172577
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,conclusion,1.0,0.03420025110244751
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,community,1.0,0.1393434703350067
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,clearly,1.0,0.01570729911327362
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,asthma,1.0,0.2230728715658188
Reaction phenotypes in IgE-mediated food allergy and anaphylaxis.,another,1.0,0.01875428482890129
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients undergoing cardiac resynchronization therapy,23.266666666666666,0.3535023838281631
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx patients undergoing crt implantation,18.1,0.17420927323400975
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,receiver operating characteristic curves,16.0,0.06894586770795286
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,patients undergoing crt implantation,15.433333333333334,0.22174531407654285
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,exhibited good discriminative capabilities,15.0,0.08117436245083809
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,seattle heart failure model,14.666666666666666,0.12998606357723475
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,already existing risk scores,12.666666666666666,0.09332914417609572
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,random forest demonstrated,9.0,0.02035261814792951
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,oxford university press,9.0,0.14006692667802176
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx %) deaths,8.666666666666666,0.05976803321391344
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implant clinical features,8.5,0.269252626846234
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,"xxx ), respectively",8.166666666666666,0.03432257194072008
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,best performing model,8.166666666666666,0.06637180348237355
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,multiple ml models,8.0,0.08587437868118286
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,"xxx ), xxx",7.833333333333332,-0.015934890136122704
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx patients,6.266666666666667,0.2216808618977666
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt patients,6.266666666666667,0.24587681517004967
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,existing scores,5.666666666666666,0.08625730872154236
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,"xxx ),",5.166666666666666,-0.015934890136122704
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,estimated risk,5.0,0.10209927521646023
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,discriminative ability,5.0,0.028918486088514328
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,predict xxx,4.666666666666666,0.006535881198942661
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,evaluated scores,4.666666666666666,0.06443625688552856
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt score,4.666666666666666,0.03668207302689552
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt ).,4.666666666666666,0.03245701640844345
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,"score ),",4.5,0.040907129645347595
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,implant parameters,4.5,0.16438641399145126
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,best performance,4.5,0.04327479936182499
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,training cohort,4.0,0.14062443375587463
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,test cohort,4.0,0.11867501214146614
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,retrospective database,4.0,0.1024093497544527
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,personalized assessment,4.0,0.07178138755261898
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,machine learning,4.0,0.03610682301223278
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,linear association,4.0,0.04281009919941425
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,independent cohort,4.0,0.08601759187877178
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,european society,4.0,0.084633007645607
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cause death,4.0,0.10442091524600983
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year follow,3.666666666666667,0.05729828216135502
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cause mortality,3.666666666666667,0.18113460391759872
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,trained classifiers,3.5,0.07140291482210159
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,three pre,3.5,0.05716896057128906
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year mortality,3.3333333333333335,0.15142212994396687
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,xxx,2.6666666666666665,-0.015934890136122704
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,model,2.6666666666666665,0.05463607236742973
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,crt,2.6666666666666665,0.03245701640844345
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,models,2.0,0.10839370638132095
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,year,1.6666666666666667,0.028578076511621475
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,mortality,1.6666666666666667,0.27426618337631226
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,trained,1.5,0.1238085925579071
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,pre,1.5,0.03698057681322098
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,valid,1.0,-0.002878095954656601
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,utilization,1.0,0.17883524298667908
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,train,1.0,0.012325972318649292
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,thirty,1.0,0.005658911541104317
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,tested,1.0,0.06802673637866974
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,superior,1.0,0.026375602930784225
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,semmelweiscrtscore,1.0,0
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,semmelweis,1.0,0
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,selected,1.0,0.03362758085131645
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,screen,1.0,0.02763313800096512
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,results,1.0,0.0652550756931305
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,published,1.0,0.10513044893741608
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,prognostication,1.0,0.09497688710689545
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,predictors,1.0,0.16273410618305206
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,prediction,1.0,0.07748128473758698
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,period,1.0,0.022214137017726898
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,p,1.0,0.11820723116397858
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,outperformed,1.0,0.10277935117483139
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,non,1.0,0.06398928165435791
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,methods,1.0,0.024640876799821854
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,eaarn,1.0,0
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,develop,1.0,0.10439212620258331
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,conclusion,1.0,0.03420025110244751
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,com,1.0,-0.008797436952590942
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,ci,1.0,0.06607142090797424
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,cardiology,1.0,1.0
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,capturing,1.0,0.02603818289935589
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,behalf,1.0,0.003146544098854065
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,available,1.0,0.03927730768918991
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,author,1.0,0.1725224107503891
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,areas,1.0,0.15646809339523315
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,among,1.0,0.09849628061056137
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,aims,1.0,0.04269438236951828
Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.,aim,1.0,0.040013544261455536
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,considering three different signals,16.0,0.04214341100305319
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,apply convolutional neural networks,16.0,0.06441126608600219
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,classical machine learning approaches,15.5,0.0630470272153616
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,ventricular tachycardia arrhythmia ).,15.0,0.27448873221874237
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,false alarm reduction task,13.25,0.045533626805990934
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,true alarms using single,13.0,0.017549444921314716
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,method efficiently using,9.5,0.015509519726037979
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,deep learning model,9.5,0.04270285740494728
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,term memory units,9.0,0.0845995085934798
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,temporal information presented,9.0,0.09301357716321945
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,requiring prior knowledge,9.0,0.01503097964450717
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,intensive care units,9.0,0.1665316546956698
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,evaluation results demonstrate,9.0,0.07833343744277954
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,automatically extract time,9.0,0.03529825806617737
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,segmented input signal,8.5,0.03833579458296299
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed method achieves,8.5,0.01928752971192201
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,step training algorithm,8.0,0.07104579359292984
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,cardiology challenge xxx,8.0,0.3375490742425124
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,"e ., pre",7.5,0.03972065821290016
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,false alarms,6.0,0.05193839594721794
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,arrhythmia analysis,5.0,0.22753757238388062
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,signal segments,4.5,0.06406820937991142
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,proposed network,4.5,0.053635960444808006
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,"g .,",4.5,0.02275453880429268
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm type,4.25,0.04680870659649372
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm classification,4.25,0.0374180655926466
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,"xxx %,",4.0,-0.015934890136122704
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,without ignoring,4.0,-0.011837407015264034
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,study proposes,4.0,0.15312867611646652
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,physionet computing,4.0,0.19677644968032837
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,modal biosignals,4.0,0.04848790913820267
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,long short,4.0,0.017329098656773567
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,lead ecg,4.0,0.20019515231251717
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,invariant features,4.0,0.0539687555283308
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,important regions,4.0,0.08360010758042336
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,existing algorithms,4.0,0.12376144900918007
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,engineered features,4.0,0.04996407404541969
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,either rule,4.0,0.0011742804199457169
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,effectively suppresses,4.0,0.006785145029425621
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,dataset provided,4.0,0.0627887211740017
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,build rules,4.0,0.020580900833010674
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,based methods,4.0,0.05490502528846264
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,attention mechanism,4.0,0.03812773339450359
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,current work,3.5,0.048871228471398354
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,single,2.5,0.015469912439584732
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,alarm,2.25,0.05517297983169556
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,xxx,2.0,-0.015934890136122704
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,training,2.0,0.1278398334980011
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,e,2.0,0.042460739612579346
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,work,1.5,0.06322342157363892
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,two,1.0,0.0741315707564354
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,tuning,1.0,0.018936164677143097
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,trained,1.0,0.1238085925579071
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,specificity,1.0,0.09074191749095917
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,sensitivity,1.0,0.0724399983882904
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,put,1.0,0.021826867014169693
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,multi,1.0,0.048057474195957184
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,literature,1.0,0.2259182184934616
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,likely,1.0,0.06529493629932404
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,icus,1.0,0
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,hand,1.0,-0.03252475708723068
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,fine,1.0,0.0010942183434963226
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,experiments,1.0,0.11820036172866821
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,emphasis,1.0,0.04609560966491699
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,depending,1.0,-0.02532743103802204
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,contribute,1.0,0.06670629978179932
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,consider,1.0,0.0554787740111351
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,capture,1.0,0.040161751210689545
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,auc,1.0,-0.016484811902046204
Single-modal and multi-modal false arrhythmia alarm reduction using attention-based convolutional and recurrent neural networks.,addition,1.0,0.1140233725309372
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,back propagation artificial neural network,23.5,0.07500344589352607
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,three common machine learning algorithms,20.65,0.06566276177763938
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,"rf ], support vector machine",19.9,0.050761915976181626
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,controlled blood glucose rate,14.916666666666666,0.11486809700727463
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,atherosclerotic cardiovascular disease history,14.666666666666666,0.2553268736228347
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx consecutive participants recruited,14.5,0.04065842228010297
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,predict blood glucose status,14.416666666666666,0.09925034129992127
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,type xxx diabetes mellitus,13.0,0.11799014313146472
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine learning algorithms,10.65,0.0537132682899634
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine learning models,9.65,0.06020245080192884
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood glucose control,9.416666666666666,0.13266404469807944
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,predict glycemic control,9.0,0.09051298846801122
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,multivariable analysis found,9.0,0.10243288551767667
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,multicenter study aimed,9.0,0.21390139559904733
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,collected via questionnaire,9.0,0.004461426287889481
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,building predictive models,9.0,0.11881967137257259
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,address variable collinearity,9.0,0.07939760759472847
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,traditional logistic model,8.5,0.06221557408571243
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,poor glycemic control,8.5,0.10205783943335216
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,stepwise logistic regression,8.166666666666666,0.09225025773048401
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic regression models,8.166666666666666,0.08953309059143066
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,developing diabetic complications,8.0,0.23149593671162924
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,elastic network,5.5,0.0007574055343866348
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,learning algorithm,5.25,0.050343846902251244
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,blood pressure,5.25,0.14018943160772324
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,"svm ],",5.0,0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,family history,4.666666666666666,0.08405948989093304
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx centers,4.5,0.10320000816136599
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,january xxx,4.5,-0.003959255293011665
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,december xxx,4.5,-0.012136124540120363
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,hypertension history,4.166666666666666,0.20879307948052883
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,en regression,4.166666666666666,0.07748933881521225
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,total cholesterol,4.0,0.12318601738661528
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,six cities,4.0,0.06386727653443813
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,risk factors,4.0,0.1105011198669672
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,related data,4.0,0.11482953280210495
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,random forest,4.0,0.0022971369326114655
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,protective factors,4.0,0.046882765367627144
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,north china,4.0,0.07139208167791367
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,higher risk,4.0,0.15365959703922272
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,glycosylated hemoglobin,4.0,0.11331010982394218
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,figures increased,4.0,0.03390362113714218
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,dimensional reduction,4.0,0.09996243193745613
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,closely related,4.0,0.08334605768322945
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,central adiposity,4.0,0.15343288332223892
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,biochemical indices,4.0,0.1657055839896202
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,basic information,4.0,0.052439759485423565
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,application value,4.0,0.018131728749722242
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,alternative choices,4.0,0.02596322726458311
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,txxxdm duration,3.75,0.043179526925086975
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,treated txxxdm,3.75,0.1644953340291977
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,respectively ).,3.5,0.08458003401756287
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,insulin dose,3.5,0.1086290031671524
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,higher sensitivity,3.5,0.09277842193841934
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,elevated hbaxxxc,3.5,0.08202844113111496
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,ann ]),3.5,0.034718528389930725
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,machine,3.4,0.04470905661582947
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,txxxdm patients,3.25,0.4592966139316559
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,rf,3.0,0.04890134930610657
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,xxx,2.5,-0.015934890136122704
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,logistic,2.5,0.07028506696224213
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,diabetes,2.5,0.31405115127563477
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,control,2.5,0.05591680109500885
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,complications,2.0,0.2546522915363312
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,txxxdm,1.75,0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,svm,1.5,0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,sensitivity,1.5,0.0724399983882904
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,respectively,1.5,0.08458003401756287
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,patients,1.5,0.4592966139316559
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,insulin,1.5,0.1587810218334198
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,hypertension,1.5,0.364623486995697
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,hbaxxxc,1.5,0
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,en,1.5,0.06505817919969559
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,ann,1.5,0.034718528389930725
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,well,1.0,0.09099400043487549
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,used,1.0,0.010911919176578522
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,simulate,1.0,-0.004721604287624359
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,results,1.0,0.0652550756931305
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,prognosis,1.0,0.23093095421791077
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,performed,1.0,0.1553603708744049
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,moreover,1.0,0.01877431571483612
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,methods,1.0,0.024640876799821854
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,half,1.0,0.06323976814746857
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,explore,1.0,0.06985367834568024
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,exercise,1.0,0.1012873649597168
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,curve,1.0,-0.04778170958161354
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,conclusions,1.0,0.07628431916236877
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,compare,1.0,0.09237030148506165
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,combining,1.0,0.01566525548696518
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,bp,1.0,0.052511051297187805
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,background,1.0,0.03833860531449318
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,areas,1.0,0.15646809339523315
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,additionally,1.0,0.012068133801221848
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,addition,1.0,0.1140233725309372
Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study.,accuracy,1.0,0.05023651197552681
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx health care provider networks,19.115384615384613,0.14577598161995411
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,machine learning methods offered,16.0,0.0371210677549243
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,deploy targeted interventions aimed,16.0,0.07570216758176684
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,compare machine learning approaches,16.0,0.051947323605418205
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emr )- derived information,15.0,0.03160948911681771
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home days loss greater,14.866666666666667,0.051847354508936405
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,conducted including xxx medicare,14.615384615384615,0.0848900475539267
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,efficient modeling approach based,14.583333333333334,0.07424812018871307
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,boosted modeling consistently provided,14.333333333333334,0.041061907075345516
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home time loss outcomes,13.366666666666665,0.0930250370875001
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home days loss claims,13.200000000000001,0.041661021299660206
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,modeled using logistic regression,12.833333333333334,0.04285163152962923
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predicting key hf outcomes,12.25,0.11348996218293905
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,"xxx ), hf hospitalization",11.365384615384615,0.11768621516724427
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,health care professionals,11.0,0.2550073266029358
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home days loss,10.866666666666667,0.038973004867633186
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,home time loss,10.7,0.04628034060200056
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predicting key outcomes,9.5,0.11432336146632831
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic regression based,9.083333333333334,0.08179157972335815
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,various threshold probabilities,9.0,0.045091199999054275
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,"massachusetts ("" providers",9.0,0.04796740598976612
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,least absolute shrinkage,9.0,0.044560267279545464
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,electronic medical record,9.0,0.20672879181802273
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,accurate risk stratification,9.0,0.11140455802281697
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,traditional logistic regression,8.833333333333334,0.07397704944014549
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,selection operation regression,8.833333333333334,0.08157629768053691
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,based predictive models,8.583333333333334,0.12280602256457011
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,based models appeared,8.583333333333334,0.06333546464641888
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,lowest brier scores,8.5,-0.014212530727187792
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,trained using data,8.0,0.06274963915348053
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,top cost decile,8.0,0.04955455412467321
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,net benefit estimates,8.0,0.030171713481346767
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,good calibration across,8.0,0.11524555087089539
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,generally similar performance,8.0,0.04026287173231443
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emr vs claims,8.0,0.06547411531209946
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx vs xxx,7.897435897435898,0.01645112658540408
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,testing set ).,7.75,0.04342283681035042
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gbms predicting mortality,7.333333333333334,0.15880807302892208
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,boosted modeling,6.333333333333334,0.07809735462069511
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,logistic regression,5.833333333333334,0.08010278269648552
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,networks ).,5.75,0.04708750545978546
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf hospitalization,5.75,0.18449676781892776
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,"xxx ),",5.615384615384615,-0.015934890136122704
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,using claims,5.333333333333334,0.00399385392665863
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx outcomes,5.282051282051282,0.10866211820393801
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,vs claims,5.0,0.06547411531209946
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,net benefit,5.0,0.045609232038259506
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx ).,4.865384615384615,-0.015934890136122704
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,regression trees,4.833333333333334,0.04729419481009245
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emr predictors,4.666666666666667,0.16273410618305206
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,main outcomes,4.666666666666666,0.15206529572606087
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,network xxx,4.615384615384615,0.018721873871982098
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,january xxx,4.615384615384615,-0.003959255293011665
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,december xxx,4.615384615384615,-0.012136124540120363
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,training set,4.5,0.06541751697659492
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,brier score,4.5,-0.016325034201145172
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx patients,4.365384615384615,0.2216808618977666
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,augmenting claims,4.333333333333334,0.08499852195382118
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,year follow,4.0,0.05729828216135502
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,recall curves,4.0,-0.00414190674200654
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,random forests,4.0,-0.009110379964113235
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,limited improvement,4.0,0.06959893368184566
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,includes physicians,4.0,0.3086783364415169
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,improve prediction,4.0,0.08128046989440918
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,high cost,4.0,0.047133004292845726
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,heart failure,4.0,0.2074820026755333
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,decision curves,4.0,0.01502574561163783
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cause mortality,4.0,0.18113460391759872
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,c statistics,4.0,0.04330148361623287
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,added value,4.0,0.04583905218169093
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,improving patients,3.75,0.27840057387948036
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gbm ).,3.75,0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,enrolled patients,3.75,0.3189901113510132
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,additional predictors,3.666666666666667,0.11644388735294342
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,prognostic study,3.5,0.27590933442115784
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,highest discrimination,3.5,0.017607683315873146
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,higher auprcs,3.0,0.11311684548854828
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,hf,2.75,0.1109897643327713
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,outcomes,2.6666666666666665,0.23325912654399872
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,xxx,2.6153846153846154,-0.015934890136122704
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,models,2.3333333333333335,0.10839370638132095
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,claims,2.3333333333333335,0.04972507059574127
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,similar,2.0,0.08377962559461594
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,mortality,2.0,0.27426618337631226
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gbms,2.0,0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,data,2.0,0.1061776876449585
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,cost,2.0,0.033558186143636703
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,calibration,2.0,0.21323038637638092
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,patients,1.75,0.4592966139316559
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,predictors,1.6666666666666667,0.16273410618305206
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,study,1.5,0.2376001477241516
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,higher,1.5,0.11311684548854828
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gbm,1.5,0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,discrimination,1.5,0.0022429823875427246
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,auprcs,1.5,0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,years,1.0,0.05066175013780594
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,total,1.0,0.003683900460600853
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,tested,1.0,0.06802673637866974
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,setting,1.0,0.04959516599774361
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,selecting,1.0,0.034643977880477905
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,sd,1.0,0.08195707201957703
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,results,1.0,0.0652550756931305
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,relevance,1.0,0.032082222402095795
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,quality,1.0,0.11005230993032455
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,precision,1.0,0.05533473938703537
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,period,1.0,0.022214137017726898
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,performed,1.0,0.1553603708744049
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,participants,1.0,0.06751469522714615
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,obtained,1.0,-0.0006794054061174393
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,objectives,1.0,0.043118979781866074
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,measures,1.0,0.031176652759313583
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,mean,1.0,0.07771239429712296
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,life,1.0,0.07387976348400116
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,institutions,1.0,0.12473896145820618
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,inclusion,1.0,0.01680990308523178
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,included,1.0,0.029688812792301178
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,importance,1.0,0.08358374238014221
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,however,1.0,-0.011453256011009216
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,gradient,1.0,0.07820996642112732
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,focus,1.0,0.08422843366861343
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,evaluate,1.0,0.08850531280040741
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,emrs,1.0,0
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,differences,1.0,0.1514238715171814
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,design,1.0,0.13118362426757812
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,critical,1.0,0.12879085540771484
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,conclusions,1.0,0.07628431916236877
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,comprise,1.0,0.08721785247325897
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,clinicians,1.0,0.43662092089653015
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,classification,1.0,0.01966315135359764
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,ci,1.0,0.06607142090797424
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,calculated,1.0,-0.0013035684823989868
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,boston,1.0,0.05194654315710068
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,area,1.0,0.1299571692943573
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,analyzed,1.0,0.13667140901088715
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes.,age,1.0,0.10348664224147797
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,analyzed using unsupervised machine learning,20.666666666666664,0.03718254342675209
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,cognitive impairment may help predict,20.0,0.03531698957085609
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,unsupervised machine learning framework,17.5,0.029263979755342007
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,identified using feature selection,15.666666666666666,0.04358128644526005
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,ad within xxx years,13.25,0.033001306001096964
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,may help distinguish,11.0,0.0008510984480381012
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,subtle cognitive alterations,10.0,0.041224939127763115
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,screening early evidence,9.0,0.08073090513547261
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,framingham heart study,9.0,0.271152138710022
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,model yielded xxx,8.75,0.020851752410332363
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx ± xxx,8.5,0.04078221941987673
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,"xxx %, xxx",8.5,-0.015934890136122704
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,early ad screening,8.5,0.0722502979139487
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,boston naming tests,8.5,0.06674937903881073
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,precede clinical evidence,8.333333333333334,0.20928849404056868
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,analyzed using,7.166666666666666,0.04746702313423157
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,ad ).,4.5,0.03272446244955063
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,clinical trials,4.333333333333334,0.3105999082326889
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,clinical practice,4.333333333333334,0.3287031501531601
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,np tests,4.166666666666667,0.061667101457715034
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,visual reproduction,4.0,0.05073693813756108
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,viable option,4.0,0.042450493201613426
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,trails b,4.0,0.05535547435283661
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,logical memory,4.0,0.06757079623639584
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,including age,4.0,0.08340635150671005
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,demographic data,4.0,0.11111131310462952
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,delayed recall,4.0,0.0006075957790017128
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,coordinating center,4.0,0.11021558381617069
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,attractive modality,4.0,0.18748723343014717
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,approach could,4.0,0.017238449305295944
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,longitudinal np,3.666666666666667,0.08868619240820408
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,subsequent development,3.5,0.08682634122669697
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,risk individuals,3.5,0.12413458526134491
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,results suggest,3.5,0.05601985938847065
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,national alzheimer,3.5,0.16505338996648788
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,predict,3.0,0.029006652534008026
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,nacc respectively,3.0,0.08458003401756287
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,xxx,2.75,-0.015934890136122704
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,ad,2.5,0.03272446244955063
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,np,1.6666666666666667,0.021217424422502518
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,risk,1.5,0.19420234858989716
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,results,1.5,0.0652550756931305
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,respectively,1.5,0.08458003401756287
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,nacc,1.5,0
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,development,1.5,0.1793753206729889
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,alzheimer,1.5,0.24842241406440735
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,testing,1.0,0.08385047316551208
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,subset,1.0,0.12691286206245422
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,specificity,1.0,0.09074191749095917
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,sensitivity,1.0,0.0724399983882904
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,progression,1.0,0.08447402715682983
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,processed,1.0,0.03618676960468292
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,neuropsychological,1.0,0.16074728965759277
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,n,1.0,-0.021267158910632133
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,methods,1.0,0.024640876799821854
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,low,1.0,0.06519334763288498
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,introduction,1.0,0.021546807140111923
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,immediate,1.0,0.05999145656824112
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,high,1.0,0.06070782244205475
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,fhs,1.0,0
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,features,1.0,0.04349645599722862
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,disease,1.0,0.1630353331565857
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,discussion,1.0,0.10436347126960754
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,context,1.0,0.04743277281522751
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,authors,1.0,0.21598771214485168
Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status.,accuracy,1.0,0.05023651197552681
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,wilcoxon signed ranked sum tests,25.0,0.04060510639101267
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,ongoing randomized trial carehnd,16.0,0.12674412628014883
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,charlson comorbidity index scores,16.0,0.13498600323994955
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,professional collaboration within patient,15.0,0.16412832774221897
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,compare care utilization frequencies,13.261904761904763,0.14457008428871632
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,often insufficiently coordinated,9.0,0.0387130423138539
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,multiple chronic conditions,9.0,0.11347085485855739
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,total care utilization,8.261904761904763,0.1499533373862505
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care utilization patterns,8.261904761904763,0.1669167180856069
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care utilization data,8.261904761904763,0.18411793311436972
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,innovative methods beyond,8.0,0.04160820320248604
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,including diagnostic data,8.0,0.21928277611732483
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd patient care,7.628571428571428,0.34116221964359283
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,integrated care interventions,7.428571428571429,0.16698380808035532
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd patients recruited,7.2,0.30508099496364594
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care utilization,5.261904761904762,0.22308805584907532
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,utilization indicators,4.833333333333334,0.14900752156972885
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patient characteristics,4.5,0.22188943438231945
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,traditional care,4.428571428571429,0.1645332258194685
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,centered care,4.428571428571429,0.19406159222126007
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care received,4.428571428571429,0.13988058175891638
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care providers,4.428571428571429,0.19536062702536583
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care outcomes,4.428571428571429,0.25029999762773514
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd patients,4.2,0.4592966139316559
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd center,4.2,0.1649731695652008
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,two groups,4.0,0.04741007462143898
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,two arms,4.0,0.12033706530928612
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,statistically significant,4.0,0.08100135251879692
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,several diagnoses,4.0,0.18671197444200516
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,regional database,4.0,0.09448611177504063
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,previous research,4.0,0.15220990404486656
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,positive effect,4.0,0.007016112795099616
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients included,4.0,0.24449271336197853
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,nctxxx ).,4.0,0
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,machine learning,4.0,0.03610682301223278
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,kidney diseases,4.0,0.23479311168193817
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,key components,4.0,0.06046810373663902
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,initial effects,4.0,0.024121366441249847
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,high utilizers,4.0,0.1618865504860878
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,high level,4.0,0.05937035009264946
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hereafter referred,4.0,0.0487165953963995
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,different specialties,4.0,0.1953858658671379
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diagnoses profiles,4.0,0.1493346355855465
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,descriptive statistics,4.0,0.02271125465631485
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,control group,4.0,0.05305405892431736
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,health care,3.9285714285714284,0.2935049533843994
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,study aims,3.5,0.14014726504683495
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,mcc patients,3.5,0.22936759982258081
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,care,2.4285714285714284,0.26734086871147156
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,hnd,2.2,0
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,patients,2.0,0.4592966139316559
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,methods,2.0,0.024640876799821854
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,integrated,2.0,0.09875309467315674
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diagnostic,2.0,0.48834457993507385
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,study,1.5,0.2376001477241516
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,mcc,1.5,-0.0005614142864942551
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,health,1.5,0.31966903805732727
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,characteristics,1.5,0.02879529818892479
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,variation,1.0,0.0704495757818222
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,sub,1.0,0.157742440700531
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,similar,1.0,0.08377962559461594
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,sicker,1.0,0.2706219553947449
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,shown,1.0,0.044945128262043
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,results,1.0,0.0652550756931305
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,rct,1.0,0
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,purpose,1.0,-0.006926483474671841
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,person,1.0,0.019730402156710625
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,performed,1.0,0.1553603708744049
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,perform,1.0,0.09922076761722565
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,multidisciplinary,1.0,0.31782692670822144
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,intervention,1.0,0.06027820706367493
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,inter,1.0,0.08877119421958923
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,intensive,1.0,0.12172117084264755
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,informed,1.0,-0.004203645512461662
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,indication,1.0,0.06315438449382782
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,impact,1.0,0.029600899666547775
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,however,1.0,-0.011453256011009216
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,heart,1.0,0.30470412969589233
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,explored,1.0,0.10362917929887772
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,explore,1.0,0.06985367834568024
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,experienced,1.0,0.08525562286376953
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,expected,1.0,0.06577444076538086
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,evaluate,1.0,0.08850531280040741
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,diabetes,1.0,0.31405115127563477
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,describe,1.0,-0.011884354054927826
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,counterparts,1.0,0.054215896874666214
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,conducted,1.0,0.055469855666160583
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,conclusion,1.0,0.03420025110244751
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,comparison,1.0,0.11286726593971252
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,collected,1.0,-0.03091895952820778
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,cardiovascular,1.0,0.5747424960136414
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic.,beginning,1.0,-0.018236802890896797
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,extended model especially performed better,23.333333333333336,0.0714992918074131
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,model improves lqts diagnosis,13.433333333333334,0.12250732257962227
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,improve lqts diagnosis,9.1,0.16598299145698547
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,retrospective cohort consisting,9.0,0.12853251894315085
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,remains challenging due,9.0,-0.0035153599455952644
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,negative family members,9.0,0.05879921838641167
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,external cohort consisting,9.0,0.11375816911458969
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,combining new polynomial,9.0,0.06328615049521129
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx %) followed,8.555555555555555,0.024757095612585545
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,first xxx hermite,8.555555555555555,0.001687728799879551
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,clinical qtc cut,8.5,0.250034530647099
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,best overall accuracy,8.5,0.04525413736701012
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,baseline qtc cut,8.5,0.03003943432122469
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave morphology parameters,8.35,0.068363801886638
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave morphology characterizations,8.35,0.05947886034846306
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave morphology features,7.85,0.06189653277397156
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx lqts patients,7.655555555555555,0.2216808618977666
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,first xxx hg,7.555555555555555,-0.026747581238547962
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,"qtc ), age",7.5,0.10348664224147797
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave morphology,5.35,0.07109657116234303
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx patients,5.055555555555555,0.2216808618977666
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,wave morphologies,4.6,0.07032989151775837
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,diagnosing lqts,4.6,0.2861221432685852
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx genotype,4.555555555555555,0.055095371790230274
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx %).,4.555555555555555,-0.015934890136122704
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,different features,4.5,0.05542314611375332
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,best fit,4.5,0.0624514352530241
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,xxx controls,4.055555555555555,0.021380837075412273
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,weight coefficients,4.0,0.04868531413376331
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,three support,4.0,0.04619416268542409
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,precordial leads,4.0,0.08328859508037567
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,low sensitivity,4.0,0.06881667301058769
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,linear combination,4.0,-0.02695499174296856
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,limb leads,4.0,0.07060671225190163
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,elsevier inc,4.0,0.007824641652405262
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,diagnosing long,4.0,0.15459847636520863
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,considerable overlap,4.0,0.06889205425977707
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,average complex,4.0,0.04190417705103755
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qt syndrome,3.666666666666667,-0.005484644323587418
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,corrected qt,3.666666666666667,0.019606608897447586
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,models fed,3.5,0.055948127061128616
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,healthy subjects,3.5,0.1198251061141491
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,finally used,3.5,-0.012762047350406647
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,model,3.3333333333333335,0.05463607236742973
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqts,2.6,0
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qtc,2.5,0
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,hg,2.0,-0.08361820131540298
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,age,2.0,0.10348664224147797
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,qt,1.6666666666666667,-0.026990704238414764
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,used,1.5,0.010911919176578522
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,subjects,1.5,0.13721111416816711
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,models,1.5,0.10839370638132095
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,controls,1.5,0.05869656428694725
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,well,1.0,0.09099400043487549
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,vector,1.0,0.09440627694129944
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,svm,1.0,0
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,study,1.0,0.2376001477241516
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,stt,1.0,0
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,specific,1.0,0.08915150165557861
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,sex,1.0,0.025031838566064835
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,segments,1.0,0.08423002809286118
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,robustness,1.0,0.028073906898498535
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,results,1.0,0.0652550756931305
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,published,1.0,0.10513044893741608
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,polynomials,1.0,0.057253893464803696
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,patient,1.0,0.4149835705757141
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,offs,1.0,-0.06257563829421997
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,objective,1.0,0.01818794757127762
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,methods,1.0,0.024640876799821854
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,machine,1.0,0.04470905661582947
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,lqt,1.0,0
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,interval,1.0,0.14205302298069
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,ii,1.0,0.06888964027166367
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,gender,1.0,0.08549608290195465
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,gauss,1.0,0.17139707505702972
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,fitting,1.0,0.04899413511157036
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,fitted,1.0,0.08199499547481537
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,error,1.0,-0.03215598687529564
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,conclusion,1.0,0.03420025110244751
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,classified,1.0,0.05302777886390686
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,check,1.0,0.018208332359790802
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,characterizing,1.0,0.0694388896226883
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,characterized,1.0,0.05963318794965744
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,characterize,1.0,0.05313561111688614
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,based,1.0,0.08516917377710342
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,background,1.0,0.03833860531449318
Improving Long-QT syndrome Diagnosis by a Polynomial-Based T-wave Morphology Characterization.,adding,1.0,0.09709080308675766
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,"xxx %), mineralocorticoid receptor antagonists",18.475,0.08886548364534974
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,"xxx %), angiotensin receptor blockers",16.475,0.08252724399790168
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,previously published registries similar,15.0,0.09421996399760246
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx %) remained similar,13.875,0.032247078294555344
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc heart failure published,13.0,0.14705964177846909
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,patients reached target doses,12.666666666666666,0.1622823541983962
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc hf guidelines despite,12.5,0.06819290015846491
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,mineralocorticoid receptor antagonists,12.0,0.12379894157250722
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc hf guidelines recommendations,11.5,0.1031226646155119
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin receptor blockers,10.0,0.1153479553759098
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,"xxx %), angiotensin",9.475,0.09499846119433641
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,reduced ejection fraction,9.0,0.003271050751209259
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting enzyme inhibitors,9.0,0.06566230580210686
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,converting enzyme inhibitor,9.0,0.05182438219587008
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,"xxx %, respectively",8.875,0.03432257194072008
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx april xxx,8.75,-0.002088606357574463
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,enrolled xxx patients,8.541666666666666,0.20734844418863455
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,"xxx %), sacubitril",8.475,-0.015934890136122704
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,results also suggest,8.0,0.05151376873254776
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,outpatient cardiology clinics,8.0,0.6046819388866425
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx catalan hospitals,7.875,0.19359958482285342
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,linx registry shows,7.5,0.06111572993298372
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,"xxx %),",6.475,-0.015934890136122704
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,target doses,6.0,0.08042247965931892
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,heart failure,6.0,0.2074820026755333
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx %),5.875,-0.015934890136122704
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc guidelines,5.75,0.0973324105143547
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,previous registries,5.0,0.10000563785433769
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,pharmacological recommendations,5.0,0.18274031206965446
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx february,4.875,-0.01597412582486868
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,may xxx,4.875,-0.012824242003262043
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf drugs,4.75,0.13704586774110794
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,linx registry,4.5,0.08399210590869188
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sons ltd,4.0,0.05613034591078758
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,new version,4.0,0.044691598042845726
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,monotherapy decreased,4.0,0.11667018383741379
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,low proportion,4.0,0.06622054055333138
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,john wiley,4.0,0.0068832337856292725
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hospitals according,4.0,0.24770694226026535
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,european society,4.0,0.084633007645607
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,appropriate adherence,4.0,0.06785585917532444
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,almost one,4.0,0.03667417913675308
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sectional study,3.5,0.2051400989294052
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,higher level,3.5,0.08557486161589622
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,esc,3.0,0.06814411282539368
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,blockers,3.0,0.045741792768239975
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,angiotensin,3.0,0.20593181252479553
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,xxx,2.875,-0.015934890136122704
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hf,2.75,0.1109897643327713
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,guidelines,2.75,0.12652070820331573
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,patients,2.6666666666666665,0.4592966139316559
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,sacubitril,2.0,0
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,results,2.0,0.0652550756931305
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,registry,2.0,0.13723981380462646
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,hospitals,2.0,0.4598262906074524
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,cardiology,2.0,1.0
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,study,1.5,0.2376001477241516
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,level,1.5,0.05803287774324417
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,valsartan,1.0,0.3132857382297516
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,use,1.0,0.0033735278993844986
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,treatment,1.0,0.27399298548698425
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,titration,1.0,0.1384366899728775
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,released,1.0,-0.011258095502853394
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,quarter,1.0,0.02147839590907097
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,publication,1.0,0.05962849035859108
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,prescription,1.0,0.16285577416419983
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,prescribed,1.0,0.13220295310020447
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,population,1.0,0.1400190144777298
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,observational,1.0,0.1594090461730957
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,multicentre,1.0,0.267255961894989
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,months,1.0,0.04044569283723831
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,methods,1.0,0.024640876799821854
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,management,1.0,0.23943668603897095
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,ivabradine,1.0,0.3274857997894287
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,greater,1.0,0.09047040343284607
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,describe,1.0,-0.011884354054927826
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,cross,1.0,0.1382628083229065
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,consequence,1.0,0.00507243350148201
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,conclusions,1.0,0.07628431916236877
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,complexity,1.0,-0.0006290450692176819
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,compared,1.0,0.10162706673145294
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,class,1.0,0.02183631807565689
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,beta,1.0,0.03460385650396347
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,behalf,1.0,0.003146544098854065
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,authors,1.0,0.21598771214485168
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,aims,1.0,0.04269438236951828
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,aim,1.0,0.040013544261455536
Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.,accomplished,1.0,0.017712406814098358
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,new dihydropyridine calcium channel blockers,22.0,0.09904947075992823
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mmol creatinine (> xxx mg,17.433333333333334,0.10890816757455468
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,diabetic hypertensive patients treated,13.75,0.30211174115538597
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,calcium channel blockers,12.0,0.06105601694434881
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,diabetic hypertensive patients,9.75,0.3479838768641154
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,validated digital device,9.0,0.12929092844327292
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significant difference among,9.0,0.07635592048366864
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,clinitek device analyzer,9.0,0.16878881305456161
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,angiotensin aldosterone system,9.0,0.16395087788502374
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mean age xxx,8.6,0.05508804880082607
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,different drug combinations,8.5,0.07228653381268184
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx mg albumin,8.433333333333334,0.05052501770357291
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx unselected patients,8.35,0.23068614614506563
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,"males xxx %),",8.266666666666666,0.02465240377932787
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx ± xxx,8.2,0.04078221941987673
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,"xxx %, p",7.6,0.05113617051392794
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,"xxx %, lercanidipine",7.6,0.127093312330544
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,"xxx %, amlodipine",7.6,0.08670748490840197
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,"xxx %), macroalbuminuria",7.266666666666667,0.12601485569030046
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,mmol creatinine,6.5,0.18026239424943924
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx mg,5.933333333333334,0.037553940899670124
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,"xxx %),",5.266666666666667,-0.015934890136122704
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,creatinine ratio,5.0,0.1493717022240162
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx years,4.6,0.017363430000841618
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx months,4.6,0.012255401350557804
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx %.,4.6,-0.015934890136122704
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx %).,4.6,-0.015934890136122704
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx %),4.6,-0.015934890136122704
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,urinary albumin,4.5,0.13936226069927216
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,several combinations,4.5,0.03447212651371956
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx subjects,4.1,0.060638112016022205
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,similar effect,4.0,0.04403757839463651
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,renal outcomes,4.0,0.34220316261053085
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,raas inhibitors,4.0,0.1365484818816185
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,pait survey,4.0,0.02947916090488434
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,low number,4.0,0.047874187119305134
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,kidney disease,4.0,0.19676077365875244
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,early marker,4.0,0.04418988898396492
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,decreased occurrence,4.0,0.04510323889553547
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,blood pressure,4.0,0.14018943160772324
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,without albuminuria,3.8,0.09529329836368561
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,control albuminuria,3.8,0.13373274356126785
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria translates,3.8,0.12359282746911049
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significantly lowered,3.666666666666667,0.05978113226592541
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significantly higher,3.666666666666667,0.10986901819705963
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treatments decrease,3.5,0.18158124387264252
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,previous treatment,3.5,0.15054703876376152
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,g ).,3.5,0.02275453880429268
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,enalapril compared,3.5,0.19556830078363419
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,analysed data,3.5,0.1061776876449585
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,amlodipine perindopril,3.5,0.23532819747924805
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,ramipril albuminuria,3.3,0.20104482769966125
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,patients,2.75,0.4592966139316559
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,xxx,2.6,-0.015934890136122704
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,p,2.0,0.11820723116397858
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,macroalbuminuria,2.0,0.26796460151672363
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,lercanidipine,2.0,0.2701215147972107
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,amlodipine,2.0,0.18934985995292664
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,albuminuria,1.8,0.21154868602752686
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,significantly,1.6666666666666667,0.10662119090557098
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treatments,1.5,0.2853734493255615
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,treatment,1.5,0.27399298548698425
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,subjects,1.5,0.13721111416816711
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,ramipril,1.5,0.19054096937179565
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,perindopril,1.5,0.28130653500556946
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,g,1.5,0.02275453880429268
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,enalapril,1.5,0.28950953483581543
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,data,1.5,0.1061776876449585
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,verapamil,1.0,0.2621586322784424
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,valsartan,1.0,0.3132857382297516
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,using,1.0,-0.04173736274242401
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,use,1.0,0.0033735278993844986
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,trandolapril,1.0,0.23690202832221985
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,showing,1.0,0.002325989305973053
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,results,1.0,0.0652550756931305
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,renin,1.0,0.18859215080738068
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,reduction,1.0,0.11836925148963928
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,reduced,1.0,0.03761252388358116
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,prevalence,1.0,0.1558399796485901
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,present,1.0,0.0756206065416336
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,normoalbuminuria,1.0,0
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,nitrendipine,1.0,0
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,multistic,1.0,0
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,microalbuminuria,1.0,0.2237807959318161
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,methods,1.0,0.024640876799821854
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,measured,1.0,0.07410861551761627
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,maintained,1.0,0.03229638934135437
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,loss,1.0,0.0528750903904438
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,introduction,1.0,0.021546807140111923
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,frequency,1.0,0.059476010501384735
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,felodipine,1.0,0.19666710495948792
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,favoring,1.0,0.08206921815872192
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,evaluate,1.0,0.08850531280040741
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,due,1.0,-0.005625979043543339
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,defined,1.0,0.009061356075108051
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,conclusions,1.0,0.07628431916236877
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,combined,1.0,0.05379888415336609
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,changes,1.0,-0.006772637367248535
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,cardiovascular,1.0,0.5747424960136414
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,baseline,1.0,0.05839666724205017
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,assessed,1.0,0.06162751466035843
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,analyzed,1.0,0.13667140901088715
PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.,aims,1.0,0.04269438236951828
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,constructed showed comparable predicting accuracy,23.0,0.0490543469786644
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,constructed using computational approaches,16.5,0.06322937924414873
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,receiver operating characteristic curve,16.0,0.053695183247327805
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,e )- stained whole,16.0,0.050068978841106095
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,term survival groups according,14.333333333333334,0.06309487577527761
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx quantitative image features,10.366666666666665,0.06421739375218749
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,west china hospital,9.0,0.18584545205036798
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tnm staging systems,9.0,0.09466038830578327
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,fully automated pipeline,9.0,0.06894889970620473
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,external validation sets,9.0,0.062281412382920585
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,distinguish hepatocellular carcinoma,9.0,0.1279252270857493
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,different time points,9.0,0.061143690099318825
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,develop quantitative feature,9.0,0.10188550750414531
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,cancer genome atlas,9.0,0.1906172583500544
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,assigned risk scores,9.0,0.07852762813369434
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,adjacent normal tissues,9.0,0.09039139499266942
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,adjacent normal tissue,9.0,0.11436919122934341
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,diagnostic classifier based,8.5,0.22222079584995905
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,classify tissue slides,8.5,0.08022588863968849
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,tissue microarray images,8.333333333333334,0.1775288830200831
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,significantly stratify patients,8.25,0.2640812247991562
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,successfully distinguish hcc,8.0,0.01990586146712303
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,learning models derived,7.833333333333334,0.04134630194554726
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,predicting patients,5.75,0.2513232883065939
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,quantitative features,5.166666666666666,0.09172767959535122
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,image features,5.166666666666666,0.06642278097569942
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,based models,4.833333333333334,0.09678144007921219
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,histopathological slides,4.5,0.1503736600279808
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx features,4.366666666666667,0.01378078293055296
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,survival outcomes,4.333333333333334,0.18590887635946274
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,statistical models,4.333333333333334,0.11060013622045517
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,slide images,4.333333333333334,0.03692284971475601
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,histopathological images,4.333333333333334,0.1540200039744377
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc patients,4.25,0.4592966139316559
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx ).,4.2,-0.015934890136122704
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,surgical resection,4.0,0.38057055324316025
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognostic model,4.0,0.1844272967427969
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,learning methods,4.0,0.026072733104228973
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,histopathological slide,4.0,0.12079568207263947
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc diagnosis,4.0,0.24688632786273956
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,findings suggest,4.0,0.12938952632248402
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,assist clinicians,4.0,0.21805593371391296
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,predict patients,3.75,0.24415163323283195
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,auc xxx,3.7,-0.016209851019084454
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,extracted features,3.6666666666666665,0.027844730764627457
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognosis prediction,3.5,0.15420611947774887
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,survival,2.3333333333333335,0.13855862617492676
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,xxx,2.2,-0.015934890136122704
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,features,2.1666666666666665,0.04349645599722862
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hcc,2.0,0
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,prognosis,1.5,0.23093095421791077
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,predict,1.5,0.029006652534008026
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,methods,1.5,0.024640876799821854
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,extracted,1.5,0.012193005532026291
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,auc,1.5,-0.016484811902046204
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,used,1.0,0.010911919176578522
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,train,1.0,0.012325972318649292
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,total,1.0,0.003683900460600853
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,test,1.0,0.08394099026918411
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,surgery,1.0,0.3447723090648651
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,study,1.0,0.2376001477241516
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,shorter,1.0,0.08764592558145523
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,set,1.0,0.0029952004551887512
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,results,1.0,0.0652550756931305
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,random,1.0,-0.09545474499464035
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,objective,1.0,0.01818794757127762
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,moreover,1.0,0.01877431571483612
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,machine,1.0,0.04470905661582947
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,longer,1.0,0.0349513441324234
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hepatectomy,1.0,0.32705748081207275
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,hematoxylin,1.0,0.20370984077453613
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,h,1.0,0.028560467064380646
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,eosin,1.0,0.23330606520175934
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,conclusions,1.0,0.07628431916236877
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,area,1.0,0.1299571692943573
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,analyze,1.0,0.0579666830599308
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,aim,1.0,0.040013544261455536
Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning.,able,1.0,-0.006554350256919861
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,among people prescribed loop diuretics,18.0,0.10049626827239991
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,less common among individuals,16.333333333333332,0.07493497617542744
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,dimensional dementia assessment scale,16.0,0.08744572475552559
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,drug classes among people,15.5,0.11046043783426285
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,collected concerning drug use,14.166666666666666,0.04832139750942588
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,performed including xxx people,13.785714285714285,0.07536793733015656
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,angiotensin ii receptor blockers,12.5,0.10373337659984827
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,people prescribed asa,10.5,0.07720055306951205
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mineralocorticoid receptor antagonists,9.5,0.12379894157250722
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,two questionnaire surveys,9.0,0.0713474452495575
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,especially regarding adherence,9.0,0.07497867941856384
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,converting enzyme inhibitors,9.0,0.06566230580210686
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,associated factors within,9.0,0.06410927201310794
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,elderly people living,8.833333333333334,0.12953860312700272
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cardiovascular drug treatment,8.833333333333332,0.3397956043481827
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,severe cognitive impairment,8.166666666666666,0.07753808796405792
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,increasing cognitive impairment,8.166666666666666,0.06519506002465884
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cardiovascular agents used,7.666666666666666,0.19537448386351267
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,four different levels,7.5,0.0594781960050265
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,"xxx %, β",7.285714285714286,0.02390179503709078
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,loop diuretics,6.166666666666666,0.08653094992041588
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx people,5.785714285714286,0.041392658837139606
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive impairment,5.166666666666666,0.07019133120775223
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,four levels,5.0,0.05554237589240074
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cardiovascular drugs,4.666666666666666,0.36892223358154297
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx living,4.619047619047619,0.04479962680488825
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,treatment patterns,4.5,0.16428351402282715
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,different drugs,4.5,0.1152259036898613
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognitive function,4.5,0.11822796240448952
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,daily living,4.333333333333334,0.06507956236600876
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx %.,4.285714285714286,-0.015934890136122704
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,significantly lower,4.0,0.10325782373547554
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,nursing homes,4.0,0.18970278091728687
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,northern sweden,4.0,0.07957284152507782
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mddas ).,4.0,0
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,heart failure,4.0,0.2074820026755333
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,describe changes,4.0,-0.00932849571108818
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,atrial fibrillation,4.0,0.26550570130348206
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx compared,3.7857142857142856,0.04284608829766512
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,results indicate,3.5,0.043764496222138405
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,diuretics,2.6666666666666665,0.21879620850086212
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,use,2.5,0.0033735278993844986
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,blockers,2.5,0.045741792768239975
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,angiotensin,2.5,0.20593181252479553
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,xxx,2.2857142857142856,-0.015934890136122704
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,β,2.0,0.06373848021030426
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,used,2.0,0.010911919176578522
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,results,1.5,0.0652550756931305
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,compared,1.5,0.10162706673145294
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,warfarin,1.0,0.32206350564956665
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,using,1.0,-0.04173736274242401
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,study,1.0,0.2376001477241516
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,room,1.0,0.1170908510684967
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,relation,1.0,0.07857805490493774
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,purpose,1.0,-0.006926483474671841
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,proxy,1.0,0.006921097636222839
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,proportion,1.0,0.06724773347377777
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,prescription,1.0,0.16285577416419983
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,population,1.0,0.1400190144777298
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,pattern,1.0,0.04877403751015663
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,multi,1.0,0.048057474195957184
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,mras,1.0,0
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,methods,1.0,0.024640876799821854
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,increased,1.0,0.07228505611419678
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,improvement,1.0,0.12947404384613037
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,improved,1.0,0.0877273678779602
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,guidelines,1.0,0.12652070820331573
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,functioning,1.0,0.0729140043258667
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,effect,1.0,0.004295531194657087
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,data,1.0,0.1061776876449585
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,conclusion,1.0,0.03420025110244751
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,cognition,1.0,0.18422648310661316
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,arbs,1.0,0.026489917188882828
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,analyse,1.0,0
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,aim,1.0,0.040013544261455536
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,adl,1.0,0.0771344006061554
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,activities,1.0,0.02935326099395752
Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.,acei,1.0,0
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,highly controlled ubiquitous posttranslational modification,25.0,0.03599901720881462
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,clinically applied risk prediction scores,19.75,0.12173875272274018
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,based type xxx diabetes score,18.576190476190476,0.09252739958465099
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycans improve type xxx diabetes,18.242857142857144,0.1145031925290823
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,prospective european prospective investigation,16.0,0.07116947881877422
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,precisely targeted primary prevention,16.0,0.0851284060627222
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,"e ., myocardial infarction",16.0,0.19994248946507773
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,epic )- potsdam cohort,14.666666666666666,0.07331506907939911
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,weighted c index xxx,14.309523809523808,0.02648088661953807
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,finland cardiovascular risk study,14.25,0.2549746581353247
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,weighted c indices men,14.166666666666666,0.05404847953468561
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan profiling may thus,14.083333333333334,0.036230096127837896
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan profiling integrates information,12.583333333333334,0.07811998389661312
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,weighted prediction scores,11.666666666666666,0.021261521925528843
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,type xxx diabetes,10.576190476190476,0.11218689816693465
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,american diabetes association,9.6,0.14200195716693997
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,verified incident cases,9.0,0.048442874724666275
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,nonlinear model building,9.0,0.04953139275312424
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,enzymatic protein glycosylation,9.0,0.1012729008992513
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,internal validation cohort,8.666666666666666,0.13578038911024728
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,baseline plasma samples,8.666666666666666,0.0941954863568147
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,validated machine learning,8.5,0.05224952474236488
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma protein n,7.833333333333332,0.07531461678445339
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx years ).,7.476190476190476,0.017363430000841618
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,selected predictive n,7.0,0.062405203158656754
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,diabetes risk,6.85,0.25412674993276596
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,applied separately,5.5,0.02309310995042324
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,chromatographic profiling,5.333333333333334,0.08542603254318237
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,risk stratification,5.25,0.16070245951414108
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx years,5.142857142857142,0.017363430000841618
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cardiovascular diseases,5.0,0.40692125260829926
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx ).,4.976190476190476,-0.015934890136122704
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,plasma n,4.833333333333333,0.07488869968801737
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx n,4.809523809523809,-0.01860102452337742
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan groups,4.75,0.07744613289833069
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,selected n,4.666666666666666,0.006180210970342159
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycans improved,4.666666666666666,0.11930149048566818
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx participants,4.642857142857142,0.025789902545511723
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,"xxx ),",4.642857142857142,-0.015934890136122704
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,time xxx,4.642857142857142,0.019245524890720844
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,ci xxx,4.642857142857142,0.02506826538592577
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,externally validated,4.5,0.07196013256907463
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,strongly predictive,4.333333333333334,0.09019435569643974
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,stroke ).,4.333333333333334,0.2592560052871704
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,moderately predictive,4.333333333333334,0.12656795978546143
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,research design,4.0,0.20425117015838623
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,relative abundance,4.0,0.03959193639457226
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,random subsample,4.0,-0.03890769463032484
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,predict incidence,4.0,0.10471471771597862
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,median follow,4.0,0.11098180711269379
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,constructed case,4.0,0.062248438596725464
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cohorts including,4.0,0.0671900138258934
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cardiometabolic diseases,4.0,0.3090708702802658
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd separately,3.666666666666667,0.039199184626340866
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd incidence,3.666666666666667,0.18042278289794922
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,based,3.0,0.08516917377710342
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycan,2.75,0.1342036873102188
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycans,2.6666666666666665,0.15087561309337616
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cohort,2.6666666666666665,0.15340903401374817
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,xxx,2.642857142857143,-0.015934890136122704
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,men,2.5,0.09247083961963654
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,information,2.5,0.07507836818695068
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,n,2.1666666666666665,-0.021267158910632133
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvd,1.6666666666666667,0
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,workflow,1.0,0.19669874012470245
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,women,1.0,0.14002981781959534
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,useful,1.0,0.07975795120000839
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,results,1.0,0.0652550756931305
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,physician,1.0,0.5361219048500061
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,objective,1.0,0.01818794757127762
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,methods,1.0,0.024640876799821854
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,investigate,1.0,0.04426265507936478
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,glycome,1.0,0
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,generated,1.0,0.05094560980796814
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,finrisk,1.0,0
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,finding,1.0,0.017409224063158035
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,established,1.0,0.06200568750500679
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cvds,1.0,0
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cross,1.0,0.1382628083229065
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,context,1.0,0.04743277281522751
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,construction,1.0,0.09718848764896393
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,conclusions,1.0,0.07628431916236877
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,cancer,1.0,0.23309507966041565
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,accuracy,1.0,0.05023651197552681
Plasma &lt;i&gt;N&lt;/i&gt;-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.,ability,1.0,-0.022223003208637238
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,found increased igfxxx protein levels,20.625,0.057593357749283314
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,like growth factor xxx,15.25,0.061309896875172853
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,systemic versus localized signaling,15.0,0.07976250723004341
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,casxxx gene activation approach,14.5,0.08306808024644852
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,igfxxx mrna transcript variants,14.208333333333332,0.04301820509135723
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,class xxx mrna variants,13.583333333333332,0.021869275098045666
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,treating skeletal muscle atrophy,13.166666666666666,0.14565661270171404
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,igfxxx mrna variants,10.208333333333332,0.059706397354602814
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,key positive regulator,9.0,0.06445485105117162
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cell culture media,9.0,0.07892321298519771
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,enhancing igfxxx signaling,8.875,0.08659395948052406
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,sgrna target location,8.5,0.0427208561450243
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increasing gene expression,8.5,0.06381330577035745
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,diverse biology seen,8.5,0.16452294091383615
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple igfxxx isoforms,8.375,0.08628405630588531
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increased cellular phosphorylation,8.25,0.0943344384431839
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,potential therapeutic applications,8.0,0.1474572072426478
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,class xxx,6.25,0.0029507139697670937
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,igfxxx signaling,5.875,0.05109945684671402
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,multiple igfxxx,5.375,0.08332659304141998
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle atrophy,5.166666666666666,0.09330413676798344
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,novel approach,5.0,0.06224964186549187
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,selectively increased,4.75,0.06518071703612804
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,induced atrophy,4.666666666666666,0.06069842632859945
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,sgrna ).,4.5,0
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle wasting,4.5,0.042959196493029594
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,muscle mass,4.5,0.043688489124178886
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,experimental biology,4.5,0.2464067041873932
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,cellular proliferation,4.5,0.14812444150447845
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,tissue expression,4.0,0.08777856919914484
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,prevented dexamethasone,4.0,0.046328664757311344
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,novel strategy,4.0,0.09888306632637978
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,main effector,4.0,0.05729024298489094
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,guide rna,4.0,0.008003558963537216
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,genome engineering,4.0,0.23896826803684235
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,findings suggest,4.0,0.12938952632248402
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,complicates treatment,4.0,0.1590868327766657
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,american societies,4.0,0.06495580892078578
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,also showed,3.5,0.04536193795502186
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,igfxxx,2.875,0
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,increased,2.75,0.07228505611419678
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,potential,2.0,0.06813585013151169
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,expression,2.0,0.0005566496402025223
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,showed,1.5,0.048222288489341736
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,well,1.0,0.09099400043487549
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,vitro,1.0,0.2126568853855133
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,using,1.0,-0.04173736274242401
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,single,1.0,0.015469912439584732
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,recapitulate,1.0,0.032004695385694504
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,quality,1.0,0.11005230993032455
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,potency,1.0,-0.0018293820321559906
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,particularly,1.0,0.09882432222366333
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,overexpression,1.0,0.07107347995042801
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,occur,1.0,0.06010684743523598
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,myotubes,1.0,0
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,life,1.0,0.07387976348400116
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,insulin,1.0,0.1587810218334198
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,injury,1.0,0.04424106702208519
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,human,1.0,0.08946964889764786
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,function,1.0,0.11069313436746597
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,disease,1.0,0.1630353331565857
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,differentiation,1.0,0.09310577064752579
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,differ,1.0,0.033852480351924896
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,crispr,1.0,0
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,changing,1.0,-0.028789706528186798
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,aktxxx,1.0,0
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,age,1.0,0.10348664224147797
CRISPR-Cas9-induced IGF1 gene activation as a tool for enhancing muscle differentiation via multiple isoform expression.,affects,1.0,0.04985688626766205
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tidal carbon dioxide partial pressure,24.2,0.07858753018081188
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,时刻i qa 、 ai及chop mrna和蛋白表达水平均显著高于t,23.666666666666664,0.012214049696922302
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,arterial oxygen partial pressure difference,22.866666666666667,0.12222025319933891
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,peak )） 的情况 。 比较两组t,21.75,0.02320476621389389
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )）、 单侧肺通气后xxx h （,21.3531746031746,0.006312788464128971
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )）、 单侧肺通 气即刻 （,21.3531746031746,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )） 和气道压力峰值 （ p,20.467460317460315,0.05113617051392794
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )]、 呼气末二氧化碳分压 （ p,20.467460317460315,0.05113617051392794
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"xxx )), oxygen partial pressure",20.405555555555555,0.05645747343078256
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung cancer undergoing thoracoscopic lobectomy,20.25,0.259964182972908
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )）、 氧分压 （ pao,19.3531746031746,0.04397840518504381
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,underwent elective thoracoscopic lobectomy,17.0,0.28585878759622574
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )）、 气管插管后即刻 （,15.353174603174603,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )）、 手术结束时 （,15.353174603174603,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )）、 双肺通气即刻 （,15.353174603174603,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pulmonary protective mechanism could,14.833333333333334,0.15206588432192802
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"hr ), oxygen saturation",14.30952380952381,0.05794923876722654
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,binding protein homologous protein,14.0,0.05706182587891817
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"xxx )), xxx hour",13.677777777777777,0.00983396420876185
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"map ), heart rate",13.642857142857142,0.1573411524295807
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"iqa ), apoptotic index",13.642857142857142,0.09493203461170197
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mean arterial pressure,11.2,0.1702456052104632
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )）、 肺泡,10.424603174603174,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,时刻 。 c组患者t,10.0,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,airway pressure peak,9.95,0.10684075206518173
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,水平均显著高于d组 （ 均p,9.928571428571429,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,水平均显著低于c组 （ 均p,9.928571428571429,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,时刻 （ 均p,9.928571428571429,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx和sod水平均显著高于c组 （ 均p,9.928571428571429,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx （ il,9.734126984126984,0.023331952281296253
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,时刻map 、 hr水平显著低于t,9.666666666666666,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )( p,9.53888888888889,0.05113617051392794
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"xxx )), immediately",9.538888888888888,-0.0036193314008414745
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx 、 il,9.472222222222221,0.023331952281296253
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,均显著高于c组 ， p,9.4,0.11820723116397858
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,unilateral pulmonary ventilation,9.333333333333334,0.24165771653254828
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,bilateral pulmonary ventilation,9.333333333333334,0.27257020274798077
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx ）； 两组患者t,9.13888888888889,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx ）， 且d组t,9.13888888888889,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx ）。 两组患者t,9.13888888888889,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx ）。 d组患者t,9.13888888888889,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"xxx )), alveolar",9.038888888888888,0.07509195525199175
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,目的 ： 探讨右美托咪啶对胸腔镜肺叶切除术老年肺癌患者肺损伤及ccaat,9.0,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tumor necrosis factor,9.0,0.12045644720395406
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,super oxide dismutase,9.0,0.06645799179871877
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,second affiliated hospital,9.0,0.182779831190904
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,improving oxidative stress,9.0,0.07301891160507996
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"xxx ), il",8.948412698412698,0.023331952281296253
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx ）、 il,8.805555555555555,0.023331952281296253
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx和mda水平均显著低于c组 ， il,8.666666666666666,0.06259879469871521
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"α ), interleukin",8.642857142857142,0.09299088642001152
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,α ）、 白细胞介素,8.5,0.06381849944591522
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dexmedetomidine could attenuate,8.5,0.11212912574410439
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,α （ tnf,8.428571428571429,0.06381849944591522
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx elderly patients,8.13888888888889,0.20924106054008007
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"xxx )], end",8.13888888888889,-0.0010676058009266853
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spontaneous breathing recovery,7.5,0.08097539842128754
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"xxx )),",6.538888888888889,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"xxx ),",6.281746031746032,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung cancer,6.25,0.24483947455883026
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx pmid,5.138888888888889,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )、,5.138888888888889,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )~,5.138888888888889,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx ).,5.138888888888889,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )-,5.138888888888889,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx )).,5.138888888888889,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,october xxx,5.138888888888889,-0.01158616878092289
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,march xxx,5.138888888888889,-0.02176338154822588
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spontaneous breathing,5.0,0.08018719404935837
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elderly patients,5.0,0.32182903587818146
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,peak )),4.75,0.02320476621389389
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung tissue,4.75,0.21579217910766602
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,lung injury,4.75,0.15041246823966503
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,"ai ),",4.642857142857142,0.07966839522123337
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,alveolar damage,4.5,0.10244164802134037
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,recovery time,4.166666666666667,0.06848887354135513
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,动脉 氧分压的差值,4.0,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,zhengzhou university,4.0,0.23365965485572815
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,two groups,4.0,0.04741007462143898
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tracheal intubation,4.0,0.26566949486732483
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly shorter,4.0,0.09713355824351311
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly lower,4.0,0.10325782373547554
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,significantly higher,4.0,0.10986901819705963
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,random phenotype,4.0,0.008278440684080124
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,postoperative awake,4.0,0.19153598695993423
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mediated apoptosis,4.0,0.11204681545495987
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,inflammatory factors,4.0,0.09863114543259144
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,anesthetic induction,4.0,0.1603073962032795
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,agitation occurrence,4.0,0.059697529301047325
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group c,3.75,0.045693403109908104
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dexmedetomidine group,3.75,0.17142814584076405
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,control group,3.75,0.05305405892431736
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,reducing chop,3.666666666666667,0.013314586132764816
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,elapsed time,3.666666666666667,0.017667675390839577
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop mrna,3.666666666666667,-0.06419391185045242
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,p,3.4,0.11820723116397858
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx,3.138888888888889,-0.015934890136122704
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,protein,3.0,0.07616645097732544
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,pao,3.0,0.10389170050621033
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,peak,2.75,0.02320476621389389
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,il,2.6666666666666665,0.06259879469871521
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,α,2.5,0.06381849944591522
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,map,2.5,0.06641704589128494
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,iqa,2.5,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,hr,2.5,0.037340112030506134
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,tnf,2.0,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,end,2.0,0.013799678534269333
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,dexmedetomidine,2.0,0.2926649749279022
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,group,1.75,0.05019131675362587
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,time,1.6666666666666667,0.05442593991756439
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,chop,1.6666666666666667,-0.06419391185045242
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ai,1.5,0.07966839522123337
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,时刻肿瘤坏死因子,1.0,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,时刻pao,1.0,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,时刻p,1.0,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,时il,1.0,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,和t,1.0,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,xxx和il,1.0,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,values,1.0,0.023721983656287193
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,total,1.0,0.003683900460600853
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,surgery,1.0,0.3447723090648651
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,spo,1.0,-0.02494291216135025
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,sod,1.0,-0.00016865134239196777
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,selected,1.0,0.03362758085131645
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,results,1.0,0.0652550756931305
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,related,1.0,0.1234813779592514
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,recorded,1.0,0.01999819651246071
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ratios,1.0,0.09756212681531906
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,publisher,1.0,0.08886848390102386
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,objective,1.0,0.01818794757127762
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,n,1.0,-0.021267158910632133
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,methods,1.0,0.024640876799821854
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,medline,1.0,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,mda,1.0,0.07220671325922012
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,malondialdehyde,1.0,0.12827050685882568
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,levels,1.0,0.04464932531118393
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,j,1.0,0.010428212583065033
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,issn,1.0,0
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,inhibition,1.0,0.03232728689908981
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,indexed,1.0,0.00026863813400268555
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,extent,1.0,0.017291061580181122
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,expression,1.0,0.0005566496402025223
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,evaluate,1.0,0.08850531280040741
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,et,1.0,0.06867760419845581
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,enhancer,1.0,-0.00576905719935894
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,effect,1.0,0.004295531194657087
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,doi,1.0,0.055976808071136475
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,divided,1.0,0.11364559084177017
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,detected,1.0,0.10373490303754807
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,conscious,1.0,0.098431795835495
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,conclusions,1.0,0.07628431916236877
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,compared,1.0,0.10162706673145294
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,co,1.0,0.08638649433851242
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,cma,1.0,-0.022496625781059265
[Effects of dexmedetomidine on injury of lungs and CHOP protein expression in elderly patients with lung cancer during one-lung ventilation].,ccaat,1.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai mimetic peptides treatment led,17.133333333333333,0.10157105103135108
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,data provides compelling proof,16.0,0.03244350757449865
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lxxxf mimetic peptide administered,14.833333333333334,0.07244823624690373
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,high density lipoprotein particles,14.5,0.109603775665164
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,also showed altered expression,14.0,0.022893853951245546
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved blood glucose clearance,13.933333333333334,0.12997659109532833
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold auc decrease compared,13.0,0.06455062702298164
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduced hepatic macrophage infiltration,12.666666666666666,0.09317235928028822
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai mimetic peptide,9.833333333333334,0.0801036184032758
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold decrease compared,9.5,0.09156243999799092
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold auc compared,9.5,0.06013782322406769
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic peptides could,9.133333333333333,0.033981618781884514
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai mimetic peptides,9.133333333333333,0.059091915686925255
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,new therapeutic option,9.0,0.1437749428053697
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,intraperitoneal injection bi,9.0,0.09728226438164711
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic mrna expression,9.0,0.07605277094990015
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai injected directly,9.0,0.047990646213293076
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved insulin tolerance,8.966666666666667,0.09339556718866031
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improved glucose homeostasis,8.933333333333334,0.1250926380356153
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,improve insulin sensitivity,8.833333333333334,0.10543355842431386
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin tolerance tests,8.633333333333333,0.09819203739364941
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin tolerance test,8.633333333333333,0.09213344131906827
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,key markers involved,8.5,0.045241216818491616
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose tolerance test,8.4,0.10037562623620033
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,induced insulin resistance,8.333333333333334,0.04638384965558847
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduce hepatic inflammation,8.25,0.1365928277373314
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,decreased hepatic inflammation,8.25,0.12185671925544739
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,test whether apo,8.0,0.07399833823243777
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,metabolic test results,8.0,0.14035562922557196
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,major apolipoprotein found,8.0,0.10412385935584705
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetic peptides,6.133333333333333,0.048803675919771194
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fold compared,6.0,0.09844914078712463
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduced infiltration,5.666666666666666,0.04464881680905819
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,reduced expression,5.666666666666666,0.019084586761891842
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose tolerance,5.4,0.10859294421970844
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,insulin resistance,5.333333333333334,0.07306778058409691
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hepatic inflammation,5.25,0.16031168401241302
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxxf showed,4.666666666666667,0.048222288489341736
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammatory markers,4.5,0.10430209711194038
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxxβ ifn,4.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,time pcr,4.0,0.05442593991756439
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,respective pathways,4.0,0.09091972559690475
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,previously demonstrated,4.0,0.03576158918440342
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,male cxxxbl,4.0,0.05418261140584946
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lipid synthesis,4.0,0.17085880041122437
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,length apo,4.0,0.07803621515631676
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hdls ).,4.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,gluconeogenic enzymes,4.0,0.08565188944339752
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,five weeks,4.0,0.05049150250852108
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,findings suggest,4.0,0.12938952632248402
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fat diet,4.0,0.09509199112653732
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,clinically feasible,4.0,0.1972884088754654
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx weeks,3.75,0.015535618178546429
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx mice,3.75,0.03642516303807497
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,genes associated,3.666666666666667,0.10460993647575378
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,associated genes,3.666666666666667,0.10460993647575378
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,overall suppression,3.5,0.0514624435454607
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxxf xxx,3.416666666666667,-0.015934890136122704
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,treatment,3.0,0.27399298548698425
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ai,3.0,0.07966839522123337
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,peptides,2.8,0.05771190673112869
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,glucose,2.6,0.18350757658481598
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,high,2.5,0.06070782244205475
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,inflammation,2.25,0.16907447576522827
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,results,2.0,0.0652550756931305
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apolipoprotein,2.0,0.20140977203845978
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apo,2.0,0.10638172924518585
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxx,1.75,-0.015934890136122704
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,xxxf,1.6666666666666667,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,associated,1.6666666666666667,0.10097402334213257
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suppression,1.5,0.06901815533638
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,γ,1.0,0.0845392495393753
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,weekly,1.0,0.045745816081762314
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,total,1.0,0.003683900460600853
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,tnfα,1.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suppressed,1.0,0.036808378994464874
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,suggesting,1.0,0.051274579018354416
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,study,1.0,0.2376001477241516
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,srebpxxxc,1.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,saaxxx,1.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,real,1.0,0.02762891724705696
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,pepck,1.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,p,1.0,0.11820723116397858
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,overnutrition,1.0,0.2756476402282715
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ns,1.0,0.09590061008930206
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,mimetics,1.0,0.22551001608371735
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,methods,1.0,0.024640876799821854
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,macrophages,1.0,0.10670876502990723
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,liver,1.0,0.23269252479076385
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,lipogenic,1.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,l,1.0,0.02060166746377945
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,iv,1.0,0.05570073053240776
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,il,1.0,0.06259879469871521
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,iii,1.0,0.040875934064388275
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,ii,1.0,0.06888964027166367
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,hfd,1.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,gxxxpase,1.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,gluconeogenesis,1.0,0.1624269038438797
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fxxx,1.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,full,1.0,0.008461154997348785
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,fed,1.0,0.0035025477409362793
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,emulate,1.0,0.05798235535621643
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,effects,1.0,0.04013404995203018
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,effect,1.0,0.004295531194657087
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,development,1.0,0.1793753206729889
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,contributes,1.0,0.05899214372038841
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,conducted,1.0,0.055469855666160583
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,conclusion,1.0,0.03420025110244751
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,concept,1.0,0.01763022691011429
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,chrebp,1.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,cdxxx,1.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,background,1.0,0.03833860531449318
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,assessed,1.0,0.06162751466035843
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,assess,1.0,0.061772990971803665
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,apoa,1.0,0
Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.,aim,1.0,0.040013544261455536
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,various bioinformatics tools focused,14.5,0.11963242618367076
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx matthews correlation coefficient,14.2,0.01237367419525981
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium channel ligand peptides,12.6,0.05837068543769419
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,bioinformatics software written,9.5,0.17731094484527907
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,python programming language,9.0,0.031231781467795372
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,primary structure information,9.0,0.05981886759400368
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,predict peptide ligands,9.0,0.07374909768501918
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,experimentally verified activity,9.0,0.03764022265871366
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,electrical impulse formation,9.0,0.06452376674860716
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,considered promising alternatives,9.0,0.09439623604218166
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,artificial neural network,9.0,0.10054086024562518
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,predict ligand peptides,8.6,0.04301730543375015
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,support vector machine,8.5,0.051382104866206646
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium channels play,8.5,0.06818718152741592
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,high predictive capacity,8.5,0.08935829624533653
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,novel ligand peptides,8.1,0.06480171779791515
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,random forest algorithm,8.0,0.02592579275369644
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,biological data used,8.0,0.08192053188880284
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,tool called pplk,7.333333333333334,-0.0033244574442505836
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ligand peptides,5.6,0.050022631883621216
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,potassium channels,5.5,0.06790807750076056
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,random forest,5.0,0.0022971369326114655
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,current tools,5.0,0.007188108749687672
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,novel tool,4.833333333333334,0.03380005061626434
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,high reliability,4.5,0.08591756969690323
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,four machine,4.5,0.05557224154472351
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,first tool,4.333333333333334,-0.0037247203290462494
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx specificity,4.2,0.03740351367741823
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx sensitivity,4.2,0.02825255412608385
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx accuracy,4.2,0.017150810919702053
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,validating models,4.0,0.088039331138134
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,plasma membrane,4.0,0.14300056546926498
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,nearest neighbors,4.0,0.05300748534500599
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,molecules used,4.0,0.04682210832834244
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,model generated,4.0,0.052790841087698936
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,many diseases,4.0,0.1429770588874817
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,learning algorithms,4.0,0.05821537412703037
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,key role,4.0,0.05408843792974949
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,hormone secretion,4.0,0.07382428739219904
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,friendly interface,4.0,0.025791128166019917
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,different activities,4.0,0.04835154861211777
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cardiovascular diseases,4.0,0.40692125260829926
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,applied research,4.0,0.14215287566184998
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,peptides,2.6,0.05771190673112869
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,xxx,2.2,-0.015934890136122704
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,used,2.0,0.010911919176578522
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,pplk,2.0,0
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,work,1.0,0.06322342157363892
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,using,1.0,-0.04173736274242401
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,treatment,1.0,0.27399298548698425
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,training,1.0,0.1278398334980011
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,study,1.0,0.2376001477241516
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,showed,1.0,0.048222288489341736
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,regulating,1.0,0.07387600094079971
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,prediction,1.0,0.07748128473758698
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,obtained,1.0,-0.0006794054061174393
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,none,1.0,0.034597981721162796
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,ions,1.0,0.010986916720867157
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,however,1.0,-0.011453256011009216
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,flow,1.0,0.06411638855934143
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,discovery,1.0,0.10541436076164246
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,developed,1.0,0.1218160092830658
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,currently,1.0,0.0543237179517746
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,cancer,1.0,0.23309507966041565
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,c,1.0,0.04119548946619034
PPLK&lt;sup&gt;+&lt;/sup&gt;C: A Bioinformatics Tool for Predicting Peptide Ligands of Potassium Channels Based on Primary Structure Information.,basic,1.0,0.029801150783896446
Machine learning: a long way from implementation in cardiovascular disease.,none declared,4.0,0.0609555933624506
Machine learning: a long way from implementation in cardiovascular disease.,interest statement,4.0,0.09834937378764153
Machine learning: a long way from implementation in cardiovascular disease.,competing interests,4.0,0.07788273692131042
Machine learning: a long way from implementation in cardiovascular disease.,xxx pmid,3.666666666666667,-0.015934890136122704
Machine learning: a long way from implementation in cardiovascular disease.,xxx conflict,3.666666666666667,0.045372446067631245
Machine learning: a long way from implementation in cardiovascular disease.,xxx,1.6666666666666667,-0.015934890136122704
Machine learning: a long way from implementation in cardiovascular disease.,heartjnl,1.0,0
Machine learning: a long way from implementation in cardiovascular disease.,doi,1.0,0.055976808071136475
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,echocardiogram data using machine learning,20.5,0.09839973673224449
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,chronic obstructive pulmonary disease,15.0,0.23184162378311157
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,"xxx ), including biomarkers",13.795454545454545,0.111453869069616
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx plasma proteins differed,13.545454545454545,0.0726906037889421
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,identified distinct hfpef phenogroups,13.0,0.05171046033501625
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,"xxx days ), mid",12.795454545454545,0.011329048002759615
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,using machine learning,12.0,0.01015876109401385
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,identified six phenogroups,9.25,0.08770859241485596
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rennes cohort study,9.0,0.1955045908689499
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,preserved ejection fraction,9.0,-0.0003367569297552109
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,laboratory variables collected,9.0,0.0909705962985754
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,false discovery rate,9.0,0.07485300054152806
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,concomitant atrial fibrillation,9.0,0.20986218998829523
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,composite end point,9.0,0.027480129152536392
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,derive hfpef phenotype,8.75,0.06330310646444559
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,"xxx %), hypertension",8.545454545454545,0.17434429842978716
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,median xxx years,8.545454545454545,0.05689066213866075
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,right ventricular function,8.5,0.11878196864078443
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx hfpef outpatients,8.295454545454545,0.19742601830512285
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,versus phenogroups xxx,8.295454545454545,0.036031817086040974
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,"af ), anaemia",8.25,0.058493904769420624
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx ); xxx,8.09090909090909,-0.015934890136122704
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx days ).,8.045454545454545,0.008284521289169788
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,compare clinical characteristics,7.5,0.20651748652259508
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx echocardiogram,6.045454545454545,0.16970491129904985
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,"xxx ),",5.795454545454545,-0.015934890136122704
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx days,5.545454545454545,0.008284521289169788
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx ).,5.045454545454545,-0.015934890136122704
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,kidney disease,5.0,0.19676077365875244
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,cardiovascular proteins,5.0,0.3253435641527176
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx months,4.545454545454545,0.012255401350557804
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx clinical,4.545454545454545,0.24122598487883806
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx )).,4.545454545454545,-0.015934890136122704
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx %).,4.545454545454545,-0.015934890136122704
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx %),4.545454545454545,-0.015934890136122704
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroup xxx,4.545454545454545,-0.015934890136122704
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,)) xxx,4.545454545454545,-0.015934890136122704
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,kidney function,4.5,0.17058967426419258
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,differential characteristics,4.5,0.028938804753124714
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,third experienced,4.0,0.06213100254535675
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,stable condition,4.0,0.1300930380821228
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,significantly different,4.0,0.0869855135679245
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,significant differences,4.0,0.11193609237670898
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,see rights,4.0,0.03032690193504095
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,secondary analyses,4.0,0.12579138576984406
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,risk factors,4.0,0.1105011198669672
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,primary outcome,4.0,0.06885062530636787
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,poorer diastolic,4.0,0.19171904027462006
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,higher burden,4.0,0.0941302590072155
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,heterogeneous syndrome,4.0,0.083293117582798
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,heart failure,4.0,0.2074820026755333
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,differential levels,4.0,0.036865818314254284
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,cause mortality,4.0,0.18113460391759872
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,based clustering,4.0,0.11250630393624306
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,applied model,4.0,0.030811553820967674
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,term follow,3.5,0.0717815961688757
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,rank p,3.5,0.06202162988483906
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,outcomes across,3.5,0.14927400648593903
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,baseline proteomics,3.5,0.18783657252788544
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,phenogroups,2.75,0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hfpef,2.75,0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,xxx,2.5454545454545454,-0.015934890136122704
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,clinical,2.0,0.49838685989379883
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,af,2.0,0.058493904769420624
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,term,1.5,0.05754470452666283
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,proteomics,1.5,0.3172764778137207
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,p,1.5,0.11820723116397858
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,outcomes,1.5,0.23325912654399872
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,well,1.0,0.09099400043487549
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,used,1.0,0.010911919176578522
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,use,1.0,0.0033735278993844986
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,two,1.0,0.0741315707564354
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,thirds,1.0,-0.0059935562312603
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,short,1.0,0.011583387851715088
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,results,1.0,0.0652550756931305
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,published,1.0,0.10513044893741608
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,prevalence,1.0,0.1558399796485901
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,permissions,1.0,0.01313965953886509
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,older,1.0,0.14530479907989502
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,observed,1.0,0.08740169554948807
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,objective,1.0,0.01818794757127762
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,methods,1.0,0.024640876799821854
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,longer,1.0,0.0349513441324234
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,log,1.0,-0.07369421422481537
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,karolinska,1.0,0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,iqr,1.0,0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,inflammatory,1.0,0.17046239972114563
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hr,1.0,0.037340112030506134
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hospitalisation,1.0,0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,hf,1.0,0.1109897643327713
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,group,1.0,0.05019131675362587
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,fifteen,1.0,0.006569189950823784
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,female,1.0,0.05358291417360306
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,fdr,1.0,0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,employer,1.0,0.03903285413980484
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,conclusions,1.0,0.07628431916236877
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,commercial,1.0,0.08596912771463394
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,ci,1.0,0.06607142090797424
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,bmj,1.0,0
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning.,aimed,1.0,0.0894685834646225
Machine Learning in Fetal Cardiology: What to Expect.,specific goals without explicitly programming,25.0,0.04552177786827087
Machine Learning in Fetal Cardiology: What to Expect.,compromised cardiovascular system potentially associated,25.0,0.17510272115468978
Machine Learning in Fetal Cardiology: What to Expect.,tissue doppler imaging among others,23.0,0.20548518598079682
Machine Learning in Fetal Cardiology: What to Expect.,still challenging mainly due,16.0,0.00848001497797668
Machine Learning in Fetal Cardiology: What to Expect.,computer science discipline focused,14.5,0.11208346672356129
Machine Learning in Fetal Cardiology: What to Expect.,evaluate fetal cardiac structure,13.714285714285715,0.2446069410070777
Machine Learning in Fetal Cardiology: What to Expect.,primary acquired images,9.0,0.06630608687798183
Machine Learning in Fetal Cardiology: What to Expect.,optimizing image acquisition,9.0,0.11049925784269969
Machine Learning in Fetal Cardiology: What to Expect.,different ultrasound approaches,9.0,0.169826560964187
Machine Learning in Fetal Cardiology: What to Expect.,several fetal conditions,8.714285714285715,0.12636536111434302
Machine Learning in Fetal Cardiology: What to Expect.,fetal cardiac remodeling,8.714285714285715,0.3410065571467082
Machine Learning in Fetal Cardiology: What to Expect.,including conventional xxx,8.5,0.045239352310697235
Machine Learning in Fetal Cardiology: What to Expect.,help extract measurements,8.0,0.054217755794525146
Machine Learning in Fetal Cardiology: What to Expect.,fetal cardiac function,7.714285714285714,0.32386235644419986
Machine Learning in Fetal Cardiology: What to Expect.,fetal echocardiography,4.714285714285714,0.42160068452358246
Machine Learning in Fetal Cardiology: What to Expect.,fetal cardiology,4.714285714285714,0.6208091229200363
Machine Learning in Fetal Cardiology: What to Expect.,cardiac abnormalities,4.5,0.4284811317920685
Machine Learning in Fetal Cardiology: What to Expect.,fetal heart,4.214285714285714,0.2731611877679825
Machine Learning in Fetal Cardiology: What to Expect.,small size,4.0,0.03336895443499088
Machine Learning in Fetal Cardiology: What to Expect.,prenatal diagnoses,4.0,0.2724864035844803
Machine Learning in Fetal Cardiology: What to Expect.,new technologies,4.0,0.1495411954820156
Machine Learning in Fetal Cardiology: What to Expect.,machine leaning,4.0,0.04164375178515911
Machine Learning in Fetal Cardiology: What to Expect.,karger ag,4.0,0.10048235952854156
Machine Learning in Fetal Cardiology: What to Expect.,involuntary movements,4.0,-0.0018107164651155472
Machine Learning in Fetal Cardiology: What to Expect.,great importance,4.0,0.08173215016722679
Machine Learning in Fetal Cardiology: What to Expect.,especially echocardiography,4.0,0.34955567494034767
Machine Learning in Fetal Cardiology: What to Expect.,currently used,4.0,0.03261781856417656
Machine Learning in Fetal Cardiology: What to Expect.,brief overview,4.0,0.04755626153200865
Machine Learning in Fetal Cardiology: What to Expect.,perform tasks,3.5,0.054614048451185226
Machine Learning in Fetal Cardiology: What to Expect.,optimal assessment,3.5,0.0816216841340065
Machine Learning in Fetal Cardiology: What to Expect.,ml techniques,3.5,0.07294395938515663
Machine Learning in Fetal Cardiology: What to Expect.,imaging,3.0,0.4709222614765167
Machine Learning in Fetal Cardiology: What to Expect.,computer,2.5,0.10320991277694702
Machine Learning in Fetal Cardiology: What to Expect.,help,2.0,0.016909226775169373
Machine Learning in Fetal Cardiology: What to Expect.,function,2.0,0.11069313436746597
Machine Learning in Fetal Cardiology: What to Expect.,perform,1.5,0.09922076761722565
Machine Learning in Fetal Cardiology: What to Expect.,ml,1.5,0.06590283662080765
Machine Learning in Fetal Cardiology: What to Expect.,heart,1.5,0.30470412969589233
Machine Learning in Fetal Cardiology: What to Expect.,assessment,1.5,0.08391694724559784
Machine Learning in Fetal Cardiology: What to Expect.,abnormalities,1.5,0.23768657445907593
Machine Learning in Fetal Cardiology: What to Expect.,well,1.0,0.09099400043487549
Machine Learning in Fetal Cardiology: What to Expect.,use,1.0,0.0033735278993844986
Machine Learning in Fetal Cardiology: What to Expect.,therefore,1.0,0.024225328117609024
Machine Learning in Fetal Cardiology: What to Expect.,teaching,1.0,0.20083385705947876
Machine Learning in Fetal Cardiology: What to Expect.,task,1.0,-0.009650083258748055
Machine Learning in Fetal Cardiology: What to Expect.,sonographers,1.0,0.39366966485977173
Machine Learning in Fetal Cardiology: What to Expect.,segmentation,1.0,0.13467922806739807
Machine Learning in Fetal Cardiology: What to Expect.,rules,1.0,-8.914992213249207e-05
Machine Learning in Fetal Cardiology: What to Expect.,review,1.0,0.06275224685668945
Machine Learning in Fetal Cardiology: What to Expect.,quantification,1.0,0.12732118368148804
Machine Learning in Fetal Cardiology: What to Expect.,provide,1.0,0.01998533308506012
Machine Learning in Fetal Cardiology: What to Expect.,potential,1.0,0.06813585013151169
Machine Learning in Fetal Cardiology: What to Expect.,monitoring,1.0,0.158101424574852
Machine Learning in Fetal Cardiology: What to Expect.,mode,1.0,0.00429178960621357
Machine Learning in Fetal Cardiology: What to Expect.,lack,1.0,0.0400080606341362
Machine Learning in Fetal Cardiology: What to Expect.,improving,1.0,0.09750453382730484
Machine Learning in Fetal Cardiology: What to Expect.,improve,1.0,0.08507965505123138
Machine Learning in Fetal Cardiology: What to Expect.,however,1.0,-0.011453256011009216
Machine Learning in Fetal Cardiology: What to Expect.,fetuses,1.0,0.11941638588905334
Machine Learning in Fetal Cardiology: What to Expect.,fetus,1.0,0.07748453319072723
Machine Learning in Fetal Cardiology: What to Expect.,expertise,1.0,0.15745125710964203
Machine Learning in Fetal Cardiology: What to Expect.,evaluation,1.0,0.14135286211967468
Machine Learning in Fetal Cardiology: What to Expect.,diagnosis,1.0,0.24688632786273956
Machine Learning in Fetal Cardiology: What to Expect.,demonstrated,1.0,0.0564635805785656
Machine Learning in Fetal Cardiology: What to Expect.,basel,1.0,0.17127791047096252
Machine Learning in Fetal Cardiology: What to Expect.,aid,1.0,0.07422354817390442
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,using optical diffraction tomography,16.0,0.12309156730771065
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,high mannose receptor specificity,14.5,0.09038802608847618
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,free living foam cells,12.5,0.04732429841533303
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,living foam cells,9.5,0.05638390965759754
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,related metabolic diseases,9.0,0.2114840696255366
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,refractive index measurement,9.0,0.19930221140384674
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam cells based,9.0,0.04959558633466562
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,explore new drugs,9.0,0.11309101432561874
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cellular imaging techniques,9.0,0.22896581888198853
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,performed quantitative morphological,8.5,0.1657244066397349
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,dimensional fluorescence imaging,8.5,0.22630095730225244
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,based image analysis,8.5,0.0926242545247078
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,demonstrated therapeutic evaluation,8.333333333333334,0.15497295434276262
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,foam cells,6.0,0.03180879261344671
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,free manner,5.0,0.016464997082948685
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,quantitative methods,4.5,0.08229988999664783
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,dimensional dynamics,4.5,0.07924415543675423
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,biophysical analysis,4.5,0.1587689220905304
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic intervention,4.333333333333334,0.16369031369686127
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,therapeutic effects,4.333333333333334,0.1536182351410389
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,targeted delivery,4.0,0.07152660563588142
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,quantitatively evaluated,4.0,0.09302292764186859
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,promising tool,4.0,0.04861261323094368
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,polyethylene glycol,4.0,0.03416683338582516
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,"odt ),",4.0,0.10110154002904892
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lipid droplet,4.0,0.1454672645777464
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,limited application,4.0,0.016728481277823448
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lapse monitoring,4.0,0.09469330869615078
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,key feature,4.0,0.06383324414491653
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,identified lds,4.0,0.054314942099153996
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,glycol chitosan,4.0,0.014412125572562218
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,fluorescein isothiocyanate,4.0,0.10863730311393738
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,findings suggest,4.0,0.12938952632248402
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,exploiting machine,4.0,0.03374647442251444
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,despite advances,4.0,0.04775756783783436
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,current noninvasive,4.0,0.16675288416445255
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,cell level,4.0,0.08076799660921097
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,attractive target,4.0,0.06326460093259811
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,mannose,2.5,0.1157321035861969
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,verifying,1.0,0.04014786332845688
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,time,1.0,0.05442593991756439
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,three,1.0,0.07735734432935715
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,single,1.0,0.015469912439584732
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,precisely,1.0,-0.023628994822502136
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,nanodrug,1.0,0
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,mmr,1.0,0
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lobeglitazone,1.0,0
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,lobe,1.0,0.07261361926794052
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,learning,1.0,0.027504589408636093
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,ld,1.0,0.035696856677532196
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,label,1.0,0.08488131314516068
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,however,1.0,-0.011453256011009216
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,furthermore,1.0,-0.04380498453974724
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,designed,1.0,0.028855949640274048
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,constitutes,1.0,0.004307400435209274
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,atherosclerosis,1.0,0.29730460047721863
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,affect,1.0,0.0651945173740387
Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.,accumulation,1.0,0.033634718507528305
Supervised machine learning models applied to disease diagnosis and prognosis.,"), licensee aims press",16.0,0.07115261008342107
Supervised machine learning models applied to disease diagnosis and prognosis.,heart disease data respectively,13.5,0.16462429612874985
Supervised machine learning models applied to disease diagnosis and prognosis.,test data based,9.5,0.09176261723041534
Supervised machine learning models applied to disease diagnosis and prognosis.,receiver operating characteristic,9.0,0.08752081419030826
Supervised machine learning models applied to disease diagnosis and prognosis.,principal component regression,9.0,0.06541918342312177
Supervised machine learning models applied to disease diagnosis and prognosis.,prediction accuracy using,9.0,0.02866014465689659
Supervised machine learning models applied to disease diagnosis and prognosis.,heart disease,6.0,0.233869731426239
Supervised machine learning models applied to disease diagnosis and prognosis.,work analyses,4.0,0.06322342157363892
Supervised machine learning models applied to disease diagnosis and prognosis.,random forest,4.0,0.0022971369326114655
Supervised machine learning models applied to disease diagnosis and prognosis.,predictive ability,4.0,0.07631609216332436
Supervised machine learning models applied to disease diagnosis and prognosis.,important variables,4.0,0.038391283713281155
Supervised machine learning models applied to disease diagnosis and prognosis.,best performance,4.0,0.04327479936182499
Supervised machine learning models applied to disease diagnosis and prognosis.,also studied,4.0,0.12316841818392277
Supervised machine learning models applied to disease diagnosis and prognosis.,causes cancer,3.666666666666667,0.16430209577083588
Supervised machine learning models applied to disease diagnosis and prognosis.,breast cancer,3.666666666666667,0.24374888837337494
Supervised machine learning models applied to disease diagnosis and prognosis.,ml algorithms,3.0,0.07741449773311615
Supervised machine learning models applied to disease diagnosis and prognosis.,cancer,1.6666666666666667,0.23309507966041565
Supervised machine learning models applied to disease diagnosis and prognosis.,ml,1.5,0.06590283662080765
Supervised machine learning models applied to disease diagnosis and prognosis.,algorithms,1.5,0.08892615884542465
Supervised machine learning models applied to disease diagnosis and prognosis.,roc,1.0,0.02677847445011139
Supervised machine learning models applied to disease diagnosis and prognosis.,rf,1.0,0.04890134930610657
Supervised machine learning models applied to disease diagnosis and prognosis.,provides,1.0,0.014026330783963203
Supervised machine learning models applied to disease diagnosis and prognosis.,prognosis,1.0,0.23093095421791077
Supervised machine learning models applied to disease diagnosis and prognosis.,predict,1.0,0.029006652534008026
Supervised machine learning models applied to disease diagnosis and prognosis.,pcr,1.0,0
Supervised machine learning models applied to disease diagnosis and prognosis.,diagnosis,1.0,0.24688632786273956
Supervised machine learning models applied to disease diagnosis and prognosis.,curve,1.0,-0.04778170958161354
Supervised machine learning models applied to disease diagnosis and prognosis.,compute,1.0,0.02463405579328537
Supervised machine learning models applied to disease diagnosis and prognosis.,compare,1.0,0.09237030148506165
Supervised machine learning models applied to disease diagnosis and prognosis.,author,1.0,0.1725224107503891
Supervised machine learning models applied to disease diagnosis and prognosis.,analyzing,1.0,0.0660758689045906
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,primary human airway smooth muscle,25.0,0.07278229594230652
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,g protein estrogen receptor antagonists,20.5,0.08759976997971534
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic camp signaling modality contributes,19.5,0.13971583247184755
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,gene expression changes induced,15.5,0.030620187520980835
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,time camp dynamics using,15.0,0.03098862525075674
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,gαs virtually eliminated glucocorticoid,13.666666666666666,0.042618626107772194
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,diverse cell signaling effects,13.333333333333334,0.07683578133583069
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx hours treated hasm,13.0,0.07823810540139675
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,requires gαs signaling,9.666666666666666,0.004757272079586983
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,immortalized cell lines,9.0,0.05235208570957184
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,faseb journal published,9.0,0.14419320970773697
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp difference detector,9.0,0.07630204906066258
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx genes represent,8.5,0.07098184836407502
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,stimulated camp responses,8.0,0.04693424825867017
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,gene budesonide signature,8.0,0.09470000738898914
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp production via,8.0,0.012308869510889053
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,g protein,7.0,0.04946049489080906
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,coupled receptor,5.5,0.047781556844711304
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoid treatment,5.0,0.2028777152299881
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic signature,5.0,0.13813412748277187
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cell surface,5.0,0.02518053911626339
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp levels,5.0,0.03949127532541752
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic actions,4.5,0.11979828402400017
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,small effects,4.333333333333334,0.03572089411318302
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,without knockdown,4.0,-0.041687896475195885
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,wiley periodicals,4.0,0.04755686596035957
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,widely used,4.0,0.02890646457672119
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,swiftly increase,4.0,0.031050567515194416
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,situ assay,4.0,0.1062611322849989
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,sirna knockdown,4.0,-0.06241370365023613
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,seq analysis,4.0,0.1043926551938057
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,measuring real,4.0,0.0665376391261816
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,little effect,4.0,0.009360174415633082
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,leading us,4.0,0.048748016357421875
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,important class,4.0,0.04684542864561081
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,experimental biology,4.0,0.2464067041873932
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,drugs exerts,4.0,0.06017414107918739
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,drugs activate,4.0,0.09366906061768532
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,american societies,4.0,0.06495580892078578
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoids tested,3.666666666666667,0.11622970551252365
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoids alone,3.666666666666667,0.1052679717540741
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,camp,3.0,0.03433322533965111
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,gαs,2.6666666666666665,0
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,xxx,2.5,-0.015934890136122704
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,hasm,2.5,0
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,genomic,2.5,0.27172142267227173
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,effects,2.3333333333333335,0.04013404995203018
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,responses,2.0,0.050901129841804504
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,production,2.0,0.043551042675971985
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,budesonide,2.0,0.1438724398612976
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,glucocorticoids,1.6666666666666667,0.16443267464637756
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,view,1.0,0.01284804381430149
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,variety,1.0,0.07650606334209442
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,unappreciated,1.0,0.03765837103128433
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,third,1.0,0.03900638222694397
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,suppression,1.0,0.06901815533638
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,suggesting,1.0,0.051274579018354416
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,shifts,1.0,0.060013603419065475
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,rna,1.0,0
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,reported,1.0,-0.00021066516637802124
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,rapid,1.0,0.0760050043463707
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,progesterone,1.0,0.16972224414348602
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,prednisone,1.0,0.1314448118209839
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,one,1.0,0.060579702258110046
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,non,1.0,0.06398928165435791
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,membrane,1.0,0.1149565726518631
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,initiated,1.0,0.01000182330608368
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,inflammation,1.0,0.16907447576522827
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,inc,1.0,0.007824641652405262
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,implying,1.0,0.02828078530728817
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,identified,1.0,0.10330121219158173
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,hypothesize,1.0,-0.003548344597220421
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,growing,1.0,0.11825673282146454
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,found,1.0,0.03727259859442711
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,fluticasone,1.0,0.14957857131958008
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,federation,1.0,0.031218651682138443
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,evidence,1.0,0.05816628411412239
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,estradiol,1.0,0.13791009783744812
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,collectively,1.0,-0.011590112000703812
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,cells,1.0,0.06259886920452118
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,behalf,1.0,0.003146544098854065
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,authors,1.0,0.21598771214485168
Glucocorticoids rapidly activate cAMP production via G&lt;sub&gt;αs&lt;/sub&gt; to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.,analyzed,1.0,0.13667140901088715
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",creatinine ratios indicating organ protection,24.0,0.11339896842837334
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pkcδ inhibition decreased leukocyte influx,20.416666666666664,0.06183050386607647
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",identified protein kinase c,16.0,0.09526320360600948
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",exhibit direct bactericidal properties,16.0,0.05096401087939739
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",reduced blood urea nitrogen,14.5,0.07309034373611212
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pkcδ inhibition increased survival,13.583333333333334,0.08105698972940445
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pkcδ inhibition improved survival,13.083333333333334,0.08620442698399226
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",decreased organ injury,10.666666666666666,0.09755001341303189
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",decreased endothelial permeability,9.666666666666666,0.07348190620541573
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",increased phagocytic activity,9.5,0.08044477303822835
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",intensive care units,9.0,0.1665316546956698
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",improved gas exchange,9.0,0.09494644403457642
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",enhanced pathogen clearance,9.0,0.07967336475849152
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",effectively clear pathogens,9.0,0.028308877410988014
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal macrophages isolated,8.666666666666666,0.14240561425685883
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal chemokine levels,8.666666666666666,0.13704270124435425
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",xxx hours post,8.0,0.05749035192032655
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pkcδ inhibition,6.75,0.03232728689908981
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",improved survival,6.333333333333334,0.11314299702644348
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pkcδ inhibitor,5.0,0.08326785266399384
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",peritoneal cavity,4.666666666666666,0.14553747326135635
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",neutrophil numbers,4.0,0.03045535460114479
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",macrophage phenotypes,4.0,0.137033149600029
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",leading cause,4.0,0.06677581369876862
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",kidney dysfunction,4.0,0.1721501424908638
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inflammatory therapeutics,4.0,0.24545498192310333
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inflammatory response,4.0,0.11321571096777916
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",important regulator,4.0,0.09456070140004158
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",important issue,4.0,0.08771714940667152
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",experimental biology,4.0,0.2464067041873932
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",cecal ligation,4.0,0.16161786019802094
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",american societies,4.0,0.06495580892078578
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",administered intra,4.0,0.06133175268769264
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",induce sepsis,3.5,0.19450661540031433
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pkcδ,3.0,0
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",blood,2.5,0.15856775641441345
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",post,2.0,0.10225207358598709
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",sepsis,1.5,0.3236554265022278
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",xxxµg,1.0,0
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",tracheally,1.0,0
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",thus,1.0,-0.023273250088095665
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",surgery,1.0,0.3447723090648651
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",study,1.0,0.2376001477241516
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",spleen,1.0,0.07567166537046432
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",risk,1.0,0.19420234858989716
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",puncture,1.0,0.05333371460437775
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",previously,1.0,0.015059597790241241
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",pbs,1.0,0.015961237251758575
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",organs,1.0,0.16247545182704926
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",mortality,1.0,0.27426618337631226
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",morbidity,1.0,0.32470452785491943
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",lung,1.0,0.2565838694572449
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",kg,1.0,0.09757691621780396
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",inability,1.0,-0.021751757711172104
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",importantly,1.0,0.0019238665699958801
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",immunosuppression,1.0,0.1757732629776001
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",evidence,1.0,0.05816628411412239
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",development,1.0,0.1793753206729889
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",delta,1.0,0.029204435646533966
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",clp,1.0,0
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",associated,1.0,0.10097402334213257
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",anti,1.0,0.10541997849941254
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",altered,1.0,0.00029489025473594666
"Protein kinase C-delta inhibition is organ-protective, enhances pathogen clearance, and improves survival in sepsis.",).,1.0,0
Innovations in pharmacological treatment of heart failure.,xxx new promising groups,14.5,0.058764024171978235
Innovations in pharmacological treatment of heart failure.,maximal tolerated doses,9.0,0.11074847479661305
Innovations in pharmacological treatment of heart failure.,hughe clinical research,9.0,0.3878527879714966
Innovations in pharmacological treatment of heart failure.,renin angiotensin blockade,8.666666666666666,0.14708236729105315
Innovations in pharmacological treatment of heart failure.,angiotensin receptor blockers,8.166666666666666,0.1153479553759098
Innovations in pharmacological treatment of heart failure.,others perspective drugs,8.0,0.07522831112146378
Innovations in pharmacological treatment of heart failure.,ace inhibitors intolerance,7.5,0.07948057353496552
Innovations in pharmacological treatment of heart failure.,heart failure treatment,7.0,0.22965233027935028
Innovations in pharmacological treatment of heart failure.,angiotensin receptor,5.166666666666666,0.15015103667974472
Innovations in pharmacological treatment of heart failure.,heart failure,5.0,0.2074820026755333
Innovations in pharmacological treatment of heart failure.,ace inhibitors,4.5,0.09943026676774025
Innovations in pharmacological treatment of heart failure.,špinarová l,4.0,0.02060166746377945
Innovations in pharmacological treatment of heart failure.,špinar j,4.0,0.010428212583065033
Innovations in pharmacological treatment of heart failure.,vítovec j,4.0,0.010428212583065033
Innovations in pharmacological treatment of heart failure.,symptoms relieve,4.0,0.12563420832157135
Innovations in pharmacological treatment of heart failure.,pharmacological treatment,4.0,0.26631876826286316
Innovations in pharmacological treatment of heart failure.,omecamtiv mecarbil,4.0,0.31335264444351196
Innovations in pharmacological treatment of heart failure.,neprilysin inhibitor,4.0,0.08962647616863251
Innovations in pharmacological treatment of heart failure.,main goal,4.0,0.06793928891420364
Innovations in pharmacological treatment of heart failure.,hf trial,4.0,0.11598029732704163
Innovations in pharmacological treatment of heart failure.,glucose co,4.0,0.1349470354616642
Innovations in pharmacological treatment of heart failure.,especially improvement,4.0,0.11350113525986671
Innovations in pharmacological treatment of heart failure.,diabetes mellitus,4.0,0.22472551465034485
Innovations in pharmacological treatment of heart failure.,selected patients,3.5,0.24646209739148617
Innovations in pharmacological treatment of heart failure.,acei according,3.5,0.03558759391307831
Innovations in pharmacological treatment of heart failure.,xxx,2.5,-0.015934890136122704
Innovations in pharmacological treatment of heart failure.,treatment,2.0,0.27399298548698425
Innovations in pharmacological treatment of heart failure.,inhibitors,2.0,0.12478162348270416
Innovations in pharmacological treatment of heart failure.,drugs,2.0,0.16310197114944458
Innovations in pharmacological treatment of heart failure.,patients,1.5,0.4592966139316559
Innovations in pharmacological treatment of heart failure.,acei,1.5,0
Innovations in pharmacological treatment of heart failure.,valsartan,1.0,0.3132857382297516
Innovations in pharmacological treatment of heart failure.,transporter,1.0,0.08719346672296524
Innovations in pharmacological treatment of heart failure.,sodium,1.0,0.11925020068883896
Innovations in pharmacological treatment of heart failure.,sgltxxx,1.0,0
Innovations in pharmacological treatment of heart failure.,sacubitril,1.0,0
Innovations in pharmacological treatment of heart failure.,results,1.0,0.0652550756931305
Innovations in pharmacological treatment of heart failure.,replace,1.0,0.0772906020283699
Innovations in pharmacological treatment of heart failure.,quality,1.0,0.11005230993032455
Innovations in pharmacological treatment of heart failure.,pmid,1.0,0
Innovations in pharmacological treatment of heart failure.,paradigm,1.0,0.11544345319271088
Innovations in pharmacological treatment of heart failure.,oedema,1.0,0
Innovations in pharmacological treatment of heart failure.,mra,1.0,0
Innovations in pharmacological treatment of heart failure.,mortality,1.0,0.27426618337631226
Innovations in pharmacological treatment of heart failure.,morbidity,1.0,0.32470452785491943
Innovations in pharmacological treatment of heart failure.,medline,1.0,0
Innovations in pharmacological treatment of heart failure.,life,1.0,0.07387976348400116
Innovations in pharmacological treatment of heart failure.,innovations,1.0,0.1336166262626648
Innovations in pharmacological treatment of heart failure.,indicated,1.0,0.047450292855501175
Innovations in pharmacological treatment of heart failure.,indexed,1.0,0.00026863813400268555
Innovations in pharmacological treatment of heart failure.,hospitalisations,1.0,0
Innovations in pharmacological treatment of heart failure.,given,1.0,0.014340896159410477
Innovations in pharmacological treatment of heart failure.,dyspnoe,1.0,0
Innovations in pharmacological treatment of heart failure.,done,1.0,0.023701651021838188
Innovations in pharmacological treatment of heart failure.,diuretics,1.0,0.21879620850086212
Innovations in pharmacological treatment of heart failure.,digoxin,1.0,0.22319909930229187
Innovations in pharmacological treatment of heart failure.,decrease,1.0,0.07778903841972351
Innovations in pharmacological treatment of heart failure.,cornerstone,1.0,0.0026033464819192886
Innovations in pharmacological treatment of heart failure.,case,1.0,0.09149735420942307
Innovations in pharmacological treatment of heart failure.,betablockers,1.0,0
Innovations in pharmacological treatment of heart failure.,arni,1.0,0
Innovations in pharmacological treatment of heart failure.,arb,1.0,0.03499434143304825
Innovations in pharmacological treatment of heart failure.,added,1.0,0.07914778590202332
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed model showed significant improvement,21.0,0.07173480018973351
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,"mmrc ), copd assessment test",18.333333333333336,0.08392896875739098
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,modified medical research council,16.0,0.21932038920931518
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic obstructive pulmonary disease,15.333333333333334,0.23184162378311157
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic obstructive lung disease,15.333333333333334,0.17300859093666077
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,incorporates previously proposed parameters,15.0,0.040034666657447815
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,previously reported pa models,14.666666666666666,0.04339719098061323
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,top xxx global causes,13.75,0.0453461273573339
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd patients within xxx,11.75,0.1693052084495624
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,"cat ), xxx",9.083333333333334,-0.019968018867075443
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,worn wearable devices,9.0,0.12437052341798942
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,positive prediction rate,9.0,0.06270675361156464
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,minute walking distance,9.0,0.04606260359287262
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx million lives,8.75,0.024856471146146458
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx copd patients,8.75,0.2216808618977666
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission prediction criteria,8.5,0.14118045568466187
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,ranked xxxrd among,8.5,0.06559723243117332
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,physicians cannot predict,8.0,0.18083805094162622
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,day readmission risk,8.0,0.16073491548498473
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,continuous pa monitoring,7.666666666666666,0.07097375268737476
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,existing diagnosis methods,7.5,0.14337464794516563
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed model,6.0,0.054264677688479424
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd patients,6.0,0.4592966139316559
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,test subjects,5.5,0.11057605221867561
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,clinical assessment,5.5,0.29115190356969833
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,"qoa ),",5.333333333333334,0
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,chronic diseases,5.333333333333334,0.2243969812989235
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,statistical model,5.0,0.08372131921350956
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,readmission risk,5.0,0.23771753162145615
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,global initiative,5.0,0.03046402893960476
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,especially within,5.0,0.08104106411337852
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,claimed xxx,4.75,-0.019235894083976746
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,prevention methods,4.5,0.1263566929847002
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,potential readmission,4.5,0.1746842823922634
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,highest among,4.5,0.06573433242738247
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx days,4.25,0.008284521289169788
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,new parameter,4.0,0.08210638165473938
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,daily living,4.0,0.06507956236600876
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,airflow obstruction,4.0,0.0615088976919651
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,adopted currently,4.0,0.045376935973763466
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,regularity index,3.75,0.04345167800784111
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,mass index,3.75,0.06871355697512627
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,physical activity,3.666666666666667,0.020183337852358818
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,based wrist,3.666666666666667,0.05970970541238785
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,based indices,3.666666666666667,0.09765568003058434
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,activity index,3.416666666666667,0.06239112466573715
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,proposed,3.0,0.053893283009529114
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,hospital discharge,3.0,0.2782559171319008
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,copd,3.0,0
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,xxx,2.75,-0.015934890136122704
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,pa,2.6666666666666665,0.05034612491726875
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,predict,2.0,0.029006652534008026
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,monitoring,2.0,0.158101424574852
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,diagnosis,2.0,0.24688632786273956
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,index,1.75,0.10827754437923431
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,based,1.6666666666666667,0.08516917377710342
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,activity,1.6666666666666667,0.01650470495223999
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,hospital,1.5,0.4200267195701599
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,discharge,1.5,0.13648511469364166
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,days,1.5,0.03250393271446228
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,sensitivity,1.0,0.0724399983882904
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,ri,1.0,0.030980270355939865
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,quality,1.0,0.11005230993032455
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,predicting,1.0,0.043349962681531906
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,paper,1.0,0.07484385371208191
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,moreover,1.0,0.01877431571483612
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,introduced,1.0,0.0400276780128479
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,gold,1.0,0.0385880172252655
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,found,1.0,0.03727259859442711
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,exercise,1.0,0.1012873649597168
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,dyspnea,1.0,0.19185543060302734
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,discharged,1.0,0.13826555013656616
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,diagnosed,1.0,0.1202194094657898
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,death,1.0,0.12083880603313446
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,data,1.0,0.1061776876449585
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,compared,1.0,0.10162706673145294
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,collected,1.0,-0.03091895952820778
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,body,1.0,0.014940984547138214
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,bode,1.0,0.05985786393284798
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,ai,1.0,0.07966839522123337
Prediction of 30-Day Readmission for COPD Patients Using Accelerometer-Based Activity Monitoring.,accelerometer,1.0,0.0423012413084507
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,bone marrow hematopoietic stem cell,25.0,0.10978166311979294
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cdxxx +/ cdxxx +) associated,20.0,0.10097402334213257
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,exhibited decreased splenic expansion,14.2,0.12433300912380219
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,hsc )- derived mo,13.25,0.039984219086666904
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mice exhibited increased mrna,13.166666666666666,0.07916917403539021
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory cytokine gene expression,13.083333333333334,0.11162370862439275
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,yolk sac origin drive,13.0,0.01964195165783167
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,flow cytometry studies showed,13.0,0.1460544615983963
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cdxxx +/ cdxxx,12.0,0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,dependent transcription factors involved,11.333333333333334,0.07021418306976557
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,κb transcriptional activity,9.0,0.09117141366004944
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,focal adhesion kinase,9.0,0.10769765079021454
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,downstream transcription factors,9.0,0.08452703058719635
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tissue inflammatory response,8.416666666666666,0.13381063689788184
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,α >> arg,8.0,0.010040659457445145
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,xxx days post,8.0,0.03960703872144222
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,fak inhibitor abrogated,8.0,0.03980506956577301
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cultured mφ confirmed,8.0,0.04626263026148081
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory cytokines response,7.666666666666666,0.08711581180493037
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,causes chagas disease,7.5,0.12196000168720882
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected mice treated,6.866666666666667,0.1014980102578799
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronically infected mice,6.866666666666667,0.07014989604552586
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,transcription factors,6.0,0.10666237957775593
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,derived cdxxxb,5.0,-0.011859389953315258
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected mice,4.866666666666667,0.06999934837222099
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory phenotype,4.75,0.14123701304197311
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammatory pathology,4.75,0.33089689910411835
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,dependent increase,4.666666666666667,0.04945408180356026
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,xxx mice,4.666666666666666,0.03642516303807497
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mφ response,4.666666666666666,0.05596902221441269
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas mice,4.666666666666666,0.09806038811802864
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas disease,4.5,0.13518544659018517
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic mo,4.45,0.17343458533287048
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,surface expression,4.333333333333334,-0.02629269380122423
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,notchxxx involved,4.333333333333334,0.03122086077928543
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory mo,4.25,0.10686515271663666
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic compartment,4.2,0.1608849000185728
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic cdxxxb,4.2,0.2681081295013428
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected mφ,4.2,0.05121348053216934
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,"xxx ),",4.0,-0.015934890136122704
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,trypanosoma cruzi,4.0,0.07082304358482361
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sinusoidal compartment,4.0,0.05503897927701473
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,regulatory role,4.0,0.07001019828021526
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory phenotype,4.0,0.12349044531583786
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory activation,4.0,0.10917668044567108
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,progenitor lineage,4.0,0.0636040698736906
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,pathogen stimulus,4.0,0.024714428931474686
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mφ proliferation,4.0,0.16025876998901367
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mφ contributing,4.0,0.00862792506814003
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,myocardial infiltration,4.0,0.16267641633749008
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,latin america,4.0,0.06314825732260942
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inherent capability,4.0,0.024718476459383965
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infection ).,4.0,0.1787572205066681
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,heart failure,4.0,0.2074820026755333
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,functional activation,4.0,0.11878135055303574
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,frequent cause,4.0,0.07947275415062904
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronic phase,4.0,0.11103755049407482
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,also detected,4.0,0.07311824522912502
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,agonistic effects,4.0,0.0391689408570528
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,acute parasitemia,4.0,0.30777977406978607
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,srtxxx reprogrammed,3.666666666666667,0.05110195279121399
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,srtxxx dampened,3.666666666666667,0.027375388890504837
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,induced fak,3.666666666666667,-0.006984012201428413
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sirtxxx agonist,3.5,0.06754408031702042
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronic cd,3.5,0.13787981867790222
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,induced increase,3.3333333333333335,0.027806519530713558
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,associated,3.0,0.10097402334213257
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,yolk,2.5,-0.04447002336382866
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,studies,2.5,0.24976284801959991
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,showed,2.5,0.048222288489341736
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sac,2.5,0.054907120764255524
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,increased,2.5,0.07228505611419678
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,involved,2.3333333333333335,0.03122086077928543
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,expression,2.3333333333333335,0.0005566496402025223
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mo,2.25,0.0787610411643982
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,splenic,2.2,0.2681081295013428
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,infected,2.2,0.05121348053216934
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,α,2.0,0.06381849944591522
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,xxx,2.0,-0.015934890136122704
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,treated,2.0,0.1644953340291977
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,proinflammatory,2.0,0.13496926426887512
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,mφ,2.0,0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,fak,2.0,0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chronically,2.0,0.07045099139213562
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,chagas,2.0,0.10733556002378464
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,srtxxx,1.6666666666666667,0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,induced,1.6666666666666667,-0.006984012201428413
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,increase,1.6666666666666667,0.06259705126285553
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,sirtxxx,1.5,0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cd,1.5,0.06606568396091461
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,vs,1.0,0.08122316002845764
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,untreated,1.0,0.11393826454877853
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tnf,1.0,0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,tc,1.0,0.0335920974612236
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,study,1.0,0.2376001477241516
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,runxxxx,1.0,0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,results,1.0,0.0652550756931305
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,respond,1.0,0.04464415833353996
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,pu,1.0,0.07325270771980286
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,protein,1.0,0.07616645097732544
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,phosphorylation,1.0,0.07472814619541168
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,nf,1.0,0.0131322480738163
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,myocardium,1.0,0.27229008078575134
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,myb,1.0,0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,monocytes,1.0,0.02856728993356228
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,monitored,1.0,0.10678759217262268
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,modulating,1.0,0.09799468517303467
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,migration,1.0,0.050750430673360825
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,methods,1.0,0.024640876799821854
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,maturation,1.0,-0.006207987666130066
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,markers,1.0,0.03814179450273514
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,macrophages,1.0,0.10670876502990723
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,instead,1.0,0.039980120956897736
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,inflammation,1.0,0.16907447576522827
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,il,1.0,0.06259879469871521
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,however,1.0,-0.011453256011009216
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,fxxx,1.0,0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,examined,1.0,0.1701224148273468
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,determined,1.0,-0.03170712664723396
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cxxxbl,1.0,0
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,controlling,1.0,0.041483066976070404
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,control,1.0,0.05591680109500885
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,conclusions,1.0,0.07628431916236877
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,cells,1.0,0.06259886920452118
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,c,1.0,0.04119548946619034
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,background,1.0,0.03833860531449318
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,anti,1.0,0.10541997849941254
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,alter,1.0,-0.003222196362912655
Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.,acutely,1.0,0.11704602837562561
Mood disorders and increased risk of non-communicable disease in adults with HIV.,examined whether prevalent mood disorders,21.583333333333332,0.12869693860411643
Mood disorders and increased risk of non-communicable disease in adults with HIV.,"obesity ), chronic kidney",16.0,0.23452904323736826
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mortality risk following multimorbidity,13.2,0.1781585564215978
Mood disorders and increased risk of non-communicable disease in adults with HIV.,adult hiv clinic cohort,13.0,0.1789909154176712
Mood disorders and increased risk of non-communicable disease in adults with HIV.,"xxx ), incident multimorbidity",12.555555555555555,-0.012258293107151985
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood disorders documented,9.583333333333334,0.11178286870320638
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood disorder diagnosed,9.25,0.0940139393011729
Mood disorders and increased risk of non-communicable disease in adults with HIV.,bipolar affective disorder,9.0,0.07190846403439839
Mood disorders and increased risk of non-communicable disease in adults with HIV.,adjusted subhazard ratios,9.0,0.04736204072833061
Mood disorders and increased risk of non-communicable disease in adults with HIV.,adjusted subhazard ratio,9.0,0.04382872208952904
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds may reduce,8.4,0.03972076065838337
Mood disorders and increased risk of non-communicable disease in adults with HIV.,≥ xxx year,8.055555555555555,0.04961262084543705
Mood disorders and increased risk of non-communicable disease in adults with HIV.,particularly metabolic syndrome,8.0,0.1289055198431015
Mood disorders and increased risk of non-communicable disease in adults with HIV.,experience high rates,8.0,0.06256085634231567
Mood disorders and increased risk of non-communicable disease in adults with HIV.,≥ xxx ncds,7.955555555555556,0.06012989301234484
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx incident ncds,7.955555555555556,-0.012258293107151985
Mood disorders and increased risk of non-communicable disease in adults with HIV.,≥ xxx ncd,7.555555555555555,0.06012989301234484
Mood disorders and increased risk of non-communicable disease in adults with HIV.,mood disorders,6.583333333333334,0.16552762687206268
Mood disorders and increased risk of non-communicable disease in adults with HIV.,incident ncds,5.4,-0.008581696078181267
Mood disorders and increased risk of non-communicable disease in adults with HIV.,metabolic syndrome,5.0,0.1439461186528206
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx adults,4.555555555555555,0.017985749058425426
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx ).,4.555555555555555,-0.015934890136122704
Mood disorders and increased risk of non-communicable disease in adults with HIV.,first year,4.5,0.02394421212375164
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk group,4.2,0.12219683267176151
Mood disorders and increased risk of non-communicable disease in adults with HIV.,increased risk,4.2,0.13324370235204697
Mood disorders and increased risk of non-communicable disease in adults with HIV.,competing risk,4.2,0.13580424711108208
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ci xxx,4.055555555555555,0.02506826538592577
Mood disorders and increased risk of non-communicable disease in adults with HIV.,study period,4.0,0.12990714237093925
Mood disorders and increased risk of non-communicable disease in adults with HIV.,people living,4.0,0.10212717577815056
Mood disorders and increased risk of non-communicable disease in adults with HIV.,major depression,4.0,0.10543613135814667
Mood disorders and increased risk of non-communicable disease in adults with HIV.,liver disease,4.0,0.19786392897367477
Mood disorders and increased risk of non-communicable disease in adults with HIV.,general population,4.0,0.14119073003530502
Mood disorders and increased risk of non-communicable disease in adults with HIV.,focused prevention,4.0,0.14420075342059135
Mood disorders and increased risk of non-communicable disease in adults with HIV.,first ncd,4.0,0.019310347735881805
Mood disorders and increased risk of non-communicable disease in adults with HIV.,defining cancers,4.0,0.10799512825906277
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cumulative incidence,4.0,0.08749265782535076
Mood disorders and increased risk of non-communicable disease in adults with HIV.,confidence interval,4.0,0.0899096429347992
Mood disorders and increased risk of non-communicable disease in adults with HIV.,communicable disease,4.0,0.10335621982812881
Mood disorders and increased risk of non-communicable disease in adults with HIV.,cardiovascular disease,4.0,0.3688889145851135
Mood disorders and increased risk of non-communicable disease in adults with HIV.,conclusively associated,3.5,0.044794896617531776
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ashr ranging,3.5,-0.015200847759842873
Mood disorders and increased risk of non-communicable disease in adults with HIV.,multimorbidity,3.0,0
Mood disorders and increased risk of non-communicable disease in adults with HIV.,xxx,2.5555555555555554,-0.015934890136122704
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hiv,2.5,0.14575514197349548
Mood disorders and increased risk of non-communicable disease in adults with HIV.,clinic,2.5,0.32195553183555603
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncds,2.4,0
Mood disorders and increased risk of non-communicable disease in adults with HIV.,risk,2.2,0.19420234858989716
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ncd,2.0,0
Mood disorders and increased risk of non-communicable disease in adults with HIV.,high,2.0,0.06070782244205475
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ci,1.5,0.06607142090797424
Mood disorders and increased risk of non-communicable disease in adults with HIV.,associated,1.5,0.10097402334213257
Mood disorders and increased risk of non-communicable disease in adults with HIV.,ashr,1.5,0
Mood disorders and increased risk of non-communicable disease in adults with HIV.,treatment,1.0,0.27399298548698425
Mood disorders and increased risk of non-communicable disease in adults with HIV.,three,1.0,0.07735734432935715
Mood disorders and increased risk of non-communicable disease in adults with HIV.,tennessee,1.0,0.0342380553483963
Mood disorders and increased risk of non-communicable disease in adults with HIV.,setting,1.0,0.04959516599774361
Mood disorders and increased risk of non-communicable disease in adults with HIV.,results,1.0,0.0652550756931305
Mood disorders and increased risk of non-communicable disease in adults with HIV.,plwh,1.0,0
Mood disorders and increased risk of non-communicable disease in adults with HIV.,non,1.0,0.06398928165435791
Mood disorders and increased risk of non-communicable disease in adults with HIV.,nashville,1.0,0.010575555264949799
Mood disorders and increased risk of non-communicable disease in adults with HIV.,methods,1.0,0.024640876799821854
Mood disorders and increased risk of non-communicable disease in adults with HIV.,included,1.0,0.029688812792301178
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hypertension,1.0,0.364623486995697
Mood disorders and increased risk of non-communicable disease in adults with HIV.,hyperlipidemia,1.0,0.2624513506889343
Mood disorders and increased risk of non-communicable disease in adults with HIV.,follow,1.0,0.08601848781108856
Mood disorders and increased risk of non-communicable disease in adults with HIV.,diabetes,1.0,0.31405115127563477
Mood disorders and increased risk of non-communicable disease in adults with HIV.,dementia,1.0,0.18816161155700684
Mood disorders and increased risk of non-communicable disease in adults with HIV.,death,1.0,0.12083880603313446
Mood disorders and increased risk of non-communicable disease in adults with HIV.,conclusions,1.0,0.07628431916236877
Mood disorders and increased risk of non-communicable disease in adults with HIV.,care,1.0,0.26734086871147156
Mood disorders and increased risk of non-communicable disease in adults with HIV.,calculated,1.0,-0.0013035684823989868
Mood disorders and increased risk of non-communicable disease in adults with HIV.,burden,1.0,0.07514367252588272
Mood disorders and increased risk of non-communicable disease in adults with HIV.,baseline,1.0,0.05839666724205017
Mood disorders and increased risk of non-communicable disease in adults with HIV.,background,1.0,0.03833860531449318
Mood disorders and increased risk of non-communicable disease in adults with HIV.,assessed,1.0,0.06162751466035843
Mood disorders and increased risk of non-communicable disease in adults with HIV.,aids,1.0,0.0020779240876436234
Mood disorders and increased risk of non-communicable disease in adults with HIV.,accumulation,1.0,0.033634718507528305
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",statistically significant differences,9.0,0.10447552551825841
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",logistic regression model,9.0,0.07161387925346692
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",conditional inference tree,9.0,0.012389281143744787
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",adjusted odds ratios,9.0,0.05823785811662674
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",acute myocardial infarction,9.0,0.3220969835917155
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",ventricular arrhythmia hospitalizations,8.666666666666666,0.3152106702327728
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",higher among patients,8.5,0.2236365800102552
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",found among drugs,8.5,0.09962361678481102
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",prior cardiac arrhythmia,8.166666666666666,0.32735601905733347
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial fibrillation hospitalizations,8.0,0.28927744428316754
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",cardiac arrhythmia,5.166666666666666,0.48549817502498627
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",atrial fibrillation,5.0,0.26550570130348206
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study found,4.5,0.13743637315928936
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",higher risk,4.25,0.15365959703922272
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study period,4.0,0.12990714237093925
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study outcomes,4.0,0.23542963713407516
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",study aimed,4.0,0.16353436559438705
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",respectively ).,4.0,0.08458003401756287
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",relevant predictors,4.0,0.1270303875207901
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",relevant predictor,4.0,0.10312579944729805
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",new users,4.0,0.0782760214060545
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",medical history,4.0,0.28095812164247036
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",data sources,4.0,0.06687838211655617
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",danish registers,4.0,0.012088241055607796
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",risk stratification,3.75,0.16070245951414108
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",increased risk,3.75,0.13324370235204697
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",xxx days,3.666666666666667,0.008284521289169788
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",ci xxx,3.666666666666667,0.02506826538592577
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",risk,1.75,0.19420234858989716
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",xxx,1.6666666666666667,-0.015934890136122704
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",used,1.0,0.010911919176578522
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",unadjusted,1.0,0.13189849257469177
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",triazolam,1.0,0.16294308006763458
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",secondly,1.0,-0.0010252296924591064
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",results,1.0,0.0652550756931305
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",promethazine,1.0,0.17892049252986908
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",perform,1.0,0.09922076761722565
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",patient,1.0,0.4149835705757141
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",p,1.0,0.11820723116397858
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",objectives,1.0,0.043118979781866074
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",methods,1.0,0.024640876799821854
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",loratadine,1.0,0.20007756352424622
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",investigation,1.0,0.0926906168460846
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",identify,1.0,0.04736902192234993
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",hospitalization,1.0,0.25800377130508423
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",fractures,1.0,0.19541451334953308
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",followed,1.0,0.06544908136129379
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",domperidone,1.0,0.17249611020088196
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",conclusion,1.0,0.03420025110244751
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",compute,1.0,0.02463405579328537
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",compare,1.0,0.09237030148506165
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.",betahistine,1.0,0
"The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine.","),",1.0,0
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,altman analysis suggested strong correlation,25.0,0.05678745824843645
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,dataset included xxx vois taken,21.0,0.0595711499452591
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,part requires full attribution,16.0,0.0022889776155352592
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,intravascular optical coherence tomography,16.0,0.2140582539141178
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,following segmentation noise cleaning,16.0,0.058252427726984024
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,performing percutaneous coronary interventions,15.5,0.24217879585921764
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,creative commons attribution xxx,15.0,0.02382316580042243
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,inhibit proper stent deployment,14.0,0.1109986703377217
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,manually annotated ivoct volumes,13.0,0.0784776359796524
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically determined calcification depth,12.833333333333334,0.0726599944755435
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,deployment calcification scores,9.333333333333334,0.07477511713902156
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,deployment calcification score,9.333333333333334,0.08377153426408768
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx ± xxx,9.0,0.04078221941987673
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx unported license,9.0,0.015934241004288197
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx clinical pullbacks,9.0,0.1661946096767982
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,two expert analysts,9.0,0.09502685690919559
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,keeping vois intact,9.0,0.04027108599742254
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,fujino et al,9.0,0.08752741664648056
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,convolutional neural network,9.0,0.09854805283248425
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,classification approach could,9.0,0.01804668332139651
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,coronary calcification lesions,8.833333333333334,0.2726018528143565
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically obtained stent,8.666666666666666,0.14883502262334028
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,automatically obtained lumen,8.0,0.07978673217197259
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,performed xxx,5.0,0.0697127403691411
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcification attributes,5.0,0.10349067114293575
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,obtained sensitivities,4.666666666666666,0.0247585317119956
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,without lesions,4.333333333333334,0.07429851591587067
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,mixed lesions,4.333333333333334,0.05186578631401062
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vascular lumen,4.0,0.3328341767191887
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,treatment planning,4.0,0.18590878695249557
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,tissue classes,4.0,0.12448721006512642
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,thickness attributes,4.0,0.029360875487327576
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,pretrained segnet,4.0,0
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,original publication,4.0,0.004803294315934181
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,impact using,4.0,-0.006068231537938118
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,great concern,4.0,0.09053497761487961
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,fold cross,4.0,0.11676701158285141
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,comprehensive software,4.0,0.11384642496705055
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,applied clinically,4.0,0.16154612600803375
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segment calcifications,3.75,0.14111110381782055
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,major calcifications,3.75,0.15375930815935135
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcifications using,3.75,0.09604602307081223
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vivo images,3.5,0.1461043357849121
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segmented regions,3.5,0.09626410156488419
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,xxx,3.0,-0.015934890136122704
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,vois,3.0,0.1336328536272049
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,stent,2.6666666666666665,0.39394140243530273
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,manually,2.5,0.020255818963050842
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,ivoct,2.5,0
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,determined,2.5,-0.03170712664723396
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lumen,2.0,0.18679653108119965
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcifications,1.75,0.23382940888404846
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,segmented,1.5,0.09718252718448639
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,images,1.5,0.07014717161655426
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,work,1.0,0.06322342157363892
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,whole,1.0,0.08689890801906586
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,validation,1.0,0.09198760986328125
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,total,1.0,0.003683900460600853
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,task,1.0,-0.009650083258748055
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,suggest,1.0,0.046784643083810806
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,spie,1.0,0
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,results,1.0,0.0652550756931305
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,respectively,1.0,0.08458003401756287
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,reproduction,1.0,0.09168039262294769
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,reported,1.0,-0.00021066516637802124
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,refined,1.0,0.0060292575508356094
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,published,1.0,0.10513044893741608
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,method,1.0,0.016362402588129044
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,lipidous,1.0,0
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,interest,1.0,0.08689615875482559
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,including,1.0,0.06332606077194214
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,good,1.0,0.0672173798084259
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,giving,1.0,0.0026437565684318542
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,four,1.0,0.06643542647361755
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,evaluated,1.0,0.1149546355009079
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,encouraging,1.0,0.04055313393473625
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,doi,1.0,0.055976808071136475
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,distribution,1.0,0.11434805393218994
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,data,1.0,0.1061776876449585
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,created,1.0,-0.00517185777425766
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,consensus,1.0,0.04067409038543701
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calculate,1.0,-0.0033954866230487823
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,calcified,1.0,0.14941717684268951
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,bland,1.0,-0.0012202747166156769
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,authors,1.0,0.21598771214485168
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,assessment,1.0,0.08391694724559784
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,annotations,1.0,0.0771874189376831
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,angle,1.0,0.03275878354907036
Coronary calcification segmentation in intravascular OCT images using deep learning: application to calcification scoring.,agreement,1.0,0.04792368784546852
Prediction of Left Ventricular Mechanics Using Machine Learning.,mechanics simulator using machine learning,25.0,0.039487116038799286
Prediction of Left Ventricular Mechanics Using Machine Learning.,predict lv mechanics much faster,21.57142857142857,0.051101071387529375
Prediction of Left Ventricular Mechanics Using Machine Learning.,used extreme gradient boosting,14.5,0.05170036666095257
Prediction of Left Ventricular Mechanics Using Machine Learning.,simulation results show ml,13.821428571428571,0.066113056614995
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml results could capture,13.821428571428571,0.04391429200768471
Prediction of Left Ventricular Mechanics Using Machine Learning.,obtain training fe models,11.083333333333334,0.06819514464586973
Prediction of Left Ventricular Mechanics Using Machine Learning.,time left ventricular,9.0,0.11121451730529468
Prediction of Left Ventricular Mechanics Using Machine Learning.,mean absolute errors,9.0,0.04038336997230848
Prediction of Left Ventricular Mechanics Using Machine Learning.,predict lv behavior,8.904761904761905,0.037892408668994904
Prediction of Left Ventricular Mechanics Using Machine Learning.,different material properties,8.8,0.014418844133615494
Prediction of Left Ventricular Mechanics Using Machine Learning.,reinforced material model,8.666666666666666,0.006163677200675011
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv constitutive equation,8.571428571428571,0.02270826914658149
Prediction of Left Ventricular Mechanics Using Machine Learning.,varied passive properties,8.3,0.022176596025625866
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive properties govern,8.3,0.011267357816298803
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume results obtained,8.25,0.05494770593941212
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml model based,8.238095238095237,0.06856936092178027
Prediction of Left Ventricular Mechanics Using Machine Learning.,real world applications,8.0,0.04875158021847407
Prediction of Left Ventricular Mechanics Using Machine Learning.,cross myofiber stress,7.833333333333334,0.11580562591552734
Prediction of Left Ventricular Mechanics Using Machine Learning.,varied active properties,7.8,0.033767037093639374
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx ± xxx,7.333333333333332,0.04078221941987673
Prediction of Left Ventricular Mechanics Using Machine Learning.,stress predictions ).,7.0,0.05870144069194794
Prediction of Left Ventricular Mechanics Using Machine Learning.,results predicted,5.25,0.061780449002981186
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml model,5.238095238095238,0.06026945449411869
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml ).,5.071428571428571,0.06590283662080765
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive behavior,4.833333333333334,0.01599915325641632
Prediction of Left Ventricular Mechanics Using Machine Learning.,myofiber stress,4.833333333333334,0.0933484435081482
Prediction of Left Ventricular Mechanics Using Machine Learning.,mechanical properties,4.8,0.06056681461632252
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx ml,4.738095238095238,0.024983973242342472
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv stresses,4.571428571428571,0.05859331041574478
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv pressures,4.571428571428571,0.025300887413322926
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv pressure,4.571428571428571,0.0867864266037941
Prediction of Left Ventricular Mechanics Using Machine Learning.,shear stress,4.5,0.05624750070273876
Prediction of Left Ventricular Mechanics Using Machine Learning.,passive tissue,4.5,0.08704498410224915
Prediction of Left Ventricular Mechanics Using Machine Learning.,training set,4.333333333333334,0.06541751697659492
Prediction of Left Ventricular Mechanics Using Machine Learning.,myofiber contractions,4.333333333333334,0.12142586708068848
Prediction of Left Ventricular Mechanics Using Machine Learning.,active behavior,4.333333333333334,0.033384814858436584
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe method,4.25,0.014418970793485641
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe computations,4.25,0.02538616582751274
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx mmhg,4.166666666666666,-0.015934890136122704
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx kpa,4.166666666666666,-0.015934890136122704
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume loops,4.0,0.05239192955195904
Prediction of Left Ventricular Mechanics Using Machine Learning.,pressure predictions,4.0,0.07293277233839035
Prediction of Left Ventricular Mechanics Using Machine Learning.,large group,4.0,0.06074954383075237
Prediction of Left Ventricular Mechanics Using Machine Learning.,hyperelastic fiber,4.0,0.01226314902305603
Prediction of Left Ventricular Mechanics Using Machine Learning.,heart resulting,4.0,0.14859699178487062
Prediction of Left Ventricular Mechanics Using Machine Learning.,finite element,4.0,-0.04499960597604513
Prediction of Left Ventricular Mechanics Using Machine Learning.,xgboost volume,3.666666666666667,0.1002674475312233
Prediction of Left Ventricular Mechanics Using Machine Learning.,xgboost pressure,3.666666666666667,0.12181110680103302
Prediction of Left Ventricular Mechanics Using Machine Learning.,cubist volume,3.666666666666667,0.07493147253990173
Prediction of Left Ventricular Mechanics Using Machine Learning.,cubist pressure,3.666666666666667,0.0857033021748066
Prediction of Left Ventricular Mechanics Using Machine Learning.,ml,2.5714285714285716,0.06590283662080765
Prediction of Left Ventricular Mechanics Using Machine Learning.,lv,2.5714285714285716,0.051761746406555176
Prediction of Left Ventricular Mechanics Using Machine Learning.,used,2.5,0.010911919176578522
Prediction of Left Ventricular Mechanics Using Machine Learning.,obtain,2.5,0.024071499705314636
Prediction of Left Ventricular Mechanics Using Machine Learning.,training,2.3333333333333335,0.1278398334980011
Prediction of Left Ventricular Mechanics Using Machine Learning.,fe,2.25,0.01247553899884224
Prediction of Left Ventricular Mechanics Using Machine Learning.,xxx,2.1666666666666665,-0.015934890136122704
Prediction of Left Ventricular Mechanics Using Machine Learning.,volume,2.0,0.1002674475312233
Prediction of Left Ventricular Mechanics Using Machine Learning.,real,2.0,0.02762891724705696
Prediction of Left Ventricular Mechanics Using Machine Learning.,predictions,2.0,0.02405443787574768
Prediction of Left Ventricular Mechanics Using Machine Learning.,active,2.0,0.03386080265045166
Prediction of Left Ventricular Mechanics Using Machine Learning.,xgboost,1.6666666666666667,0
Prediction of Left Ventricular Mechanics Using Machine Learning.,cubist,1.6666666666666667,0.04959549754858017
Prediction of Left Ventricular Mechanics Using Machine Learning.,well,1.0,0.09099400043487549
Prediction of Left Ventricular Mechanics Using Machine Learning.,volumes,1.0,0.07075798511505127
Prediction of Left Ventricular Mechanics Using Machine Learning.,tool,1.0,-0.026759788393974304
Prediction of Left Ventricular Mechanics Using Machine Learning.,systole,1.0,0.2340625375509262
Prediction of Left Ventricular Mechanics Using Machine Learning.,subjects,1.0,0.13721111416816711
Prediction of Left Ventricular Mechanics Using Machine Learning.,smoother,1.0,0.04971789941191673
Prediction of Left Ventricular Mechanics Using Machine Learning.,simulations,1.0,0.05079309642314911
Prediction of Left Ventricular Mechanics Using Machine Learning.,similar,1.0,0.08377962559461594
Prediction of Left Ventricular Mechanics Using Machine Learning.,shape,1.0,0.05461088567972183
Prediction of Left Ventricular Mechanics Using Machine Learning.,provide,1.0,0.01998533308506012
Prediction of Left Ventricular Mechanics Using Machine Learning.,prediction,1.0,0.07748128473758698
Prediction of Left Ventricular Mechanics Using Machine Learning.,predictability,1.0,-0.0036656539887189865
Prediction of Left Ventricular Mechanics Using Machine Learning.,paper,1.0,0.07484385371208191
Prediction of Left Ventricular Mechanics Using Machine Learning.,myocardium,1.0,0.27229008078575134
Prediction of Left Ventricular Mechanics Using Machine Learning.,improve,1.0,0.08507965505123138
Prediction of Left Ventricular Mechanics Using Machine Learning.,goal,1.0,0.06500711292028427
Prediction of Left Ventricular Mechanics Using Machine Learning.,follows,1.0,0.03413863107562065
Prediction of Left Ventricular Mechanics Using Machine Learning.,experiments,1.0,0.11820036172866821
Prediction of Left Ventricular Mechanics Using Machine Learning.,diastole,1.0,0.2708514630794525
Prediction of Left Ventricular Mechanics Using Machine Learning.,describe,1.0,-0.011884354054927826
Prediction of Left Ventricular Mechanics Using Machine Learning.,conducted,1.0,0.055469855666160583
Prediction of Left Ventricular Mechanics Using Machine Learning.,added,1.0,0.07914778590202332
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",molecular dynamic simulations showed,16.0,0.08770374581217766
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",linking two privileged scaffolds,16.0,0.09349417872726917
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.","xxx ), monoamine oxidases",13.666666666666668,0.10527323000133038
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.","hbuche ), β",9.333333333333334,0.06373848021030426
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.","b ), lipoxygenase",9.333333333333334,0.10664971172809601
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",treat neurodegenerative diseases,9.0,0.17449221014976501
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",target directed ligands,9.0,0.05927034715811411
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",obtaining effective drugs,9.0,0.06981081701815128
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",neurotoxic cascades could,9.0,0.008372226729989052
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",namely human cholinesterases,9.0,0.07256103307008743
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",long wanted remedies,9.0,0.02530847117304802
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",could synergistically contribute,9.0,0.04028247048457464
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hybrid xxx,4.333333333333334,0.01434998121112585
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",valid approach,4.0,0.013630649074912071
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",type screening,4.0,0.0939894188195467
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",sigma receptors,4.0,0.10349312052130699
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",repair properties,4.0,0.08163597621023655
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",relevant drug,4.0,0.13098900020122528
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",protein interactions,4.0,0.04674859344959259
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",new cns,4.0,0.12606481835246086
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",neuronal regeneration,4.0,0.1511332094669342
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",neurogenic properties,4.0,0.13461929000914097
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",known activities,4.0,0.03329196758568287
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",interesting mtd,4.0,0.0133853480219841
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",highlighted due,4.0,0.020590148400515318
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",first steps,4.0,-0.0026558153331279755
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",complex pathologies,4.0,0.13732530176639557
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",combine neuro,4.0,0.205549662001431
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",biological evaluation,4.0,0.1350124254822731
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",σxxxr ).,3.5,0
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",targets involved,3.5,0.043086275458335876
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",permeable flavonoid,3.5,0.08249499276280403
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",nds ).,3.5,-0.023514673113822937
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",dbma hybrids,3.5,0.07075037062168121
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",block neurodegeneration,3.5,0.0975866736844182
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",xxx,2.3333333333333335,-0.015934890136122704
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",σxxxr,1.5,0
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",targets,1.5,0.05495169013738632
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",nds,1.5,-0.023514673113822937
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",flavonoid,1.5,0.11331182718276978
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",dbma,1.5,0
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",block,1.5,-0.012133484706282616
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",well,1.0,0.09099400043487549
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",subjected,1.0,-0.031078075990080833
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",secretase,1.0,0.0699610710144043
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",profile,1.0,0.06660210341215134
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",obtained,1.0,-0.0006794054061174393
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",nd,1.0,0.009890026412904263
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",n,1.0,-0.021267158910632133
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",multi,1.0,0.048057474195957184
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",mtdls,1.0,0
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",methyl,1.0,0.0280783548951149
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hmao,1.0,0
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hlox,1.0,0
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hbace,1.0,0
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",hache,1.0,0.018492121249437332
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",funnel,1.0,0.03538220003247261
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",fragments,1.0,-0.018060170114040375
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",disease,1.0,0.1630353331565857
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",dimethoxychromone,1.0,0
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",dibenzyl,1.0,0
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",design,1.0,0.13118362426757812
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",battery,1.0,0.04219137877225876
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",amine,1.0,0.06245746091008186
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",alzheimer,1.0,0.24842241406440735
"New flavonoid - &lt;i&gt;N&lt;/i&gt;,&lt;i&gt;N&lt;/i&gt;-dibenzyl(&lt;i&gt;N&lt;/i&gt;-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties.",ad,1.0,0.03272446244955063
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,exclusive licensee american association,16.0,0.06039516848977655
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,display ad jnkxxx deficiency,13.1,0.05491651346286138
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dependent mapk signaling pathway,12.433333333333334,0.04733747119704882
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,fibroblasts displayed impaired jnkxxx,10.266666666666666,0.0764965998629729
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mapk signaling pathway,9.833333333333334,0.05285065062344074
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,signaling pathways involved,9.333333333333334,0.05852337678273519
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,previously undescribed form,9.0,-0.018303414806723595
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,key extracellular matrix,9.0,0.07821637640396754
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,chronic mucocutaneous candidiasis,9.0,0.18391571442286173
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,causing gene products,9.0,0.11159297327200572
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,impaired ex vivo,8.666666666666666,0.06474139665563901
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dietz syndrome caused,8.5,0.022021150216460228
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,connective tissue disorders,8.5,0.17188597718874613
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,terminal kinase xxx,8.333333333333334,0.06454281819363435
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dependent mucocutaneous immunity,8.1,0.049762625247240067
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,unusual ctd phenotype,8.0,0.08233420364558697
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,gene encoding c,8.0,0.08507865170637767
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,disrupt human il,7.5,0.06284187113245328
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,human jnkxxx,5.1,0.08946964889764786
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dependent immunity,5.1,0.009203566238284111
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,responsive pathway,5.0,0.04763247258961201
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,"jnkxxx ),",4.6,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dependent induction,4.6,0.06701848655939102
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,dependent homeostasis,4.6,0.07017704099416733
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,danlos syndrome,4.5,0.01602141559123993
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,connective tissues,4.5,0.0907307118177414
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,transcriptional pattern,4.0,0.10730607993900776
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,rights reserved,4.0,0.030988029204308987
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,probably due,4.0,0.018082431983202696
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,private splice,4.0,0.04516913369297981
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,original u,4.0,0.0014337841421365738
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,often impair,4.0,0.030322120524942875
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,nature indicates,4.0,-0.026937332469969988
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mucosal surfaces,4.0,0.04328795336186886
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,incompletely understood,4.0,0.009634997695684433
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,government works,4.0,0.06858580186963081
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,genetic etiologies,4.0,0.17322345823049545
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,generation family,4.0,0.0887647271156311
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,clinically overlaps,4.0,0.1724366657435894
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,autosomal dominant,4.0,0.11971911042928696
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,β different,3.5,0.06554415822029114
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,thxxx cells,3.5,0.06259886920452118
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,site variant,3.5,0.028172087855637074
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,jun n,3.5,0.02815354708582163
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,eds ).,3.5,0.2012859284877777
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,impaired,2.6666666666666665,0.012190107256174088
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,jnkxxx,2.6,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,fibroblasts,2.5,0.157394677400589
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,displayed,2.5,0.05990501493215561
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ad,2.5,0.03272446244955063
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,xxx,2.3333333333333335,-0.015934890136122704
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,il,2.0,0.06259879469871521
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ctd,2.0,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,c,2.0,0.04119548946619034
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,β,1.5,0.06373848021030426
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,variant,1.5,0.04247875139117241
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,jun,1.5,0.07757425308227539
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,eds,1.5,0.2012859284877777
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,cells,1.5,0.06259886920452118
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,xxxf,1.0,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,xxxa,1.0,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,whereas,1.0,0.10153888165950775
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,vitro,1.0,0.2126568853855133
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,three,1.0,0.07735734432935715
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,tgfbrxxx,1.0,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,tgf,1.0,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,smadxxx,1.0,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,science,1.0,0.26585233211517334
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,responses,1.0,0.050901129841804504
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,response,1.0,0.05596902221441269
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,report,1.0,0.05636989697813988
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,regulators,1.0,0.08656861633062363
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,patients,1.0,0.4592966139316559
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mutations,1.0,0.1048092395067215
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,moreover,1.0,0.01877431571483612
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,mapkxxx,1.0,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,loss,1.0,0.0528750903904438
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,loeys,1.0,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,involvement,1.0,-0.02553686872124672
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,integrity,1.0,0.04435562342405319
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,heterozygous,1.0,0.08078410476446152
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,haploinsufficiency,1.0,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,furthermore,1.0,-0.04380498453974724
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,function,1.0,0.11069313436746597
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,f,1.0,0.004203930497169495
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,expression,1.0,0.0005566496402025223
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,experiment,1.0,0.025291113182902336
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,essential,1.0,0.026568148285150528
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ehlers,1.0,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ecm,1.0,0.14004570245742798
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,development,1.0,0.1793753206729889
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,ctds,1.0,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,consistently,1.0,0.017067428678274155
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,components,1.0,0.05457521229982376
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,component,1.0,0.011329900473356247
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,complex,1.0,0.07974846661090851
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,combination,1.0,-0.03356827795505524
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,cmc,1.0,0.10947288572788239
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,claim,1.0,-0.01065855659544468
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,candida,1.0,0.11155124753713608
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,authors,1.0,0.21598771214485168
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,atf,1.0,0
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,advancement,1.0,0.2000112533569336
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,accounting,1.0,0.17098435759544373
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β.,abolished,1.0,0.010531069710850716
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,coupled inward rectifier potassium current,24.0,0.050656255707144736
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado induced greater rate slowing,18.861111111111114,0.045344434678554535
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced inward rectifying current,16.75,0.018905228935182095
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,perforated patch clamp recordings,16.0,0.03732100501656532
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,subsequent negative chronotropic effects,15.333333333333334,0.019369281828403473
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,exert negative chronotropic effects,15.333333333333334,0.032897185534238815
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,physiologically relevant ado concentrations,13.277777777777779,0.08304133266210556
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,selective girk blocker ).,13.166666666666666,0.08939442411065102
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk expression enhances ikado,13.0,0.03919874969869852
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf san pacemaker cells,11.488095238095237,0.11774853616952896
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced rate slowing,11.083333333333334,0.03886594126621882
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk mrna expression,9.5,0.0005566496402025223
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,induced chronic hf,9.321428571428571,0.10456656850874424
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,slow diastolic depolarization,9.0,0.10761023871600628
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,maximum diastolic potential,9.0,0.08864259347319603
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk mrna quantification,9.0,0.12732118368148804
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk blockade may,9.0,0.01850477233529091
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,canine chronic hf,8.571428571428571,0.15429352223873138
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,xxx μm ado,8.527777777777779,0.04694578858713309
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,selective axxxr antagonist,8.5,0.09892789646983147
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,"bpm ), slope",8.5,0.0697761382907629
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,adenosine axxx receptors,8.0,0.1537301503121853
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tpq prevented ado,7.777777777777778,-0.00017736386507749557
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,dpcpx prevented ado,7.777777777777778,-0.00017736386507749557
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf vs ctl,7.571428571428571,0.09610646218061447
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado effects,6.111111111111111,0.029893998056650162
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,xxx ).,5.416666666666666,-0.015934890136122704
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,firing rate,5.333333333333334,0.07240081951022148
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf cells,5.238095238095238,0.08679431676864624
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf ).,5.238095238095238,0.1109897643327713
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,san cells,4.916666666666666,0.03139955550432205
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado axxxrs,4.777777777777778,0.01965394616127014
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado ].,4.777777777777778,0.01965394616127014
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,"sdd ),",4.5,0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,san tissue,4.25,0.08760036528110504
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,useful strategy,4.0,0.09158209711313248
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,sinus arrest,4.0,0.10634906217455864
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,sinoatrial node,4.0,0.06437795609235764
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,significantly increased,4.0,0.08945312350988388
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,rights reserved,4.0,0.030988029204308987
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,observed significantly,4.0,0.09701144322752953
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,normal controls,4.0,0.07243950106203556
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mitigate bradycardia,4.0,0.15236296877264977
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,membrane hyperpolarization,4.0,0.16566138714551926
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,main methods,4.0,0.047756170853972435
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,key findings,4.0,0.13917770236730576
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,heart failure,4.0,0.2074820026755333
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,g protein,4.0,0.04946049489080906
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,causing hyperpolarization,4.0,0.12481030076742172
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,bradycardia contributes,4.0,0.19110211543738842
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,brady arrhythmias,4.0,0.2043253779411316
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,axxxr signaling,4.0,0.05109945684671402
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,assess contributions,4.0,0.035462601110339165
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,action potentials,4.0,0.010774865746498108
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,girk,3.0,0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ado,2.7777777777777777,0.01965394616127014
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,xxx,2.75,-0.015934890136122704
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,hf,2.5714285714285716,0.1109897643327713
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,relevant,2.5,0.09132666885852814
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ikado,2.5,0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,san,2.25,0.0002002418041229248
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tpq,2.0,0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,dpcpx,2.0,0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,ctl,2.0,0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,axxxr,2.0,0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,adenosine,2.0,0.19145116209983826
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,upregulated,1.0,0.11492399871349335
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tachypacing,1.0,0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,tachy,1.0,0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,studied,1.0,0.20383524894714355
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,significance,1.0,0.06315870583057404
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,role,1.0,0.04181588068604469
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,recorded,1.0,0.01999819651246071
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,p,1.0,0.11820723116397858
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,measured,1.0,0.07410861551761627
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,mdp,1.0,0
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,known,1.0,0.03723067417740822
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,isolated,1.0,0.07487837970256805
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,investigated,1.0,0.0572904571890831
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,increase,1.0,0.06259705126285553
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,frequently,1.0,0.06269361078739166
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,dogs,1.0,0.02954474836587906
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,currents,1.0,-0.027551185339689255
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,collected,1.0,-0.03091895952820778
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,aps,1.0,0.028580810874700546
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,aims,1.0,0.04269438236951828
Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I&lt;sub&gt;Kado&lt;/sub&gt;.,addition,1.0,0.1140233725309372
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,unrelated task effects could account,21.666666666666668,0.029703212156891822
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,diametrically opposed across breaths,16.0,0.06360549898818135
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,dynamic neural network integrated,14.5,0.08997562807053328
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced inspiration could organize,14.0,0.023213588632643223
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,participants performed paced breathing,13.733333333333334,0.10264897346496582
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,volitionally controlled change,9.0,0.007185075432062149
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,simple gas exchange,9.0,0.04997153083483378
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,recurrent temporal frame,9.0,0.0803207978606224
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,neither cardiac fluctuations,9.0,0.2333414057890574
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,different neurophysiological systems,9.0,0.14828146000703177
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,widespread brain areas,8.666666666666666,0.12001476436853409
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,organizing brain processes,8.666666666666666,0.08633280235032241
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,regulate mental processes,8.5,0.062481485307216644
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,magnetoencephalography study demonstrates,8.5,0.1987015356620153
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase angles underlying,8.4,0.0400790236890316
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,two rhythmic systems,8.333333333333334,0.11672884970903397
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,regularized phase pattern,7.9,0.039478382716576256
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,track respiratory inputs,7.833333333333334,0.11441681782404582
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythmic cortical activity,7.833333333333334,0.10528445243835449
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,controlled slow breathing,7.566666666666666,0.04578600389262041
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow inspiratory inputs,7.5,0.02635521503786246
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,consistent phase adjustment,7.4,-0.01837041477362315
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,could reorganize,5.666666666666666,0.03808271884918213
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,paced relative,5.333333333333334,0.05293092504143715
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,modulation effects,5.0,0.06617017835378647
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inspiration stage,5.0,0.0339374216273427
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,effects became,5.0,0.03258681017905474
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,cortical phase,4.9,0.09599739871919155
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,brain rhythms,4.666666666666666,0.16197484731674194
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow breathing,4.566666666666666,0.06043161917477846
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,structured pattern,4.5,0.049263859167695045
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,simultaneous magnetoencephalography,4.5,0.18678748980164528
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,respiratory measurements,4.5,0.24121078848838806
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,mental regulation,4.5,0.04132341407239437
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,noteworthy breathing,4.4,0.07424820587038994
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow train,4.166666666666666,0.0017623202875256538
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow relative,4.166666666666666,0.019502130337059498
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,volitional control,4.0,0.0504638496786356
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,subject level,4.0,0.0403435193002224
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,structured manner,4.0,0.03126910515129566
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,specifically locked,4.0,0.028949055820703506
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,results reveal,4.0,0.03705036221072078
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,numerous cognitive,4.0,0.0770424297079444
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,information coding,4.0,0.1543533056974411
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,indicating unique,4.0,0.01874690316617489
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,external influences,4.0,0.04310125112533569
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,emotional functions,4.0,0.06660359352827072
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,commonly associated,4.0,0.05726354382932186
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,integrated,2.5,0.09875309467315674
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,phase,2.4,0.012381147593259811
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,breathing,2.4,0.1296645700931549
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,rhythmic,2.3333333333333335,0.1197350025177002
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,inputs,2.3333333333333335,-0.037293896079063416
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,slow,2.1666666666666665,-0.008801331743597984
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,adjustment,2.0,-0.028223916888237
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,well,1.0,0.09099400043487549
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,used,1.0,0.010911919176578522
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,timing,1.0,0.006664525717496872
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,suggest,1.0,0.046784643083810806
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,single,1.0,0.015469912439584732
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,revealing,1.0,0.020938735455274582
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,response,1.0,0.05596902221441269
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,report,1.0,0.05636989697813988
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,relationship,1.0,0.0036004912108182907
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,provides,1.0,0.014026330783963203
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,often,1.0,0.02440001629292965
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,normal,1.0,0.08618243783712387
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,new,1.0,0.10631739348173141
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,middle,1.0,0.0016252081841230392
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,low,1.0,0.06519334763288498
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,likely,1.0,0.06529493629932404
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,hypothesized,1.0,0.10675053298473358
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,however,1.0,-0.011453256011009216
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,given,1.0,0.014340896159410477
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,frequency,1.0,0.059476010501384735
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,found,1.0,0.03727259859442711
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,findings,1.0,0.21199440956115723
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,exhibited,1.0,0.07643724977970123
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,essential,1.0,0.026568148285150528
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,complicated,1.0,0.0745171383023262
Slow-paced inspiration regularizes alpha phase dynamics in the human brain.,based,1.0,0.08516917377710342
Implications for REDUCE IT in clinical practice.,inhibitors provides additional risk reduction,21.428571428571427,0.10430664457380771
Implications for REDUCE IT in clinical practice.,triglyceride rich lipoproteins contribute,16.0,0.08706390019506216
Implications for REDUCE IT in clinical practice.,low density lipoprotein cholesterol,16.0,0.16851907409727573
Implications for REDUCE IT in clinical practice.,type ii diabetes mellitus,15.5,0.1391962757334113
Implications for REDUCE IT in clinical practice.,especially among high risk,14.761904761904763,0.11273366957902908
Implications for REDUCE IT in clinical practice.,substantial residual risk remains,14.428571428571429,0.04333528969436884
Implications for REDUCE IT in clinical practice.,kexin type xxx,10.5,0.011254771612584591
Implications for REDUCE IT in clinical practice.,markedly lower risk,9.428571428571429,0.12468116730451584
Implications for REDUCE IT in clinical practice.,proprotein convertase subtilisin,9.0,0.06505677849054337
Implications for REDUCE IT in clinical practice.,guide combination lipid,9.0,0.07310087854663531
Implications for REDUCE IT in clinical practice.,established atherosclerotic cvd,9.0,0.14628634043037891
Implications for REDUCE IT in clinical practice.,high risk patients,8.761904761904763,0.2380689283212026
Implications for REDUCE IT in clinical practice.,high ascvd risk,8.761904761904763,0.12745508551597595
Implications for REDUCE IT in clinical practice.,residual risk,6.428571428571429,0.06334085389971733
Implications for REDUCE IT in clinical practice.,statin treatment,4.0,0.2845439016819
Implications for REDUCE IT in clinical practice.,secondary prevention,4.0,0.1769319474697113
Implications for REDUCE IT in clinical practice.,rights reserved,4.0,0.030988029204308987
Implications for REDUCE IT in clinical practice.,icosapent ethyl,4.0,0.044373609125614166
Implications for REDUCE IT in clinical practice.,elevated triglycerides,4.0,0.155887883156538
Implications for REDUCE IT in clinical practice.,decision pathway,4.0,0.03571615368127823
Implications for REDUCE IT in clinical practice.,current guidelines,4.0,0.08051987178623676
Implications for REDUCE IT in clinical practice.,ascvd events,4.0,0.04950091242790222
Implications for REDUCE IT in clinical practice.,statin therapy,3.666666666666667,0.2950754016637802
Implications for REDUCE IT in clinical practice.,lowering therapy,3.666666666666667,0.18020547181367874
Implications for REDUCE IT in clinical practice.,reduction,3.0,0.11836925148963928
Implications for REDUCE IT in clinical practice.,patients,2.0,0.4592966139316559
Implications for REDUCE IT in clinical practice.,ascvd,2.0,0
Implications for REDUCE IT in clinical practice.,therapy,1.6666666666666667,0.29505598545074463
Implications for REDUCE IT in clinical practice.,synthesized,1.0,0.04292112961411476
Implications for REDUCE IT in clinical practice.,statins,1.0,0.3408559560775757
Implications for REDUCE IT in clinical practice.,shown,1.0,0.044945128262043
Implications for REDUCE IT in clinical practice.,recently,1.0,0.026306796818971634
Implications for REDUCE IT in clinical practice.,primary,1.0,0.07534971833229065
Implications for REDUCE IT in clinical practice.,pcskxxx,1.0,0
Implications for REDUCE IT in clinical practice.,ezetimibe,1.0,0.2120060920715332
Implications for REDUCE IT in clinical practice.,effective,1.0,0.024374470114707947
Implications for REDUCE IT in clinical practice.,discussed,1.0,0.10835075378417969
Implications for REDUCE IT in clinical practice.,data,1.0,0.1061776876449585
Implications for REDUCE IT in clinical practice.,context,1.0,0.04743277281522751
Implications for REDUCE IT in clinical practice.,atherogenesis,1.0,0.2615824341773987
Implications for REDUCE IT in clinical practice.,addition,1.0,0.1140233725309372
Implications for REDUCE IT in clinical practice.,add,1.0,0.027234449982643127
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,preserved left ventricular systolic function,25.0,0.1455035012215376
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,propensity score matching analysis,16.0,0.027967897476628423
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,major clinical end point,15.5,0.15548406448215246
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,segment elevation myocardial infarction,15.0,0.18192845676094294
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,major adverse cardiac events,15.0,0.20323358848690987
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx vs arbs group,11.033333333333333,0.03549237595871091
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,recurrent myocardial infarction,10.0,0.24611127376556396
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,term clinical outcomes,9.5,0.26306356365482014
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,new generation drug,9.0,0.11311395714680354
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,converting enzyme inhibitors,9.0,0.06566230580210686
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,target vessel revascularization,8.666666666666666,0.15812091281016669
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,target lesion revascularization,8.666666666666666,0.19599323719739914
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,mi reduction benefits,8.0,0.08640441919366519
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,angiotensin receptor blockers,8.0,0.1153479553759098
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,aceis group showed,7.5,0.0492068026214838
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,"maces ), defined",7.333333333333334,0.013623733539134264
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cardiac death,5.0,0.37005724757909775
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,arbs group,4.833333333333334,0.03834061697125435
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,repeat revascularization,4.666666666666666,0.234511598944664
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,"xxx ),",4.533333333333333,-0.015934890136122704
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,arb group,4.5,0.04259282909333706
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,aceis group,4.5,0.05019131675362587
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,acei group,4.5,0.05019131675362587
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,"mi ),",4.333333333333334,0.08957851678133011
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx groups,4.2,0.002376844175159931
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,year follow,4.0,0.05729828216135502
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,well established,4.0,0.07649984396994114
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,significantly higher,4.0,0.10986901819705963
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,relative superiority,4.0,0.06780146062374115
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,prominent ability,4.0,0.04136021435260773
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,hazard ratio,4.0,0.09787516295909882
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,eluting stents,4.0,0.31975655257701874
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cumulative incidences,4.0,0.04763193987309933
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,confidence interval,4.0,0.0899096429347992
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,cause death,4.0,0.10442091524600983
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx patients,3.7,0.2216808618977666
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,tvr compared,3.5,0.10162706673145294
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,arbs,2.3333333333333335,0.026489917188882828
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,xxx,2.2,-0.015934890136122704
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,mi,2.0,0.08957851678133011
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,maces,2.0,0.018186111003160477
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,angiotensin,2.0,0.20593181252479553
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,aceis,2.0,0
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,tvr,1.5,0
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,patients,1.5,0.4592966139316559
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,total,1.0,0.003683900460600853
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,st,1.0,-0.026569277048110962
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,similar,1.0,0.08377962559461594
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,period,1.0,0.022214137017726898
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,p,1.0,0.11820723116397858
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,occurrences,1.0,0.021733582019805908
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,nstemi,1.0,0
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,non,1.0,0.06398928165435791
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,n,1.0,-0.021267158910632133
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,mortality,1.0,0.27426618337631226
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,long,1.0,0.023074809461832047
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,however,1.0,-0.011453256011009216
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,hence,1.0,0.006936868652701378
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,era,1.0,0.007774367928504944
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,enrolled,1.0,0.17868360877037048
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,decrease,1.0,0.07778903841972351
ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.,although,1.0,-0.010549046099185944
Women had favourable reverse left ventricle remodelling after TAVR.,investigate whether gender difference affects,24.0,0.05388221740722656
Women had favourable reverse left ventricle remodelling after TAVR.,multivariable logistic regression analysis showed,23.0,0.09569078236818314
Women had favourable reverse left ventricle remodelling after TAVR.,observed since three months later,21.333333333333332,0.05088477730751038
Women had favourable reverse left ventricle remodelling after TAVR.,earlier lv mass regression post,17.666666666666668,0.06476770490407943
Women had favourable reverse left ventricle remodelling after TAVR.,transcatheter aortic valve replacement,16.0,0.25545426085591316
Women had favourable reverse left ventricle remodelling after TAVR.,clinical investigation journal foundation,14.0,0.21006745658814907
Women had favourable reverse left ventricle remodelling after TAVR.,clinical investigation published,10.0,0.23206930855909982
Women had favourable reverse left ventricle remodelling after TAVR.,indicating female gender,9.333333333333334,0.054391159365574517
Women had favourable reverse left ventricle remodelling after TAVR.,xxx months post,9.266666666666666,0.0422542920957009
Women had favourable reverse left ventricle remodelling after TAVR.,repeated upon discharge,9.0,0.05604597677787145
Women had favourable reverse left ventricle remodelling after TAVR.,lv mass index,9.0,0.06306295345226924
Women had favourable reverse left ventricle remodelling after TAVR.,higher survival rates,9.0,0.11164130767186482
Women had favourable reverse left ventricle remodelling after TAVR.,stichting european society,8.5,0.07841567695140839
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi regression occurred,8.5,0.06567401997745037
Women had favourable reverse left ventricle remodelling after TAVR.,favourable reverse remodelling,8.5,-0.026650352403521538
Women had favourable reverse left ventricle remodelling after TAVR.,xxx days post,8.433333333333334,0.03960703872144222
Women had favourable reverse left ventricle remodelling after TAVR.,favourable lv remodelling,8.166666666666666,0.051761746406555176
Women had favourable reverse left ventricle remodelling after TAVR.,greater lvmi regression,7.833333333333334,0.09019545093178749
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi regressed xxx,7.766666666666667,0.03202227223664522
Women had favourable reverse left ventricle remodelling after TAVR.,xxx ± xxx,7.533333333333333,0.04078221941987673
Women had favourable reverse left ventricle remodelling after TAVR.,greater baseline lvmi,6.833333333333334,0.07443353533744812
Women had favourable reverse left ventricle remodelling after TAVR.,lv mass,6.0,0.0404556579887867
Women had favourable reverse left ventricle remodelling after TAVR.,european journal,5.5,0.11452768370509148
Women had favourable reverse left ventricle remodelling after TAVR.,lv remodelling,5.166666666666666,0.051761746406555176
Women had favourable reverse left ventricle remodelling after TAVR.,significant regression,5.0,0.08118440583348274
Women had favourable reverse left ventricle remodelling after TAVR.,early regression,5.0,0.06220626272261143
Women had favourable reverse left ventricle remodelling after TAVR.,nine months,4.833333333333334,0.039835453033447266
Women had favourable reverse left ventricle remodelling after TAVR.,xxx days,4.766666666666667,0.008284521289169788
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi reduction,4.5,0.11836925148963928
Women had favourable reverse left ventricle remodelling after TAVR.,female sex,4.333333333333334,0.039307376369833946
Women had favourable reverse left ventricle remodelling after TAVR.,female patients,4.333333333333334,0.25643976405262947
Women had favourable reverse left ventricle remodelling after TAVR.,xxx women,4.266666666666667,0.06204746384173632
Women had favourable reverse left ventricle remodelling after TAVR.,xxx patients,4.266666666666667,0.2216808618977666
Women had favourable reverse left ventricle remodelling after TAVR.,xxx men,4.266666666666667,0.038267974741756916
Women had favourable reverse left ventricle remodelling after TAVR.,xxx g,4.266666666666667,0.0034098243340849876
Women had favourable reverse left ventricle remodelling after TAVR.,xxx ).,4.266666666666667,-0.015934890136122704
Women had favourable reverse left ventricle remodelling after TAVR.,decreased xxx,4.266666666666667,0.014505949802696705
Women had favourable reverse left ventricle remodelling after TAVR.,achieved xxx,4.266666666666667,0.0066064028069376945
Women had favourable reverse left ventricle remodelling after TAVR.,women exhibited,4.0,0.10823353379964828
Women had favourable reverse left ventricle remodelling after TAVR.,sons ltd,4.0,0.05613034591078758
Women had favourable reverse left ventricle remodelling after TAVR.,remodelling process,4.0,-0.029840530827641487
Women had favourable reverse left ventricle remodelling after TAVR.,periprocedural complications,4.0,0.27054356038570404
Women had favourable reverse left ventricle remodelling after TAVR.,one year,4.0,0.04457888938486576
Women had favourable reverse left ventricle remodelling after TAVR.,men seemed,4.0,0.06016843393445015
Women had favourable reverse left ventricle remodelling after TAVR.,male patients,4.0,0.25673961266875267
Women had favourable reverse left ventricle remodelling after TAVR.,left ventricle,4.0,0.1010191198438406
Women had favourable reverse left ventricle remodelling after TAVR.,john wiley,4.0,0.0068832337856292725
Women had favourable reverse left ventricle remodelling after TAVR.,independent predictor,4.0,0.06677553988993168
Women had favourable reverse left ventricle remodelling after TAVR.,important role,4.0,0.05683520995080471
Women had favourable reverse left ventricle remodelling after TAVR.,better lvef,4.0,0.06907322257757187
Women had favourable reverse left ventricle remodelling after TAVR.,baseline began,4.0,0.014667555689811707
Women had favourable reverse left ventricle remodelling after TAVR.,almost one,4.0,0.03667417913675308
Women had favourable reverse left ventricle remodelling after TAVR.,tavr compared,3.75,0.10162706673145294
Women had favourable reverse left ventricle remodelling after TAVR.,follows tavr,3.75,0.03413863107562065
Women had favourable reverse left ventricle remodelling after TAVR.,independently associated,3.5,0.04205207899212837
Women had favourable reverse left ventricle remodelling after TAVR.,tavr procedure,3.25,0.2543809711933136
Women had favourable reverse left ventricle remodelling after TAVR.,three,3.0,0.07735734432935715
Women had favourable reverse left ventricle remodelling after TAVR.,regression,3.0,0.08992049843072891
Women had favourable reverse left ventricle remodelling after TAVR.,lv,2.6666666666666665,0.051761746406555176
Women had favourable reverse left ventricle remodelling after TAVR.,lvmi,2.5,0
Women had favourable reverse left ventricle remodelling after TAVR.,greater,2.3333333333333335,0.09047040343284607
Women had favourable reverse left ventricle remodelling after TAVR.,xxx,2.2666666666666666,-0.015934890136122704
Women had favourable reverse left ventricle remodelling after TAVR.,baseline,2.0,0.05839666724205017
Women had favourable reverse left ventricle remodelling after TAVR.,tavr,1.75,0
Women had favourable reverse left ventricle remodelling after TAVR.,process,1.5,-0.029840530827641487
Women had favourable reverse left ventricle remodelling after TAVR.,procedure,1.5,0.2543809711933136
Women had favourable reverse left ventricle remodelling after TAVR.,nine,1.5,0.03922521322965622
Women had favourable reverse left ventricle remodelling after TAVR.,associated,1.5,0.10097402334213257
Women had favourable reverse left ventricle remodelling after TAVR.,woman,1.0,0.03228583559393883
Women had favourable reverse left ventricle remodelling after TAVR.,total,1.0,0.003683900460600853
Women had favourable reverse left ventricle remodelling after TAVR.,results,1.0,0.0652550756931305
Women had favourable reverse left ventricle remodelling after TAVR.,play,1.0,0.06874538958072662
Women had favourable reverse left ventricle remodelling after TAVR.,performed,1.0,0.1553603708744049
Women had favourable reverse left ventricle remodelling after TAVR.,p,1.0,0.11820723116397858
Women had favourable reverse left ventricle remodelling after TAVR.,mxxx,1.0,0
Women had favourable reverse left ventricle remodelling after TAVR.,methods,1.0,0.024640876799821854
Women had favourable reverse left ventricle remodelling after TAVR.,median,1.0,0.135945126414299
Women had favourable reverse left ventricle remodelling after TAVR.,materials,1.0,0.04768626391887665
Women had favourable reverse left ventricle remodelling after TAVR.,increase,1.0,0.06259705126285553
Women had favourable reverse left ventricle remodelling after TAVR.,half,1.0,0.06323976814746857
Women had favourable reverse left ventricle remodelling after TAVR.,gradual,1.0,-0.03031037375330925
Women had favourable reverse left ventricle remodelling after TAVR.,enrolled,1.0,0.17868360877037048
Women had favourable reverse left ventricle remodelling after TAVR.,echocardiography,1.0,0.6015831232070923
Women had favourable reverse left ventricle remodelling after TAVR.,despite,1.0,-0.03288298472762108
Women had favourable reverse left ventricle remodelling after TAVR.,contrast,1.0,0.11486168205738068
Women had favourable reverse left ventricle remodelling after TAVR.,considered,1.0,0.11262063682079315
Women had favourable reverse left ventricle remodelling after TAVR.,conclusion,1.0,0.03420025110244751
Women had favourable reverse left ventricle remodelling after TAVR.,behalf,1.0,0.003146544098854065
Women had favourable reverse left ventricle remodelling after TAVR.,background,1.0,0.03833860531449318
Women had favourable reverse left ventricle remodelling after TAVR.,authors,1.0,0.21598771214485168
Women had favourable reverse left ventricle remodelling after TAVR.,aim,1.0,0.040013544261455536
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high dose high potency statins,22.0,0.10378384068608285
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated atherosclerotic cardiovascular disease risk,16.733333333333334,0.24891512244939804
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,"ldlr ), apolipoprotein b",16.0,0.11756717413663864
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,frequent genetic disorder characterized,16.0,0.09232321754097939
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,risk equations like one,15.333333333333334,0.11184229888021946
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,mainly coronary heart disease,13.4,0.24235273245722055
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,called fh phenocopy individuals,12.583333333333334,0.02448871297140916
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c levels since birth,12.5,0.04354667291045189
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,atherosclerotic cardiovascular disease,10.65,0.32278160750865936
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,previous cardiovascular disease,9.65,0.2549596404035886
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,subclinical coronary atherosclerosis,9.5,0.29939383268356323
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,recent studies show,9.0,0.0998884712656339
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,regulate ldl catabolism,8.285714285714285,0.09057123586535454
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,better treat ldl,8.285714285714285,0.10818373039364815
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,latter monogenic defects,7.833333333333334,0.09441300729910533
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl )- cholesterol,7.285714285714286,0.2426881343126297
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high cardiovascular,6.75,0.31772515922784805
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,high ldl,5.785714285714286,0.06070782244205475
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,monogenic disease,5.733333333333333,0.17803233861923218
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,approximately xxx,5.5,0.020467941649258137
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated ldl,5.035714285714286,0.08202844113111496
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated low,4.75,0.07361089438199997
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,elevated lipoprotein,4.75,0.1627451740205288
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,molecular defects,4.5,0.135272778570652
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c levels,4.5,0.042922407388687134
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,monogenic cause,4.333333333333334,0.14051618427038193
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh patients,4.333333333333334,0.22929252870380878
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl receptor,4.285714285714286,0.09437026083469391
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,normolipidemic individuals,4.25,0.054066821932792664
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,many individuals,4.25,0.050460465252399445
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c lowering,4.25,0.053275223821401596
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,adequate levels,4.25,0.03662216290831566
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,safeheart cohort,4.0,0.15340903401374817
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,rights reserved,4.0,0.030988029204308987
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,reduce cholesterol,4.0,0.1659216247498989
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,powered enough,4.0,0.042844364419579506
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,polygenes predominate,4.0,0.05826834589242935
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,phenotype may,4.0,0.05114901624619961
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,pcskxxx inhibitors,4.0,0.12478162348270416
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,male sex,4.0,0.039607224985957146
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,main stain,4.0,0.0192350372672081
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,low hdl,4.0,0.05944899097084999
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,familial hypercholesterolemia,4.0,0.19116144813597202
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,early onset,4.0,0.03782423585653305
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,density lipoprotein,4.0,0.18309740722179413
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,pcskxxx ).,3.5,0
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,risk,3.3333333333333335,0.19420234858989716
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,mainly,2.5,0.039543602615594864
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,fh,2.3333333333333335,-0.0007115565240383148
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ldl,2.2857142857142856,0
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,levels,2.25,0.04464932531118393
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,individuals,2.25,0.054066821932792664
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,c,2.25,0.04119548946619034
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,cholesterol,2.0,0.2426881343126297
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,).,1.5,0
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,used,1.0,0.010911919176578522
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,subjects,1.0,0.13721111416816711
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,smoking,1.0,0.14800035953521729
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,situations,1.0,0.05585839971899986
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,presence,1.0,0.03234631195664406
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,order,1.0,-0.015195201151072979
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,obesity,1.0,0.2634069621562958
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,mutations,1.0,0.1048092395067215
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,medications,1.0,0.24668212234973907
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,lower,1.0,0.0998944565653801
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,hypertension,1.0,0.364623486995697
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,however,1.0,-0.011453256011009216
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,heterogenous,1.0,0.1322057694196701
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,heterogeneity,1.0,0.1402048021554947
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,genes,1.0,0.108245849609375
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,gain,1.0,0.01733916625380516
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,function,1.0,0.11069313436746597
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,ezetimibe,1.0,0.2120060920715332
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,exposed,1.0,0.025203905999660492
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,explains,1.0,0.09325501322746277
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,encountered,1.0,0.0034485915675759315
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,effects,1.0,0.04013404995203018
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,diabetes,1.0,0.31405115127563477
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,detection,1.0,0.17702502012252808
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,depends,1.0,0.026171132922172546
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,comparison,1.0,0.11286726593971252
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,caused,1.0,0.028020884841680527
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,carrying,1.0,-0.010842062532901764
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,captured,1.0,-0.0027890652418136597
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,burden,1.0,0.07514367252588272
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,apob,1.0,0
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.,also,1.0,0.04250158742070198
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",severe chronic neutropenia international registry,23.0,0.13782743513584136
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",quite variable across patient cohorts,23.0,0.13068503215909005
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",treat infections based upon long,22.0,0.08863883838057518
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",recurrent otitis media,9.0,0.13500850399335226
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",human papilloma virus,9.0,0.05660587425033251
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",features occur consistently,9.0,0.040223577370246254
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",congenital heart disease,9.0,0.219012051820755
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",ongoing clinical trials,8.666666666666666,0.21310368676980337
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",reviewed clinical manifestations,8.166666666666666,0.22332385182380676
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",another important complication,7.0,0.09809832895795505
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",respiratory infections,5.5,0.2784971222281456
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",treat whims,5.0,0.0559285469353199
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",clinical consequences,4.666666666666666,0.28612667694687843
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",diverse manifestations,4.5,0.07809659466147423
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",xxx families,4.0,0.008811648003757
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",within families,4.0,0.04905604384839535
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",term observations,4.0,0.06953352503478527
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",stimulating factor,4.0,0.058027416467666626
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",recent findings,4.0,0.12625432386994362
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",novel agents,4.0,0.04741446301341057
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",natural history,4.0,0.051918359473347664
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",less commonly,4.0,0.03545660339295864
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",hearing loss,4.0,0.05086369812488556
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",granulocyte colony,4.0,0.08714257832616568
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",family concerns,4.0,0.09108347445726395
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",associated malignancies,4.0,0.17831076681613922
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",xxx patients,3.666666666666667,0.2216808618977666
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patients enrolled,3.666666666666667,0.3189901113510132
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whim syndrome,3.5,-0.025024790316820145
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",review indicates,3.5,0.035861756186932325
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",mild hypogammaglobulinemia,3.5,0.01283789798617363
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",expand understanding,3.5,0.07533526048064232
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patient,3.0,0.4149835705757141
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",neutropenia,3.0,0.1346380114555359
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",important,2.0,0.07185453921556473
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",complication,2.0,0.2036861628293991
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",patients,1.6666666666666667,0.4592966139316559
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",whims,1.5,-0.035437144339084625
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",understanding,1.5,0.037985511124134064
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",syndrome,1.5,0.01602141559123993
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",review,1.5,0.06275224685668945
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",hypogammaglobulinemia,1.5,0
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",warts,1.0,0.052361562848091125
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",vulvular,1.0,0
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",treatment,1.0,0.27399298548698425
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",summary,1.0,0.08503544330596924
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",source,1.0,0.07131574302911758
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",purpose,1.0,-0.006926483474671841
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",prevent,1.0,0.01288067176938057
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",myelokathexis,1.0,0
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",mutations,1.0,0.1048092395067215
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",morbidity,1.0,0.32470452785491943
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",lymphomas,1.0,0.15060022473335266
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",lymphocytopenia,1.0,0
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",immunodeficiency,1.0,0.18632446229457855
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",however,1.0,-0.011453256011009216
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",example,1.0,0.03917788714170456
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",effective,1.0,0.024374470114707947
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",diversity,1.0,0.10632647573947906
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cxcrxxx,1.0,0
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",controversial,1.0,0.08313564956188202
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",common,1.0,0.08981665968894958
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cervical,1.0,0.21568307280540466
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cellulitis,1.0,0.1427091509103775
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",cause,1.0,0.08800302445888519
"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.",almost,1.0,0.012768656015396118
Prime time for ticagrelor monotherapy.,n engl j med,16.0,0.10432880433897178
Prime time for ticagrelor monotherapy.,xxx nov xxx,8.2,-0.006914984434843063
Prime time for ticagrelor monotherapy.,xxx ): xxx,8.2,-0.015934890136122704
Prime time for ticagrelor monotherapy.,xxx,2.6,-0.015934890136122704
Prime time for ticagrelor monotherapy.,comment,1.0,0.0671435296535492
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,time quantitative polymerase chain reaction,25.0,0.061556193977594376
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa mimic could partly reverse,21.166666666666664,-0.008894834667444229
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,found bil negatively regulated mir,20.75,0.06471881698817014
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,linked immunosorbent assay also,16.0,0.10051629071434338
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,nuclear factor kappa b,15.666666666666666,0.11395830474793911
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,"α ), matrix metalloproteinases",15.0,0.069158340493838
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,detect inflammatory factor levels,11.666666666666666,0.08969968184828758
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,tumor necrosis factor,9.666666666666666,0.12045644720395406
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,greatly destructive disease,9.0,0.08561034873127937
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mir )- xxxa,8.666666666666666,0.12070408463478088
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory injury model,8.333333333333334,0.08977984637022018
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,induced inflammatory injury,8.333333333333334,0.0692398181806008
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,western blot tested,8.0,0.07977622374892235
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,induced cell viability,8.0,0.05290961576004823
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,il )- xxx,8.0,0.023331952281296253
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa via jnk,7.666666666666666,-0.04095765948295593
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil inhibited il,7.583333333333334,0.0565016803642114
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,κb signaling pathways,7.0,0.07217463478446007
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa mimic,6.166666666666666,0.001996072009205818
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil inhibited,5.25,0.053453123196959496
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inflammatory factors,5.0,0.09863114543259144
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cell viability,5.0,0.08285642974078655
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa level,4.666666666666666,0.05803287774324417
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,"mmps ),",4.5,0
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,terminal kinase,4.0,0.10478167235851288
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,related proteins,4.0,0.09971300512552261
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,preliminarily studied,4.0,0.11615649610757828
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,opposite effect,4.0,0.007860364159569144
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,jun n,4.0,0.02815354708582163
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,high disability,4.0,0.05748571269214153
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,atdcxxx cells,4.0,0.06259886920452118
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,ankylosing spondylitis,4.0,0.14915217459201813
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,migration assays,3.5,0.10793172381818295
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mir,3.0,0.12070408463478088
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bil,2.75,0.07958370447158813
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxxa,2.6666666666666665,0
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,xxx,2.6666666666666665,-0.015934890136122704
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,levels,2.5,0.04464932531118393
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,detect,2.5,0.10594243556261063
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,injury,2.3333333333333335,0.04424106702208519
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,il,2.3333333333333335,0.06259879469871521
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,κb,2.0,0
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,tested,2.0,0.06802673637866974
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,pathways,2.0,0.09324981272220612
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,jnk,2.0,0
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mmps,1.5,0
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,migration,1.5,0.050750430673360825
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,used,1.0,0.010911919176578522
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,transfection,1.0,0.11005806177854538
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,study,1.0,0.2376001477241516
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,showed,1.0,0.048222288489341736
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,real,1.0,0.02762891724705696
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,pathway,1.0,0.054601844400167465
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,nf,1.0,0.0131322480738163
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,moreover,1.0,0.01877431571483612
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,microrna,1.0,0
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,mechanism,1.0,0.045044392347335815
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,interleukin,1.0,0.12216327339410782
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,inc,1.0,0.007824641652405262
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,furthermore,1.0,-0.04380498453974724
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,functions,1.0,0.08823495358228683
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,function,1.0,0.11069313436746597
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,finally,1.0,-0.036436013877391815
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,expressions,1.0,-0.01272740587592125
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,enzyme,1.0,0.04809921979904175
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,effects,1.0,0.04013404995203018
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,downregulation,1.0,0.13587923347949982
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,construct,1.0,0.023823019117116928
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,changed,1.0,-0.02320229262113571
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,cck,1.0,0
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,c,1.0,0.04119548946619034
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,bilobalide,1.0,0
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,based,1.0,0.08516917377710342
Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a.,additionally,1.0,0.012068133801221848
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",vivo behavioral studies signified learning,23.5,0.1286583488807082
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",parallel artificial membrane permeation assay,23.0,0.10376918017864227
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",good oral absorption characteristics ascertained,23.0,0.06265176981687545
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",syxxxy neuroblastoma cell lines,16.0,0.07794227947791417
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx showed significant displacement,15.11111111111111,0.037722854409366846
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",induced cognitive dysfunctions performed,15.0,0.08844016073271632
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",terminal phenyl ring considered,14.5,0.042713040485978127
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",synthesized compounds suggested significant,14.5,0.048220605589449406
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx also exhibited anti,13.61111111111111,0.05210598139092326
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",compound xxx containing xxx,13.222222222222221,-0.012946299277245998
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.","xxx μm ), butyrylcholinesterase",13.11111111111111,0.08973726443946362
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",synthesized molecular hybrids,9.5,0.1004725955426693
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",peripheral anionic site,9.0,0.11839019445081551
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",enzyme kinetics study,9.0,0.12617216259241104
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",atomic force microscopy,9.0,0.14697259478271008
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx μm ).,8.61111111111111,0.060591709800064564
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",balanced inhibitory potential,8.333333333333334,0.04376453968385855
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",morris water maze,8.0,0.0377460444966952
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",aβ aggregation activity,8.0,0.026591509580612183
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx μm,6.111111111111111,0.060591709800064564
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",compound xxx,6.111111111111111,-0.009301784448325634
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pharmacokinetic studies,5.5,0.19361627846956253
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.","pampa ),",5.0,-0.011587128043174744
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",induced thioflavin,5.0,-0.006984012201428413
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hache suggested,4.5,0.0354318842291832
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",afm ).,4.5,0
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",potential lead,4.333333333333334,0.07358148694038391
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",antioxidant potential,4.333333333333334,0.07892356440424919
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",target enzymes,4.0,0.059819769114255905
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",rights reserved,4.0,0.030988029204308987
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",propidium iodide,4.0,0.08535055071115494
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",prompted researchers,4.0,0.12055285274982452
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",neuroprotective ability,4.0,0.08796503767371178
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",morphological characterization,4.0,0.15465334430336952
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",mixed type,4.0,-0.013691557571291924
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",memory improvement,4.0,0.1075974702835083
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",functional agents,4.0,0.07732382044196129
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",excellent blood,4.0,0.10497142560780048
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",diverse nature,4.0,0.024880286306142807
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",difluoro substitution,4.0,-0.011218826286494732
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",develop multi,4.0,0.07622480019927025
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",brain barrier,4.0,0.06310593336820602
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",biological activities,4.0,0.07901262491941452
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",xxx,3.111111111111111,-0.015934890136122704
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",assay,3.0,0.17269374430179596
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ascertained,3.0,0.024712640792131424
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",phenyl,2.5,0.05197799205780029
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",also,2.5,0.04250158742070198
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",maze,2.0,0.013208538293838501
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",aβ,2.0,0
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hache,1.5,0.018492121249437332
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",sh,1.0,0.026814039796590805
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",self,1.0,0.05501733347773552
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",secretase,1.0,0.0699610710144043
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",scopolamine,1.0,0.12554436922073364
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pyridylpiperazine,1.0,0
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",permeability,1.0,0.017746534198522568
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",pas,1.0,0.02408768981695175
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",particular,1.0,0.09978539496660233
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",oxadiazoles,1.0,0
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",moreover,1.0,0.01877431571483612
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ki,1.0,0.08903081715106964
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",inhibition,1.0,0.03232728689908981
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",icxxx,1.0,0
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",herein,1.0,-0.04331117123365402
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hbche,1.0,0
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",hbace,1.0,0
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",disease,1.0,0.1630353331565857
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",designed,1.0,0.028855949640274048
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",beta,1.0,0.03460385650396347
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",bbb,1.0,0.034773342311382294
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",alzheimer,1.0,0.24842241406440735
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ad,1.0,0.03272446244955063
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",ache,1.0,0.08014021068811417
"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",acetylcholinesterase,1.0,0.10516519844532013
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",molecular docking data showed,16.0,0.11127792485058308
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",synthesized sixteen novel pyrazolo,14.5,0.051882890363534294
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",active compound xxxc binds,12.1,-0.0014075711369514465
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead compound xxxc inhibited,11.933333333333334,0.034560328970352806
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nucleoside binding pocket,9.0,0.07732871423165004
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",drug resistant isolates,9.0,0.08392754259208839
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",bl cell line,9.0,0.027544931198159855
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",find novel anti,8.5,0.06820598524063826
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx reverse transcriptase,8.4,-0.02129262126982212
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",therapeutic indices xxx,8.4,0.12043657215933005
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",icxxx value xxx,8.4,-0.0017022858373820782
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv drug development,8.0,0.16526059806346893
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype c ).,7.0,0.06712322309613228
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compound xxxc,5.6,-0.0026686787605285645
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead compound,5.333333333333334,0.038179222494363785
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",synthesized compounds,5.0,0.034031230956315994
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxc may,4.6,-0.009713593870401382
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx μm,4.4,0.060591709800064564
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",toa assay,4.0,0.10975470393896103
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype c,4.0,0.06712322309613228
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype b,4.0,0.06338776648044586
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",study indicated,4.0,0.1425252202898264
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",rights reserved,4.0,0.030988029204308987
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",pbmc assays,4.0,0.16511301696300507
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",one derivatives,4.0,0.10068754106760025
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv compounds,4.0,0.08544823713600636
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",continuing efforts,4.0,0.012935364618897438
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",compounds xxxa,4.0,0.025141332298517227
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",also tested,4.0,0.05526416189968586
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv activity,3.5,0.08112992346286774
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxc,2.6,0
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",active,2.5,0.03386080265045166
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxx,2.4,-0.015934890136122704
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",lead,2.3333333333333335,0.07902712374925613
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",subtype,2.0,0.09305095672607422
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",hiv,2.0,0.14575514197349548
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",c,2.0,0.04119548946619034
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",anti,2.0,0.10541997849941254
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",activity,1.5,0.01650470495223999
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxx,1.0,0.029383309185504913
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxvbxxx,1.0,0
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxugxxx,1.0,0
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",xxxe,1.0,0
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",tzm,1.0,0
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",thus,1.0,-0.023273250088095665
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",screened,1.0,0.115809865295887
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",rxxx,1.0,0
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",respectively,1.0,0.08458003401756287
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",pyridin,1.0,0
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",non,1.0,0.06398928165435791
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nnrti,1.0,0
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nih,1.0,0.08235933631658554
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",nari,1.0,0.10476217418909073
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",found,1.0,0.03727259859442711
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",explored,1.0,0.10362917929887772
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",effectively,1.0,-0.01126827858388424
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",dr,1.0,0.21335847675800323
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",considered,1.0,0.11262063682079315
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",confirmed,1.0,0.0016915816813707352
"Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.",br,1.0,-0.004848262295126915
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",trypanocidal drugs four decades ago,21.5,0.08616766892373562
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",dependent cell defense mechanism,16.0,0.08661556988954544
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",group previously reported memantine,14.666666666666666,0.06525926757603884
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",increased survival rate,9.0,0.10391532133022945
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",glutamate receptor antagonist,9.0,0.08470403651396434
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",central nervous system,9.0,0.09717598309119542
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cardiac parasitic load,9.0,0.2107420414686203
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",c mice ).,8.333333333333334,0.06499035283923149
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",serious side effects,8.0,0.05199796830614408
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",neglected tropical disease,8.0,0.11899714668591817
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",xxx million people,7.75,0.0292698722332716
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",results indicate memantine,7.666666666666666,0.09450860445698102
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",trypanocidal drug,5.166666666666667,0.17065133154392242
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infected people,4.5,0.07496684417128563
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infected mice,4.333333333333334,0.06999934837222099
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",raw xxx,4.25,-0.024170187301933765
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",affects xxx,4.25,0.016960998065769672
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",two compounds,4.0,0.04963645152747631
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",present work,4.0,0.06942201405763626
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",limited due,4.0,0.00204892223700881
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",like death,4.0,0.10400816425681114
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",led us,4.0,0.054266976192593575
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",inflammatory infiltrates,4.0,0.11255189403891563
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",induce apoptosis,4.0,0.10251691192388535
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",endemic areas,4.0,0.11304600536823273
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",eliminate parasitemia,4.0,0.11919957026839256
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",diminished parasitemia,4.0,0.11071067303419113
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chronic phase,4.0,0.11103755049407482
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chemotherapy relies,4.0,0.09224571147933602
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",chagas disease,4.0,0.13518544659018517
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",avoid seroconversion,4.0,0.06705493852496147
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",acute phase,4.0,0.21065268479287624
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",treated mice,3.8333333333333335,0.12664027512073517
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",xxx macrophages,3.75,0.04538693744689226
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",candidate drug,3.666666666666667,0.14972596615552902
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",trypanosoma cruzi,3.5,0.07082304358482361
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",taken together,3.5,0.009802590124309063
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",oxidant non,3.5,0.042899807915091515
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",also able,3.5,0.01797361858189106
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",activated cells,3.5,0.033779398538172245
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drugs,3.0,0.16310197114944458
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",memantine,2.6666666666666665,0.19599682092666626
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",results,2.0,0.0652550756931305
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",effects,2.0,0.04013404995203018
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",disease,2.0,0.1630353331565857
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",drug,1.6666666666666667,0.17065133154392242
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",treated,1.5,0.1644953340291977
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",together,1.5,0.0037281587719917297
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",non,1.5,0.06398928165435791
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",macrophages,1.5,0.10670876502990723
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cruzi,1.5,0.07082304358482361
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",activated,1.5,0.004959927871823311
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",able,1.5,-0.006554350256919861
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",vivo,1.0,0.22206149995326996
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",used,1.0,0.010911919176578522
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",use,1.0,0.0033735278993844986
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",treatment,1.0,0.27399298548698425
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",time,1.0,0.05442593991756439
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",showed,1.0,0.048222288489341736
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",reduce,1.0,0.08915511518716812
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",proposed,1.0,0.053893283009529114
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",propose,1.0,0.06627984344959259
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",pro,1.0,0.06096011772751808
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",presently,1.0,0.08407662808895111
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",nifurtimox,1.0,0.2219683825969696
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",mammals,1.0,0.07202176004648209
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",majority,1.0,0.026061898097395897
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",lps,1.0,0.03776899352669716
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",investigated,1.0,0.0572904571890831
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",infection,1.0,0.1787572205066681
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",however,1.0,-0.011453256011009216
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",finally,1.0,-0.036436013877391815
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",fact,1.0,0.015725847333669662
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",entry,1.0,-0.009438621811568737
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",diminish,1.0,0.013176504522562027
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",diagnosed,1.0,0.1202194094657898
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",caxxx,1.0,0
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",caused,1.0,0.028020884841680527
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",cases,1.0,0.1337328851222992
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",benznidazole,1.0,0
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",balb,1.0,0
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",americas,1.0,0.012291006743907928
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",alzheimer,1.0,0.24842241406440735
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",addition,1.0,0.1140233725309372
"The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.",activate,1.0,0.024236150085926056
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,traditional chinese drug usually used,25.0,0.05796513520181179
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,examined using recombinant human il,22.5,0.08760987371206283
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,assessed using histopathological examinations,16.5,0.10306078009307384
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,arthritic potential remains unexplored,15.0,0.0617015203461051
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,κb signaling pathways,9.0,0.07217463478446007
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,treat cardiovascular diseases,9.0,0.320378914475441
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,novel therapeutic strategy,9.0,0.1549561843276024
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,normal control group,9.0,0.06409685189525287
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondrocyte apoptosis observed,9.0,0.13236662497123083
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo results indicate,8.666666666666666,0.10319683079918225
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo chondroprotective effects,8.166666666666666,0.13109777495265007
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inflammatory factor secretion,8.0,0.0749932782103618
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,primary rabbit chondrocytes,7.5,0.06711513424913089
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,arthritic effect,4.75,0.05117087974213064
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rabbit chondrocytes,4.5,0.062997842207551
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,protective effects,4.5,0.05354984477162361
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vivo studies,4.166666666666666,0.23591217398643494
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxx weeks,4.0,0.015535618178546429
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxx h,4.0,0.006312788464128971
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,western blotting,4.0,0.05865995213389397
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rights reserved,4.0,0.030988029204308987
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,randomly divided,4.0,0.04281321354210377
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,partially regulated,4.0,0.0385645367205143
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,main methods,4.0,0.047756170853972435
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,key findings,4.0,0.13917770236730576
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,immunohistochemical analysis,4.0,0.17761285603046417
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,elsevier inc,4.0,0.007824641652405262
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,broad range,4.0,0.0716087594628334
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,apoptotic caspase,4.0,0.08858315274119377
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,apoptotic bcl,4.0,0.025635533034801483
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,protective effect,3.75,0.035630585392937064
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inhibitory effect,3.75,0.03054074547253549
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,dap inhibits,3.666666666666667,0.02131127892062068
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,dap exerts,3.666666666666667,0.001331103965640068
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,oa may,3.5,-0.008101554587483406
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,il,3.0,0.06259879469871521
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxx,2.0,-0.015934890136122704
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inflammatory,2.0,0.17046239972114563
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,chondrocytes,2.0,0.15534254908561707
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,effect,1.75,0.004295531194657087
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,dap,1.6666666666666667,0.04541589692234993
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,studies,1.5,0.24976284801959991
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,oa,1.5,-0.00648951530456543
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,xxxβ,1.0,0
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,vitro,1.0,0.2126568853855133
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,tumor,1.0,0.1627335548400879
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,treatment,1.0,0.27399298548698425
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,suppression,1.0,0.06901815533638
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,study,1.0,0.2376001477241516
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,stimulates,1.0,0.04101589322090149
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,significance,1.0,0.06315870583057404
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,rabbits,1.0,0.023824229836463928
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,qrt,1.0,0
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,published,1.0,0.10513044893741608
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,provides,1.0,0.014026330783963203
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,prospects,1.0,0.11707088351249695
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,production,1.0,0.043551042675971985
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,pro,1.0,0.06096011772751808
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,pixxxk,1.0,0
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,pcr,1.0,0
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,osteoarthritis,1.0,0.21574752032756805
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,nf,1.0,0.0131322480738163
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,neuro,1.0,0.39875543117523193
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,mmps,1.0,0
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,mmp,1.0,0
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,mapk,1.0,0
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,investigate,1.0,0.04426265507936478
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,insecticidal,1.0,0.05981256067752838
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,inhibition,1.0,0.03232728689908981
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,induced,1.0,-0.006984012201428413
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,however,1.0,-0.011453256011009216
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,groups,1.0,0.020688578486442566
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,expression,1.0,0.0005566496402025223
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,decrease,1.0,0.07778903841972351
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,daphnetin,1.0,0
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,confirmed,1.0,0.0016915816813707352
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,bax,1.0,0.07125139981508255
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,bacterial,1.0,0.040336839854717255
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,authors,1.0,0.21598771214485168
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,attributed,1.0,0.03468674421310425
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,antioxidant,1.0,0.0897112786769867
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,anti,1.0,0.10541997849941254
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,akt,1.0,0
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,aims,1.0,0.04269438236951828
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,aim,1.0,0.040013544261455536
Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.,activation,1.0,0.08338409662246704
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,reduce treatment selection bias,16.0,0.1082306350581348
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,term mortality rate compared,15.0,0.1335850590839982
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,day mortality compared,10.0,0.12755431110660234
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,propensity scores matching,9.0,-0.006157381770511468
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,angiotensin system inhibitors,9.0,0.13192020108302435
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,without preoperative rasi,7.916666666666666,0.13641111552715302
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx %); postrasi,7.0,-0.015934890136122704
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,without postoperative rasi,6.916666666666666,0.12899243831634521
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,without one,4.666666666666666,0.019808806478977203
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,perioperative rasi,4.25,0.46739816665649414
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx groups,4.0,0.002376844175159931
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx ).,4.0,-0.015934890136122704
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,"xxx ),",4.0,-0.015934890136122704
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,valve surgery,4.0,0.26824405044317245
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,study shows,4.0,0.1264815628528595
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,significant reduction,4.0,0.09540878236293793
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,significant benefit,4.0,0.06701212003827095
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,results suggest,4.0,0.05601985938847065
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,remains disputable,4.0,-0.009189076721668243
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,postoperative xxx,4.0,0.13150603789836168
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,outcome effects,4.0,0.05124279111623764
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,year ).,3.5,0.028578076511621475
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,reduced long,3.5,0.030343666672706604
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,perioperative use,3.5,0.23538584727793932
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,rasi,2.25,0
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,xxx,2.0,-0.015934890136122704
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,postrasi,2.0,0
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,postoperative,2.0,0.27894696593284607
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,year,1.5,0.028578076511621475
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,use,1.5,0.0033735278993844986
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,long,1.5,0.023074809461832047
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,vs,1.0,0.08122316002845764
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,using,1.0,-0.04173736274242401
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,renin,1.0,0.18859215080738068
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,prerasi,1.0,0
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,patients,1.0,0.4592966139316559
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,outcomes,1.0,0.23325912654399872
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,n,1.0,-0.021267158910632133
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,exclusion,1.0,0.015597571618855
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,divided,1.0,0.11364559084177017
Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.,associated,1.0,0.10097402334213257
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx pmid,3.5,-0.015934890136122704
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,xxx,1.5,-0.015934890136122704
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,rec,1.0,0.15348844230175018
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,medline,1.0,0
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,j,1.0,0.010428212583065033
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,indexed,1.0,0.00026863813400268555
Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.,doi,1.0,0.055976808071136475
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rat aortic rings relaxation assay,25.0,0.13167040646076203
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",phenylephrine precontracted rat aortic rings,25.0,0.13973170891404152
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",brine shrimp acute toxicity test,25.0,0.12034483924508095
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",study highlights potential benefits,15.5,0.0864059729501605
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus fruit extract exerted,14.1,0.005876739198962848
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",viburnum opulus fruit extracts,13.399999999999999,0.055094242095947266
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mas fruit extracts showed,12.733333333333334,0.04573616664856672
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus fruit extract,10.1,0.01784648559987545
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",present study investigated,9.5,0.12350373715162277
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",complex metabolite profiling,9.0,0.061626508831977844
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",chlorogenic acid accounting,9.0,0.019680649042129517
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",significantly weaker activity,8.666666666666666,0.06576179464658101
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",highest vasorelaxant activity,8.666666666666666,0.02473854459822178
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aucuparia fruit extracts,8.399999999999999,0.04416560009121895
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx ± xxx,8.333333333333332,0.04078221941987673
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ms studies revealed,8.0,0.11274281082053979
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",three extracts,4.8,0.06411066837608814
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx μg,4.666666666666666,0.01705158594995737
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx mg,4.666666666666666,0.037553940899670124
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",cornus mas,4.333333333333334,0.04639117792248726
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arginase activity,4.166666666666666,0.0887756496667862
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",sorbus aucuparia,4.0,0
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",significant inhibition,4.0,0.05238780006766319
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",rights reserved,4.0,0.030988029204308987
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",main mechanism,4.0,0.057957928627729416
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",important anti,4.0,0.08863725885748863
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",endothelial dysfunction,4.0,0.13578323274850845
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",diseases associated,4.0,0.17003701627254486
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",declared non,4.0,0.07565124332904816
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",impaired vasodilation,3.666666666666667,0.12070568092167377
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arterial vasodilation,3.666666666666667,0.27021728456020355
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",respectively ).,3.5,0.08458003401756287
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ml ).,3.5,0.06590283662080765
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",opulus,3.0,0
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",extracts,2.8,0.05086399242281914
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",xxx,2.6666666666666665,-0.015934890136122704
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",mas,2.3333333333333335,0.04639117792248726
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ms,2.0,0.06711772084236145
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",aucuparia,2.0,0
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",vasodilation,1.6666666666666667,0.22922125458717346
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",respectively,1.5,0.08458003401756287
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ml,1.5,0.06590283662080765
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",arginase,1.5,0.1610465943813324
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",v,1.0,0.019843820482492447
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",toxic,1.0,-0.0018287282437086105
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",tof,1.0,0.06353136152029037
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",q,1.0,0.06233245134353638
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",proven,1.0,0.05978071689605713
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",icxxx,1.0,0
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",hplc,1.0,0
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",g,1.0,0.02275453880429268
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",esi,1.0,0.09011191129684448
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",endothelium,1.0,0.18098554015159607
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",effects,1.0,0.04013404995203018
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",ecxxx,1.0,0
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",dependent,1.0,0.036311112344264984
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",contrast,1.0,0.11486168205738068
"Metabolite profiling, arginase inhibition and vasorelaxant activity of Cornus mas, Sorbus aucuparia and Viburnum opulus fruit extracts.",c,1.0,0.04119548946619034
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",studied xxx infectious molecular clones,20.90909090909091,0.1087236650288105
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx acquisition among women using,20.40909090909091,0.05883641578257084
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",female reproductive tract cells compared,18.833333333333332,0.10996303856372833
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",morbidity worldwide among reproductive,16.75,0.17867686785757542
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",lower reproductive tract due,16.583333333333332,0.10656870505772531
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",upper female reproductive tract,15.583333333333332,0.10771976411342621
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",acting injectable progestin contraceptive,15.5,0.17082791775465012
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mucosal immune cell distribution,14.5,0.08633079938590527
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",healthy female volunteers,10.0,0.07352676490942638
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",aged cisgender women,10.0,0.09913576953113079
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx entry using,9.40909090909091,-0.02237029156337182
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mucosal immune cells,9.25,0.06335696578025818
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",observational studies suggest,9.0,0.15198551242550215
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",copper intrauterine device,9.0,0.12362731186052163
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",containing oral contraceptive,9.0,0.115378404657046
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx fusion assay,8.90909090909091,0.1156615149229765
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx participants ).,8.40909090909091,0.025789902545511723
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",comparing fusion susceptibility,8.25,0.11908148477474849
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx fusion susceptibility,8.15909090909091,0.08542060169080894
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.","iud ), levonorgestrel",7.5,0.11790083348751068
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",upper compared,6.5,0.07345843315124512
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",immune cells,5.75,0.04092058539390564
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx entry,5.409090909090909,-0.01268675597384572
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx susceptibility,5.159090909090909,0.033018057234585285
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",containing iud,5.0,-0.017246738076210022
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx transmission,4.909090909090909,0.031248790211975574
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx risk,4.909090909090909,0.08913372922688723
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",xxx infection,4.909090909090909,0.0814111651852727
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",three participants,4.5,0.07243601977825165
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",variable effects,4.0,0.067708820104599
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",unexposed controls,4.0,0.041146586649119854
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",understanding effects,4.0,0.03905978053808212
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",transmitted founder,4.0,0.024048829451203346
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",tissue composition,4.0,0.11519806273281574
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",sex steroids,4.0,0.03221854008734226
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",potential mechanism,4.0,0.05659012123942375
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",peripheral blood,4.0,0.1928161382675171
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",medroxyprogesterone acetate,4.0,0.10168490000069141
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",luteal phase,4.0,0.10715164802968502
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",little influence,4.0,0.03261604253202677
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",leading cause,4.0,0.06677581369876862
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",increased risk,4.0,0.13324370235204697
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",higher rates,4.0,0.09818264842033386
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",four groups,4.0,0.04356200248003006
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",endometrial biopsies,4.0,0.278115451335907
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",chronic control,4.0,0.13280537724494934
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",control samples,3.5,0.05453101731836796
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",based hiv,3.5,0.11546215787529945
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",studied,3.0,0.20383524894714355
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cells,2.75,0.06259886920452118
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",susceptibility,2.25,0.08197100460529327
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",levonorgestrel,2.0,0.11790083348751068
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",samples,1.5,0.053145233541727066
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",hiv,1.5,0.14575514197349548
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",virus,1.0,-0.01899149641394615
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",virion,1.0,0.020628144964575768
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",users,1.0,0.05023464933037758
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",unclear,1.0,-0.022680476307868958
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",subtype,1.0,0.09305095672607422
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",study,1.0,0.2376001477241516
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",role,1.0,0.04181588068604469
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",origin,1.0,0.02528408169746399
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",none,1.0,0.034597981721162796
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",n,1.0,-0.021267158910632133
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mid,1.0,0.01741810142993927
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",mechanisms,1.0,0.07097586244344711
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",measured,1.0,0.07410861551761627
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",may,1.0,-0.009713593870401382
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",long,1.0,0.023074809461832047
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",likely,1.0,0.06529493629932404
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",importance,1.0,0.08358374238014221
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",highlighting,1.0,0.04498844966292381
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",globally,1.0,0.039971571415662766
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",fuse,1.0,0.015544218942523003
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",found,1.0,0.03727259859442711
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",endometrium,1.0,0.15803372859954834
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",effect,1.0,0.004295531194657087
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",differences,1.0,0.1514238715171814
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",differ,1.0,0.033852480351924896
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",depo,1.0,0.0018054842948913574
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",data,1.0,0.1061776876449585
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",contraceptives,1.0,0.19597306847572327
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",cervix,1.0,0.179752379655838
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",c,1.0,0.04119548946619034
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",b,1.0,0.033724576234817505
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",associated,1.0,0.10097402334213257
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",aids,1.0,0.0020779240876436234
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",activity,1.0,0.01650470495223999
"Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.",ability,1.0,-0.022223003208637238
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated plasma renin activity concentrations,22.366666666666667,0.10867338627576828
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated plasma renin activity reduced,20.866666666666667,0.09915647581219673
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",aliskiren improved cardiac systolic function,20.666666666666664,0.27129637748003005
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",elevated plasma renin activity,17.366666666666667,0.11454246379435062
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma renin activity retards,16.7,0.08512858673930168
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",improving cardiac systolic function,16.666666666666664,0.2845727540552616
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",significantly alter pathological changes,15.0,0.0661270956043154
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",appropriately selected hf patients,13.5,0.1512090959586203
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",direct renin inhibitor,10.2,0.08969574297467868
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",blinded fashion beginning,9.0,0.06423555500805378
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",atrial natriuretic peptide,9.0,0.1882064938545227
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage c hf,8.166666666666666,0.06909085065126419
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage b hf,7.666666666666666,0.06660054624080658
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.","xxx ), retarding",7.5,-0.0087157366797328
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",significantly reduced,6.5,0.07211685739457607
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.","sarcopenia ), p",6.5,0.13964923471212387
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",plasma aldosterone,6.0,0.19595910608768463
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cardiac output,5.666666666666666,0.3348730728030205
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",stage b,5.166666666666666,0.04440593719482422
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",patients frequently,5.0,0.2609951123595238
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.","xxx ),",4.5,-0.015934890136122704
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",human hf,4.5,0.10022970661520958
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",experimental hf,4.5,0.13953248411417007
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",xxx ).,4.0,-0.015934890136122704
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",relevant model,4.0,0.07298137061297894
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",prolonged survival,4.0,0.08372540213167667
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",progressive stages,4.0,0.062101783230900764
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",neprilysin levels,4.0,0.07031721249222755
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",lean mass,4.0,0.04157595708966255
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",heart failure,4.0,0.2074820026755333
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",female mice,4.0,0.07118406519293785
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",extracellular water,4.0,0.10508124530315399
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",ejection fraction,4.0,-0.013899685814976692
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",dilated cardiomyopathy,4.0,0.20382152497768402
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.","dcm ),",4.0,0
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",data suggest,4.0,0.07648116536438465
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",corin levels,4.0,0.04464932531118393
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",body fat,4.0,0.0442979671061039
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",angiotensin ii,4.0,0.1374107263982296
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",systemic edema,3.5,0.13503113016486168
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",longitudinal development,3.5,0.16776514053344727
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",aliskiren,3.0,0.2279680371284485
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",hf,2.5,0.1109897643327713
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",xxx,2.0,-0.015934890136122704
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",sarcopenia,2.0,0.16109123826026917
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",p,2.0,0.11820723116397858
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",edema,1.5,0.14654508233070374
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",development,1.5,0.1793753206729889
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",dcm,1.5,0
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",treated,1.0,0.1644953340291977
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",translationally,1.0,0.11587049067020416
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",transition,1.0,-0.028071455657482147
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",summary,1.0,0.08503544330596924
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",significance,1.0,0.06315870583057404
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",replicates,1.0,0.002351558767259121
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",reducing,1.0,0.09082308411598206
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",randomized,1.0,0.24115030467510223
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",progression,1.0,0.08447402715682983
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",normalization,1.0,0.1007525622844696
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",mortality,1.0,0.27426618337631226
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",loss,1.0,0.0528750903904438
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",examined,1.0,0.1701224148273468
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",controls,1.0,0.05869656428694725
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",comparison,1.0,0.11286726593971252
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",cachexia,1.0,0.1702251434326172
"Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.",beneficial,1.0,0.11789856851100922
Sensor Networks for Aerospace Human-Machine Systems.,"atm ), commercial airliner single",23.333333333333336,0.03694464126601815
Sensor Networks for Aerospace Human-Machine Systems.,obtain accurate cognitive state estimations,21.5,0.04422376565635204
Sensor Networks for Aerospace Human-Machine Systems.,suitable data analysis techniques based,21.0,0.07714296877384186
Sensor Networks for Aerospace Human-Machine Systems.,including air traffic management,15.5,0.09536956995725632
Sensor Networks for Aerospace Human-Machine Systems.,paper discusses recent advances,15.0,0.07442516647279263
Sensor Networks for Aerospace Human-Machine Systems.,many unmanned aircraft systems,14.666666666666666,0.08779137395322323
Sensor Networks for Aerospace Human-Machine Systems.,key neurophysiological measurements used,14.666666666666666,0.11149143986403942
Sensor Networks for Aerospace Human-Machine Systems.,various challenging aerospace applications,13.0,0.11143393022939563
Sensor Networks for Aerospace Human-Machine Systems.,techniques allow processing,10.0,0.06853713591893514
Sensor Networks for Aerospace Human-Machine Systems.,based inference engine,9.5,0.035875300566355385
Sensor Networks for Aerospace Human-Machine Systems.,"sipo ), one",9.333333333333334,0.060579702258110046
Sensor Networks for Aerospace Human-Machine Systems.,space operations management,9.0,0.14083928366502127
Sensor Networks for Aerospace Human-Machine Systems.,neurophysiological observations becoming,8.666666666666666,0.10737424964706103
Sensor Networks for Aerospace Human-Machine Systems.,proper sensor selection,8.5,0.07969367783516645
Sensor Networks for Aerospace Human-Machine Systems.,various state,6.5,0.05060252919793129
Sensor Networks for Aerospace Human-Machine Systems.,"uas ),",5.333333333333334,0
Sensor Networks for Aerospace Human-Machine Systems.,paper addresses,5.0,0.05757912062108517
Sensor Networks for Aerospace Human-Machine Systems.,operational data,5.0,0.10690224915742874
Sensor Networks for Aerospace Human-Machine Systems.,exchange data,5.0,0.09993807971477509
Sensor Networks for Aerospace Human-Machine Systems.,cognitive states,5.0,0.06911525130271912
Sensor Networks for Aerospace Human-Machine Systems.,cognitive hmixxx,5.0,0.12576279044151306
Sensor Networks for Aerospace Human-Machine Systems.,aerospace cyber,5.0,0.14712340664118528
Sensor Networks for Aerospace Human-Machine Systems.,physical systems,4.666666666666666,0.09009097330272198
Sensor Networks for Aerospace Human-Machine Systems.,machine systems,4.666666666666666,0.10051451623439789
Sensor Networks for Aerospace Human-Machine Systems.,statistical inference,4.5,0.05711063276976347
Sensor Networks for Aerospace Human-Machine Systems.,sensor networks,4.5,0.11384519189596176
Sensor Networks for Aerospace Human-Machine Systems.,pilot operations,4.5,0.08071406930685043
Sensor Networks for Aerospace Human-Machine Systems.,chmixxx applications,4.5,0.10713335126638412
Sensor Networks for Aerospace Human-Machine Systems.,trusted autonomy,4.0,0.040518591180443764
Sensor Networks for Aerospace Human-Machine Systems.,technological developments,4.0,0.09738796204328537
Sensor Networks for Aerospace Human-Machine Systems.,states using,4.0,-0.01463482528924942
Sensor Networks for Aerospace Human-Machine Systems.,sensors collect,4.0,0.05022886395454407
Sensor Networks for Aerospace Human-Machine Systems.,results show,4.0,0.037321701645851135
Sensor Networks for Aerospace Human-Machine Systems.,remote sensors,4.0,0.11022158712148666
Sensor Networks for Aerospace Human-Machine Systems.,reliable methodology,4.0,0.03223274648189545
Sensor Networks for Aerospace Human-Machine Systems.,performance characterisation,4.0,0.034930430352687836
Sensor Networks for Aerospace Human-Machine Systems.,operational performance,4.0,0.07127862051129341
Sensor Networks for Aerospace Human-Machine Systems.,notable advantages,4.0,0.02596551924943924
Sensor Networks for Aerospace Human-Machine Systems.,mission execution,4.0,0.03462985996156931
Sensor Networks for Aerospace Human-Machine Systems.,measurement uncertainties,4.0,0.09318517241626978
Sensor Networks for Aerospace Human-Machine Systems.,machine monitors,4.0,0.09576742351055145
Sensor Networks for Aerospace Human-Machine Systems.,machine learning,4.0,0.03610682301223278
Sensor Networks for Aerospace Human-Machine Systems.,machine interfaces,4.0,0.06854701042175293
Sensor Networks for Aerospace Human-Machine Systems.,information sharing,4.0,0.07782907783985138
Sensor Networks for Aerospace Human-Machine Systems.,increasing level,4.0,0.056617697700858116
Sensor Networks for Aerospace Human-Machine Systems.,hmixxx ).,4.0,0
Sensor Networks for Aerospace Human-Machine Systems.,controlled remotely,4.0,0.03470151871442795
Sensor Networks for Aerospace Human-Machine Systems.,art sensors,4.0,0.1333623230457306
Sensor Networks for Aerospace Human-Machine Systems.,also presented,4.0,0.0762170534580946
Sensor Networks for Aerospace Human-Machine Systems.,loop human,3.75,0.021867670118808746
Sensor Networks for Aerospace Human-Machine Systems.,effective human,3.75,0.0569220595061779
Sensor Networks for Aerospace Human-Machine Systems.,intelligent automation,3.5,0.10952947847545147
Sensor Networks for Aerospace Human-Machine Systems.,human operator,3.25,0.08290145918726921
Sensor Networks for Aerospace Human-Machine Systems.,neurophysiological,2.6666666666666665,0.22117456793785095
Sensor Networks for Aerospace Human-Machine Systems.,human,1.75,0.08946964889764786
Sensor Networks for Aerospace Human-Machine Systems.,operator,1.5,0.07633326947689056
Sensor Networks for Aerospace Human-Machine Systems.,chmixxx,1.5,0
Sensor Networks for Aerospace Human-Machine Systems.,automation,1.5,0.17014488577842712
Sensor Networks for Aerospace Human-Machine Systems.,wearable,1.0,0.13427463173866272
Sensor Networks for Aerospace Human-Machine Systems.,variety,1.0,0.07650606334209442
Sensor Networks for Aerospace Human-Machine Systems.,time,1.0,0.05442593991756439
Sensor Networks for Aerospace Human-Machine Systems.,tasks,1.0,0.010007329285144806
Sensor Networks for Aerospace Human-Machine Systems.,synchronised,1.0,0
Sensor Networks for Aerospace Human-Machine Systems.,support,1.0,0.015030981041491032
Sensor Networks for Aerospace Human-Machine Systems.,seen,1.0,0.05622411519289017
Sensor Networks for Aerospace Human-Machine Systems.,relationship,1.0,0.0036004912108182907
Sensor Networks for Aerospace Human-Machine Systems.,real,1.0,0.02762891724705696
Sensor Networks for Aerospace Human-Machine Systems.,propagation,1.0,0.03586232662200928
Sensor Networks for Aerospace Human-Machine Systems.,order,1.0,-0.015195201151072979
Sensor Networks for Aerospace Human-Machine Systems.,operation,1.0,0.10335259139537811
Sensor Networks for Aerospace Human-Machine Systems.,maximise,1.0,0
Sensor Networks for Aerospace Human-Machine Systems.,making,1.0,-0.03939424455165863
Sensor Networks for Aerospace Human-Machine Systems.,led,1.0,0.05658652260899544
Sensor Networks for Aerospace Human-Machine Systems.,lastly,1.0,0.010791603475809097
Sensor Networks for Aerospace Human-Machine Systems.,introduced,1.0,0.0400276780128479
Sensor Networks for Aerospace Human-Machine Systems.,interactions,1.0,0.01733073592185974
Sensor Networks for Aerospace Human-Machine Systems.,integration,1.0,0.10788127779960632
Sensor Networks for Aerospace Human-Machine Systems.,implementations,1.0,0.1259773075580597
Sensor Networks for Aerospace Human-Machine Systems.,implementation,1.0,0.045003779232501984
Sensor Networks for Aerospace Human-Machine Systems.,humans,1.0,0.06040411442518234
Sensor Networks for Aerospace Human-Machine Systems.,focusing,1.0,0.07314138859510422
Sensor Networks for Aerospace Human-Machine Systems.,evolution,1.0,0.007969394326210022
Sensor Networks for Aerospace Human-Machine Systems.,evaluate,1.0,0.08850531280040741
Sensor Networks for Aerospace Human-Machine Systems.,enhanced,1.0,0.06512656807899475
Sensor Networks for Aerospace Human-Machine Systems.,effectiveness,1.0,0.07677281647920609
Sensor Networks for Aerospace Human-Machine Systems.,due,1.0,-0.005625979043543339
Sensor Networks for Aerospace Human-Machine Systems.,discussed,1.0,0.10835075378417969
Sensor Networks for Aerospace Human-Machine Systems.,development,1.0,0.1793753206729889
Sensor Networks for Aerospace Human-Machine Systems.,decision,1.0,0.016830462962388992
Sensor Networks for Aerospace Human-Machine Systems.,context,1.0,0.04743277281522751
Sensor Networks for Aerospace Human-Machine Systems.,collaboration,1.0,0.08787193149328232
Sensor Networks for Aerospace Human-Machine Systems.,closed,1.0,0.02425248920917511
Sensor Networks for Aerospace Human-Machine Systems.,approach,1.0,0.030139394104480743
Sensor Networks for Aerospace Human-Machine Systems.,adoption,1.0,0.05928677320480347
Sensor Networks for Aerospace Human-Machine Systems.,adapts,1.0,-0.004205208271741867
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,third experiment using various classifiers,15.666666666666666,0.022256070002913474
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,presented short video clips,15.0,0.023751873522996902
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,"knn ), centroid displacement",15.0,0.08893360197544098
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,machine learning model constructed,13.166666666666666,0.03996231034398079
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,different video clips,9.75,0.01361380765835444
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,various physiological signals,9.666666666666666,0.07556999723116557
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,xxx features used,9.0,0.01282449501256148
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,three addictive games,9.0,0.039771584483484425
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,linear discriminant analysis,9.0,0.05840437735120455
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,intraclass correlation coefficient,9.0,0.012439290061593056
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,increasing public concern,9.0,0.0830568956832091
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,galvanic skin response,9.0,0.04630898932615916
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,cue exposure therapy,9.0,0.09801152752091487
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,different experimental conditions,8.75,0.09427235275506973
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,support vector machine,8.666666666666666,0.051382104866206646
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high prevalence rate,8.5,0.10581669459740321
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,three different days,8.25,0.059070371091365814
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,physiological signals recorded,8.0,0.05899506931503614
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,internet gaming disorder,8.0,0.050860609859228134
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,previous study demonstrated,7.833333333333334,0.10705494011441867
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,fairly high accuracy,7.5,0.03963771462440491
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,accumulating datasets recorded,7.333333333333334,0.05349446274340153
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving detection system,7.333333333333333,0.08742143462101619
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving detection method,7.333333333333333,0.07119317973653476
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,third experiment,6.0,0.03214874770492315
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,different days,5.25,0.04992688447237015
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based knn,5.0,0.08516917377710342
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,previous study,4.833333333333334,0.1323506198823452
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based detection,4.666666666666666,0.13109709694981575
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,achieved using,4.666666666666666,-0.006294833496212959
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,system needs,4.5,0.06787129119038582
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,second experiment,4.5,0.03395992424339056
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high accuracy,4.5,0.05547216720879078
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,based method,4.5,0.050765788182616234
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,previous experiments,4.333333333333334,0.0726507268846035
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,physiological data,4.166666666666666,0.13151440024375916
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,maintaining craving,4.166666666666666,0.03588820621371269
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detect craving,4.166666666666666,0.06306727603077888
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving states,4.166666666666666,0.016329914331436157
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,young adults,4.0,0.07127301953732967
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,still questionable,4.0,0.00432188156992197
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,selected based,4.0,0.05939837731420994
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,second experiments,4.0,0.0804145485162735
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,retest reliability,4.0,0.0854695700109005
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,repeatedly applied,4.0,0.01758459396660328
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,random forest,4.0,0.0022971369326114655
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,practical use,4.0,0.030082608573138714
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,potential risk,4.0,0.13116909936070442
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,participant experienced,4.0,0.06560114212334156
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,nine participants,4.0,0.053369954228401184
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,nearest neighbors,4.0,0.05300748534500599
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,high test,4.0,0.07232440635561943
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,gaming could,4.0,0.05794065073132515
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,feature vectors,4.0,0.05559572950005531
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,extensively employed,4.0,0.054523808881640434
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,core factor,4.0,0.06389402598142624
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classification performance,4.0,0.02729679085314274
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,calibration sessions,4.0,0.12268585711717606
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,brain functions,4.0,0.12975287064909935
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,treatment processes,3.666666666666667,0.16884028911590576
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classified whether,3.5,0.0423500370234251
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addiction treatment,3.166666666666667,0.18182269111275673
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classifiers,3.0,0.01899723708629608
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,using,2.6666666666666665,-0.04173736274242401
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,machine,2.6666666666666665,0.04470905661582947
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,learning,2.5,0.027504589408636093
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,experiment,2.5,0.025291113182902336
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,recorded,2.3333333333333335,0.01999819651246071
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,craving,2.1666666666666665,0.020192116498947144
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,gaming,2.0,0.11154379695653915
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,datasets,2.0,0.14062902331352234
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,accuracy,2.0,0.05023651197552681
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,treatment,1.6666666666666667,0.27399298548698425
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,test,1.5,0.08394099026918411
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,data,1.5,0.1061776876449585
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,classified,1.5,0.05302777886390686
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addiction,1.5,0.0896523967385292
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,without,1.0,-0.02096208930015564
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,user,1.0,0.06738777458667755
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,trained,1.0,0.1238085925579071
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,train,1.0,0.012325972318649292
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,tool,1.0,-0.026759788393974304
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,thus,1.0,-0.023273250088095665
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,suggesting,1.0,0.051274579018354416
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,reuse,1.0,0.06399834156036377
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,repeated,1.0,0.06608778983354568
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,relapse,1.0,0.17986296117305756
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,reducing,1.0,0.09082308411598206
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,proposed,1.0,0.053893283009529114
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,practicality,1.0,-0.0022749854251742363
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,organizations,1.0,0.03319929540157318
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,non,1.0,0.06398928165435791
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,monitor,1.0,0.09350521117448807
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,k,1.0,0.017621368169784546
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,investigated,1.0,0.0572904571890831
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,initially,1.0,0.02090536803007126
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,importance,1.0,0.08358374238014221
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,implemented,1.0,0.01216113567352295
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,however,1.0,-0.011453256011009216
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,first,1.0,0.019310347735881805
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,enhanced,1.0,0.06512656807899475
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,electrooculogram,1.0,0
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,efficacy,1.0,0.19373440742492676
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,effectiveness,1.0,0.07677281647920609
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,detected,1.0,0.10373490303754807
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,designed,1.0,0.028855949640274048
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,demonstrating,1.0,0.04213862493634224
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,day,1.0,0.006769683212041855
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,consequently,1.0,-0.014644097536802292
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,computing,1.0,0.19677644968032837
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,comparable,1.0,0.07046344876289368
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,characteristic,1.0,0.01731044426560402
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,become,1.0,0.05435512214899063
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,alteration,1.0,0.0038754730485379696
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,adolescents,1.0,0.19675688445568085
Machine-Learning-Based Detection of Craving for Gaming Using Multimodal Physiological Signals: Validation of Test-Retest Reliability for Practical Use.,addition,1.0,0.1140233725309372
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,sensitive caxxx +- permeable channel,24.5,0.05570216756314039
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,causes sustained intracellular caxxx,16.5,0.06682328196863334
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,trpvxxx ameliorates muscle dysgenesis,14.333333333333334,0.107497521986564
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,improve cardiac function,9.0,0.2716828261812528
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,potential therapeutic target,8.5,0.12307530641555786
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,degenerative muscular disease,8.333333333333334,0.11757361888885498
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,trpvxxx inhibitors available,7.833333333333334,0.08202946558594704
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,trpvxxx inhibitors,4.833333333333334,0.12478162348270416
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,therapeutic applications,4.5,0.18711788579821587
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,"trpvxxx ),",4.333333333333334,0
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,muscular dystrophy,4.333333333333334,0.13088549673557281
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,muscular cells,4.333333333333334,0.08377685397863388
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,although trpvxxx,4.333333333333334,-0.010549046099185944
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,treatment options,4.0,0.18409168347716331
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,survival prognosis,4.0,0.18474479019641876
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,reports showed,4.0,0.030123181641101837
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,recent reports,4.0,0.026269156485795975
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,recent findings,4.0,0.12625432386994362
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,pathophysiological feature,4.0,0.13152123987674713
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,member xxx,4.0,0.03298392612487078
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,intractable diseases,4.0,0.18455736339092255
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,heart failure,4.0,0.2074820026755333
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,current progress,4.0,0.031809890642762184
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,dilated cardiomyopathy,3.666666666666667,0.20382152497768402
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy associated,3.666666666666667,0.1778019666671753
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,trpvxxx,2.3333333333333335,0
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyopathy,1.6666666666666667,0.254629909992218
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,stretch,1.0,-0.03446945548057556
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,sarcolemma,1.0,0
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,review,1.0,0.06275224685668945
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,recently,1.0,0.026306796818971634
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,myocytes,1.0,0.1898742914199829
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,limited,1.0,0.009723823517560959
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,introduce,1.0,0.06314089149236679
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,increase,1.0,0.06259705126285553
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,inactivation,1.0,0.028842192143201828
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,furthermore,1.0,-0.04380498453974724
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,discuss,1.0,0.09245206415653229
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,development,1.0,0.1793753206729889
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,concentrated,1.0,0.06568844616413116
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,clarified,1.0,0.05862269178032875
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,cardiomyocytes,1.0,0.25375694036483765
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.,activated,1.0,0.004959927871823311
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,j respir crit care med,25.0,0.16384608950465918
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,chronic obstructive pulmonary disease ).,22.75,0.23184162378311157
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,trend toward reduced ilc populations,22.642857142857142,0.0698625585064292
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immune cells regulating pathologic inflammation,21.5,0.09947758466005326
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,grade xxx within xxx h,20.5,-0.004712549597024917
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,interstitial lung disease transplant recipients,19.535714285714285,0.17811925411224366
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,chronic obstructive pulmonary disease,17.75,0.23184162378311157
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,derived lung ilc populations,14.928571428571429,0.1203025197610259
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,seven patients developed pgd,13.5,0.2072365308801333
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc subset composition within,13.142857142857142,0.08228746677438419
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,interstitial lung disease,11.535714285714285,0.15872031450271606
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung transplant recipients,11.285714285714285,0.22367306550343832
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,regulating lung injury,10.285714285714285,0.12490031247337659
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor immune cells,10.0,0.08816746870676677
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,natural killer cells,9.5,0.06161953260501226
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,innate lymphoid cells,9.5,0.07472498808056116
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx jan xxx,9.0,-0.004340975234905879
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx ): xxx,9.0,-0.015934890136122704
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,significantly decreased frequencies,9.0,0.06376730153958003
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,primary graft dysfunction,9.0,0.10181743899981181
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,center cohort study,9.0,0.18532745043436685
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,beneficial tissue repair,9.0,0.14428570369879404
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,distinct ilc subsets,8.809523809523808,0.0824311189353466
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung transplantation patients,8.785714285714285,0.3863736192385356
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,elevated ilcxxx frequencies,8.5,0.06088118255138397
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor tissue taken,8.5,0.12451291518906753
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor ilc subsets,8.309523809523808,0.17370188236236572
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,determine whether pgd,8.0,0.014357341453433037
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,allograft reperfusion resulted,7.0,0.13279395177960396
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx patients,6.0,0.2216808618977666
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc subsets,5.809523809523809,0.16474252939224243
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,lung transplantation,5.785714285714286,0.3499121218919754
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilcxxx subset,5.5,0.12691286206245422
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,"xxx %),",5.0,-0.015934890136122704
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd development,4.5,0.1793753206729889
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,whether changes,4.0,0.012449828907847404
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,surgical biopsies,4.0,0.41907769441604614
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,selective reduction,4.0,0.10598104819655418
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,poorly understood,4.0,0.0295539740473032
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,main results,4.0,0.06806327030062675
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,leading cause,4.0,0.06677581369876862
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immunologic mechanisms,4.0,0.11082618311047554
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilcs may,4.0,-0.009713593870401382
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,heterogeneous family,4.0,0.13286056369543076
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,flow cytometry,4.0,0.14311635494232178
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,early morbidity,4.0,0.1795982774347067
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,characterized phenotypically,4.0,0.06442966684699059
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,cell resolution,4.0,0.09417501091957092
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,allograft reperfusion,4.0,0.20151324570178986
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,ilc,3.142857142857143,0
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,xxx,3.0,-0.015934890136122704
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,pgd,2.5,0
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,donor,2.5,0.182661235332489
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,composition,2.5,0.05539563670754433
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,reperfusion,2.0,0.21687349677085876
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,allograft,2.0,0.18615299463272095
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,changes,1.5,-0.006772637367248535
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,suggesting,1.0,0.051274579018354416
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,single,1.0,0.015469912439584732
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,regardless,1.0,0.007859854027628899
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,rationale,1.0,0.023891299962997437
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,performed,1.0,0.1553603708744049
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,percentage,1.0,0.051493167877197266
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,objectives,1.0,0.043118979781866074
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,never,1.0,-0.008689116686582565
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,mortality,1.0,0.27426618337631226
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,methods,1.0,0.024640876799821854
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,measurements,1.0,0.14751827716827393
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,involved,1.0,0.03122086077928543
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,immediately,1.0,0.008696227334439754
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,however,1.0,-0.011453256011009216
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,examined,1.0,0.1701224148273468
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,diagnosis,1.0,0.24688632786273956
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,conversely,1.0,0.008514180779457092
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,conclusions,1.0,0.07628431916236877
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,comment,1.0,0.0671435296535492
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,associated,1.0,0.10097402334213257
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,assessed,1.0,0.06162751466035843
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,altered,1.0,0.00029489025473594666
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,alterations,1.0,0.027870547026395798
Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.,accompanied,1.0,0.08995422720909119
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancer treatment would thus appear,20.5,0.1097944762557745
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin could decreases tumor growth,18.333333333333336,0.10697400867938996
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,substantial pathological processes accompanying,16.0,0.09587276354432106
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,many key circadian genes,15.5,0.08500510454177856
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,major signaling pathways involved,14.5,0.06231483444571495
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,circadian clock disruption related,14.5,0.06638471782207489
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,circadian clock disruption,10.5,0.04735249777634939
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,tumor growth control,10.333333333333334,0.1183009147644043
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,control circadian clocks,9.5,0.08741341531276703
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,interesting therapeutic strategy,9.0,0.1279646704594294
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,stimulating pparγ expression,8.5,0.039433457888662815
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,pparγ activity levels,8.5,0.03057701513171196
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,repress chronic inflammation,8.0,0.12960136433442435
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin administration participates,7.5,0.11374848584334056
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin could,6.0,0.0712696835398674
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,tumor therapy,5.333333333333334,0.22889477014541626
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,chronic inflammation,5.0,0.18938421458005905
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,use curcumin,4.5,0.07078769523650408
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,pparγ agonists,4.5,0.1410360336303711
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,pparγ act,4.5,-0.07634148746728897
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin act,4.5,0.030930187553167343
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancer therapy,4.5,0.26407553255558014
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancer process,4.5,0.10162727441638708
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,several hypotheses,4.0,0.0797027125954628
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,review focuses,4.0,0.06432617083191872
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,positive effect,4.0,0.007016112795099616
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,oxidative stress,4.0,0.06077610049396753
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,opposed manner,4.0,0.04035537876188755
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,numerous studies,4.0,0.13904245849698782
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,catenin pathway,4.0,0.06291821040213108
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,regulating wnt,3.5,0.04472519736737013
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,promoting cancers,3.5,0.15228036046028137
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,thus,3.0,-0.023273250088095665
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,involved,2.5,0.03122086077928543
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,curcumin,2.5,0.13820186257362366
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancer,2.5,0.23309507966041565
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,administration,2.0,0.11781518906354904
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,wnt,1.5,0.015574393793940544
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,cancers,1.5,0.2263445258140564
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,β,1.0,0.06373848021030426
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,upregulation,1.0,0.041890837252140045
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,upregulated,1.0,0.11492399871349335
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,role,1.0,0.04181588068604469
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,regulation,1.0,0.03000696375966072
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,prevention,1.0,0.22807250916957855
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,presented,1.0,0.10993251949548721
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,one,1.0,0.060579702258110046
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,invasion,1.0,0.0024318788200616837
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,interest,1.0,0.08689615875482559
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,highlighted,1.0,0.046806275844573975
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,downregulation,1.0,0.13587923347949982
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,common,1.0,0.08981665968894958
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,co,1.0,0.08638649433851242
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,appears,1.0,-0.012369683012366295
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,acts,1.0,-0.05734111741185188
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,action,1.0,-0.06811089813709259
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway.,acting,1.0,0.03581047058105469
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,modify ectopic soxxxx overexpression driven,24.0,0.08044958114624023
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,k )- specific demethylase xxxa,23.5,0.08775223294893901
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,lsdxxx cofactor flavin adenosine dinucleotide,22.5,0.12273293547332287
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,specific histone demethylase xxxa,16.5,0.08877549072106679
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,extra virgin olive oil,16.0,-0.0011164299212396145
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,dynamic simulation approaches revealed,16.0,0.0631281272508204
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,biophenol secoiridoid naturally present,15.5,0.05532580986618996
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,naturally occurring phenolic inhibitor,15.0,0.05393440183252096
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,"corest ), likely disturbing",15.0,0.0466467160731554
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,transcription factor soxxxx,10.0,0.11213471740484238
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,design new secoiridoid,9.5,0.11875050887465477
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,vitro assays confirmed,9.0,0.12648716134329638
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,targeted distal enhancer,9.0,0.06773514362672965
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,sex determining region,9.0,0.04799190846582254
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,central epigenetic regulator,9.0,0.12990684807300568
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,induced pluripotent stem,8.5,0.06821111527582009
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein fully suppressed,8.25,0.031690606847405434
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,based lsdxxx inhibitors,7.5,0.1049753986299038
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein could target,7.25,0.019162576645612717
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,histone hxxx,5.0,0.020691141486167908
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,"evoo ),",5.0,0
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,direct inhibitor,5.0,0.040247539058327675
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,target lsdxxx,4.5,0.03398764878511429
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,recombinant lsdxxx,4.5,0.15759587287902832
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,lsdxxx co,4.5,0.08638649433851242
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein failed,4.25,-0.006138162687420845
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,specifically occurs,4.0,0.048731833696365356
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,neurological disorders,4.0,0.2871481329202652
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,molecular docking,4.0,0.14535586163401604
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,metabolic reprogramming,4.0,0.17070072889328003
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,higher concentrations,4.0,0.09915696084499359
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,high affinity,4.0,0.06177264451980591
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,first evidence,4.0,0.0387383159250021
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,findings provide,4.0,0.11598987132310867
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,evoo contains,4.0,0.012064103037118912
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,constitutive promoter,4.0,0.032824086025357246
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cancer stem,4.0,0.13126375153660774
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,binding site,4.0,0.014497044496238232
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,associated diseases,4.0,0.17003701627254486
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,also known,4.0,0.0398661307990551
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,xxx μmol,3.666666666666667,0.03492676932364702
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,box xxx,3.666666666666667,-0.02525900211185217
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,low concentrations,3.5,0.07519521191716194
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,lsdxxx,2.5,0
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,oleacein,2.25,0
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,target,2.0,0.03398764878511429
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,based,2.0,0.08516917377710342
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,xxx,1.6666666666666667,-0.015934890136122704
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,low,1.5,0.06519334763288498
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cancer,1.5,0.23309507966041565
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,use,1.0,0.0033735278993844986
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,template,1.0,0.018535267561674118
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,support,1.0,0.015030981041491032
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,repressor,1.0,0.03532378003001213
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,rcorxxx,1.0,0
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,predicted,1.0,0.05830582231283188
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,overall,1.0,0.0339067317545414
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,obesity,1.0,0.2634069621562958
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,lysine,1.0,-0.0017932914197444916
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,like,1.0,0.08717752248048782
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,l,1.0,0.02060166746377945
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,kdmxxxa,1.0,0
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,ips,1.0,0.08871375024318695
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,interaction,1.0,0.03199315816164017
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,icxxx,1.0,0
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,expression,1.0,0.0005566496402025223
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,evaluated,1.0,0.1149546355009079
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,conversely,1.0,0.008514180779457092
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,control,1.0,0.05591680109500885
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,chromatin,1.0,0.06535216420888901
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,cells,1.0,0.06259886920452118
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,anchorage,1.0,0.02128317952156067
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,alphascreen,1.0,0
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,act,1.0,-0.07634148746728897
Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.,ability,1.0,-0.022223003208637238
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,tunel )- positive apoptotic nuclei,25.0,0.07236016541719437
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,akt cell survival signaling molecules,23.5,0.09397337399423122
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,western blotting analysis revealed,16.0,0.06050556292757392
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mediated dutp nick end,16.0,0.04515171299378077
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,rescued terminal deoxynucleotide transferase,15.0,0.04080377146601677
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,underlying molecular mechanism,9.0,0.09948426733414333
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,sirna completely abrogated,9.0,0.00400182232260704
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,related neurodegenerative disorders,9.0,0.17427562673886618
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,reactive oxygen species,9.0,0.049748859678705536
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,quinazoline alkaloid isolated,9.0,0.08642268925905228
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,protection depended critically,9.0,0.04266317064563433
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mapk )/ c,9.0,0.04119548946619034
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,adhatoda vasica plant,9.0,0.12410486489534378
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,activated protein kinase,8.5,0.08050534687936306
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,induced cellular apoptosis,8.0,0.08956070678929488
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,terminal kinase,5.5,0.10478167235851288
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cell viability,5.5,0.08285642974078655
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,suppressed generation,4.0,0.049590762704610825
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,protective effect,4.0,0.035630585392937064
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,potential candidate,4.0,0.09846822544932365
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,oxidative stress,4.0,0.06077610049396753
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,neuroprotective effect,4.0,0.10122430487535894
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,jun n,4.0,0.02815354708582163
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,induced loss,4.0,0.022945539094507694
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,findings indicated,4.0,0.1297223512083292
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dependent manner,4.0,0.024547820910811424
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasicinone reduced,3.666666666666667,0.03761252388358116
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasicinone increased,3.666666666666667,0.07228505611419678
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,syxxxy cells,3.5,0.06259886920452118
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,induced,2.0,-0.006984012201428413
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,vasicinone,1.6666666666666667,0
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,cells,1.5,0.06259886920452118
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,treatment,1.0,0.27399298548698425
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,treated,1.0,0.1644953340291977
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,study,1.0,0.2376001477241516
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,silencing,1.0,-0.04259086772799492
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,sh,1.0,0.026814039796590805
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,ros,1.0,0.03682184964418411
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,possibly,1.0,0.03695425018668175
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,pixxxk,1.0,0
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,phosphorylation,1.0,0.07472814619541168
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,parkinson,1.0,0.1659034639596939
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,paraquat,1.0,0.04611168056726456
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,observed,1.0,0.08740169554948807
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,mitogen,1.0,0.1692083328962326
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,labeling,1.0,0.08040857315063477
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,igfxxxr,1.0,0
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,explored,1.0,0.10362917929887772
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,downregulated,1.0,0.0983925461769104
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,dose,1.0,0.05847698450088501
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,disease,1.0,0.1630353331565857
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.,activation,1.0,0.08338409662246704
Practical guide for the use of PCSK9 inhibitors in Portugal.,publicado por elsevier españa,16.0,0.038392797112464905
Practical guide for the use of PCSK9 inhibitors in Portugal.,xxx %) reduces ldl,13.0,0.015233089216053486
Practical guide for the use of PCSK9 inhibitors in Portugal.,new therapeutic option,9.0,0.1437749428053697
Practical guide for the use of PCSK9 inhibitors in Portugal.,density lipoprotein cholesterol,9.0,0.20296098291873932
Practical guide for the use of PCSK9 inhibitors in Portugal.,consensus document aims,9.0,0.06068861484527588
Practical guide for the use of PCSK9 inhibitors in Portugal.,achieve recommended ldl,8.5,0.06611990556120872
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical trials translates,8.333333333333334,0.2189455951253573
Practical guide for the use of PCSK9 inhibitors in Portugal.,good safety profile,8.0,0.10886812955141068
Practical guide for the use of PCSK9 inhibitors in Portugal.,higher cardiovascular risk,7.5,0.29402056336402893
Practical guide for the use of PCSK9 inhibitors in Portugal.,cardiovascular events,4.5,0.3121217042207718
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical practice,4.333333333333334,0.3287031501531601
Practical guide for the use of PCSK9 inhibitors in Portugal.,high ldl,4.166666666666667,0.06070782244205475
Practical guide for the use of PCSK9 inhibitors in Portugal.,rights reserved,4.0,0.030988029204308987
Practical guide for the use of PCSK9 inhibitors in Portugal.,pcskxxx inhibitors,4.0,0.12478162348270416
Practical guide for the use of PCSK9 inhibitors in Portugal.,may benefit,4.0,0.025931166484951973
Practical guide for the use of PCSK9 inhibitors in Portugal.,make recommendations,4.0,0.0458347462117672
Practical guide for the use of PCSK9 inhibitors in Portugal.,main data,4.0,0.08852457627654076
Practical guide for the use of PCSK9 inhibitors in Portugal.,important strategies,4.0,0.07461995258927345
Practical guide for the use of PCSK9 inhibitors in Portugal.,additional reduction,4.0,0.09426146000623703
Practical guide for the use of PCSK9 inhibitors in Portugal.,clinical use,3.8333333333333335,0.25088019389659166
Practical guide for the use of PCSK9 inhibitors in Portugal.,lowering therapy,3.666666666666667,0.18020547181367874
Practical guide for the use of PCSK9 inhibitors in Portugal.,high proportion,3.666666666666667,0.06397777795791626
Practical guide for the use of PCSK9 inhibitors in Portugal.,reducing low,3.5,0.07800821587443352
Practical guide for the use of PCSK9 inhibitors in Portugal.,cost therapy,3.166666666666667,0.16430708579719067
Practical guide for the use of PCSK9 inhibitors in Portugal.,c levels,3.0,0.042922407388687134
Practical guide for the use of PCSK9 inhibitors in Portugal.,xxx,2.5,-0.015934890136122704
Practical guide for the use of PCSK9 inhibitors in Portugal.,ldl,2.5,0
Practical guide for the use of PCSK9 inhibitors in Portugal.,risk,2.0,0.19420234858989716
Practical guide for the use of PCSK9 inhibitors in Portugal.,profile,2.0,0.06660210341215134
Practical guide for the use of PCSK9 inhibitors in Portugal.,therapy,1.6666666666666667,0.29505598545074463
Practical guide for the use of PCSK9 inhibitors in Portugal.,high,1.6666666666666667,0.06070782244205475
Practical guide for the use of PCSK9 inhibitors in Portugal.,use,1.5,0.0033735278993844986
Practical guide for the use of PCSK9 inhibitors in Portugal.,reducing,1.5,0.09082308411598206
Practical guide for the use of PCSK9 inhibitors in Portugal.,levels,1.5,0.04464932531118393
Practical guide for the use of PCSK9 inhibitors in Portugal.,cost,1.5,0.033558186143636703
Practical guide for the use of PCSK9 inhibitors in Portugal.,c,1.5,0.04119548946619034
Practical guide for the use of PCSK9 inhibitors in Portugal.,u,1.0,0.052889470010995865
Practical guide for the use of PCSK9 inhibitors in Portugal.,therefore,1.0,0.024225328117609024
Practical guide for the use of PCSK9 inhibitors in Portugal.,take,1.0,0.00886952131986618
Practical guide for the use of PCSK9 inhibitors in Portugal.,summarize,1.0,0.045041151344776154
Practical guide for the use of PCSK9 inhibitors in Portugal.,statins,1.0,0.3408559560775757
Practical guide for the use of PCSK9 inhibitors in Portugal.,significantly,1.0,0.10662119090557098
Practical guide for the use of PCSK9 inhibitors in Portugal.,priority,1.0,0.06046057492494583
Practical guide for the use of PCSK9 inhibitors in Portugal.,portugal,1.0,0.023968953639268875
Practical guide for the use of PCSK9 inhibitors in Portugal.,pcskxxxi,1.0,0
Practical guide for the use of PCSK9 inhibitors in Portugal.,patients,1.0,0.4592966139316559
Practical guide for the use of PCSK9 inhibitors in Portugal.,one,1.0,0.060579702258110046
Practical guide for the use of PCSK9 inhibitors in Portugal.,lipid,1.0,0.24486735463142395
Practical guide for the use of PCSK9 inhibitors in Portugal.,lifestyle,1.0,0.1476355940103531
Practical guide for the use of PCSK9 inhibitors in Portugal.,l,1.0,0.02060166746377945
Practical guide for the use of PCSK9 inhibitors in Portugal.,however,1.0,-0.011453256011009216
Practical guide for the use of PCSK9 inhibitors in Portugal.,given,1.0,0.014340896159410477
Practical guide for the use of PCSK9 inhibitors in Portugal.,ezetimibe,1.0,0.2120060920715332
Practical guide for the use of PCSK9 inhibitors in Portugal.,effectiveness,1.0,0.07677281647920609
Practical guide for the use of PCSK9 inhibitors in Portugal.,account,1.0,0.002082366496324539
